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This thesis outlines three pieces of exploration relating to the experience of living with a 
neurodegenerative condition: a meta synthesis of the literature on how individuals adjust to a 
diagnosis of Parkinson’s disease (PD); an interpretive phenomenological analysis of the 
experience of 10 individuals living in the pre-manifest stage of Huntington’s disease (HD) and a 
critical analysis incorporating my reflections on the research. 
In the first section, the meta-synthesis is described, which reviewed 20 papers exploring how an 
individual adjusts to a diagnosis of PD. Three main themes emerged relating to the adjustment 
process: ‘maintaining coherent sense of self’, ‘feeling in control' and 'holding a positive 
mindset’. The findings provide insight into how an individual manages the challenges faced by 
their condition and the importance of maintaining a positive mindset. The review also discussed 
clinical implications, including ways to empower individuals with PD to self-manage their 
condition. 
The second section outlines the empirical research, in which 10 individuals living in the pre-
manifest stage of HD were interviewed. Three major themes emerged: ‘feeling limited by time’-
“trigger for a countdown”, 'the perception of stalling time’-“I have no intention of becoming 
symptomatic” and 'making the most of time’-“I could be hit by a bus tomorrow”. 
 In the final section, the critical analysis considers the similarities and differences between the 
two papers and the strengths and limitations of each piece of research. The researcher 
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Abstract 
Parkinson’s disease is a progressive, neurodegenerative condition, which causes a range of 
physical difficulties including tremor, rigidity, slowness of movement and postural instability. 
Psychological difficulties are also common. Adjustment is thus required to manage the effects of 
the condition and this review presents a synthesis of research in this area. A systematic search of 
three databases (MEDLINE, CINAHL and PsycINFO) was carried out. After exclusion based on 
eligibility criteria, 20 articles were included when analysing the data. Three main themes are 
proposed relating to the process of adjustment: ‘maintaining a coherent sense of self’, ‘feeling in 
control’ and ‘holding a positive mindset’. Although many of the studies described challenges of 
living with PD, the results are dominated by the determination of individuals to self-manage their 
condition and maintain positive wellbeing. The results highlight the need to empower patients to 
self-manage their illness, mitigating the effects of Parkinson’s disease and supporting future 
wellbeing. 
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Introduction 
PD is a debilitating, progressive condition normally diagnosed after the age of 50 
although onset at a younger age is also possible. In 2016, 6.1 million individuals had Parkinson's 
disease globally, compared with 2.5 million in 1990, reflective of increasing numbers of older 
people, longer disease duration and environmental factors (Dorsey et al., 2016). The symptoms 
of PD are wide-ranging, but individuals typically start with motor difficulties including tremor, 
rigidity, bradykinesia and loss of postural reflexes (Montel, 2009). Other physical symptoms 
commonly experienced include excessive saliva and dribbling, urinary urgency and constipation 
(Khoo et al., 2013). These symptoms frequently cause difficulties for an individual to carry out 
daily activities and may contribute to activity limitations (Smith & Shaw, 2017). Furthermore, 
psychological difficulties are also common. The most commonly experienced psychological 
difficulty in PD is depression; although prevalence rates vary between 2 and 67%, the average 
prevalence is about 35% (Reijnders et al., 2008). Anxiety is also frequently experienced and  
substantial anxiety is believed to occur in up to 40% of individuals with PD (Walsh & Bennett, 
2001). Anxiety and depression co-occur quite often and there is evidence to suggest that anxiety 
may cause a significant deterioration in physical symptoms, which may in turn exacerbate 
anxiety (Schneider et al., 2008). Estimates of the prevalence of psychotic symptoms in 
individuals with PD vary from 15 to 52% in those who receive treatment (Schneider et al., 2008). 
In the early stages, psychosis in PD typically occurs with a high level of insight, and 
psychological support can be sufficient in managing symptoms. However, psychotic symptoms 
are typically recurrent and likely to worsen over time, resulting in significant anxiety and 
increasing the likelihood of social and functional impairment (Wint et al., 2004). Additionally, 
apathy occurs in approximately 40% of individuals with PD (Starkstein et al., 2009) and can 
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occur independently of depression and cognitive impairment (Kirsch-Darrow et al., 2006). 
Finally, impulse control disorders (ICDs) are estimated to occur in around 13% of individuals 
and are associated with greater functional impairment in activities of daily living compared with 
those with PD with no ICDs, despite similar symptom severity (Voon et al., 2011). 
 Given the extent of the psychological difficulties of PD, and ample research which 
documents the relationship between psychological difficulties and excess disability, worse 
quality of life, poorer outcomes and increased caregiver burden (Weitraub & Burn, 2011), it is 
essential to better understand the factors which might facilitate an individual’s adjustment to PD. 
Despite growing literature in the area, there is still little consensus on what constitutes 
psychological adjustment, especially with regard to individuals living with a chronic illness. 
Typically, literature has framed the concept as both a state and a process (Hammond & 
Winthrop, 2018). Adjustment as a state can be considered the outcome of an individual adapting 
to their circumstances. Optimal adjustment is when the person manages to balance the 
difficulties of their condition with a good quality of life (Sharpe & Curran, 2006), resulting in 
good physical, cognitive and emotional functioning (Hammond & Winthrop, 2018). The state of 
adjustment is normally defined according to objective measurement such as low negative affect 
and maintaining function, but this may not necessarily reflect subjective considerations of an 
individual (Stanton et al., 2007).  
An alternative conceptualisation is to recognise that adjustment is likely to involve a 
process of adaptation, which is iterative and dynamic, the end goal of which might be to reach 
the state of living well with PD. Defining adjustment as a process enables one to consider the 
idiosyncratic nature of how an individual adapts to a chronic illness, including how this process 
may not be captured by functional outcomes (Moss-Morris, 2013). Considering adjustment as a 
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process acknowledges how adjustment is likely to be condition specific and that the adaptive 
tasks required in adjusting to a condition will vary according to the specific illness challenges. It 
also recognises that the process of adjustment will differ according to specific time points in the 
individual’s journey with their disease. For instance, there is evidence to suggest that physical 
aspects of the disease, such as severity of motor symptoms, may be linked to psychological 
difficulties such as anxiety and depression (Sagna et al., 2014). Physical aspects of the disease 
alongside psychological aspects such as anxiety and stress also decrease an individual’s ability to 
engage in social activity, increasing their social isolation and contributing to depression (Hartley 
et al., 2014). How an individual is able to adjust to their condition is clearly integrated with both 
the physical and psychological aspects of the disease process, and a better understanding of this 
relationship is needed. As such, adjustment in this review was based on the Moss-Morris (2013) 
model of adjustment. This model defines adjustment as the process by which an individual is 
able to return to equilibrium in the face of specific illness triggers (such as when one receives 
their diagnosis or in the case of physical deterioration) or maintain equilibrium in the face of day 
to day illness demands (Moss-Morris, 2013). Equilibrium involves factors such as good illness 
management, positive affect and less illness interference on an individual’s roles and 
relationships (Moss-Morris, 2013).  Adjustment in this sense is a dynamic process, as factors 
which may be successful for adjustment at one stage of disease severity may no longer be 
successful with advancing deterioration. This is especially relevant in PD, given in the latter 
stages motor control and active problem-solving strategies may be rendered impossible by 
worsening of symptoms.   
Consequently, the present review is focused on individual adjustment processes, with the 
research question ‘how do individuals adjust to living with Parkinson’s disease?’ In addressing 
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this question, the current review brings together the qualitative literature on adjustment to PD by 
conducting a meta-synthesis of relevant papers. The need to promote an individual’s adjustment 
to their condition is highlighted by studies which outline the consequences of poor adjustment to 
PD, such a loss of independence and self-esteem, social withdrawal, increasing frustration and 
perceived stigma (Caap-Ahlgren, 2002). Individuals living with PD still have a need for 
preventative interventions which promote an individual’s wellbeing and mitigate further 
deterioration in health (Grady & Gough, 2014), and a better understanding of adjustment in PD 
can help to inform such interventions. Although a diversity of psychological interventions have 
been adopted with people with PD and have evidenced preliminary positive findings of their 
effectiveness (Zarotti et al., 2020), there is a need to focus on factors which support people’s 
adjustment to the condition, rather than just focusing on the reduction of symptoms.   
 
Methods 
A meta-ethnography was chosen because it is an approach which not only synthesises 
information but also seeks to broaden conceptual knowledge, as was the aim of the present 
review (Booth et al., 2016). Meta-ethnography was developed by Noblit and Hare following their 
perceived failure of existing approaches to synthesis to preserve the context of the individual 
studies (Campbell et al., 2011) and their recognition of the importance of this context in shaping 
the findings of a study. The approach of meta-ethnography is therefore informed by an 
interpretive rather than aggregative intent. There are three possible types of relationships that 
guide translation and subsequent synthesis (Campbell et al., 2011). The first of these is 
reciprocal, where studies are translated into one another and overarching metaphors are revealed 
which provide explanatory power for the individual studies. Reciprocal translation can be guided 
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by an interpretive intent, where the goal is to develop novel insight from the metaphors. 
Alternatively, reciprocal translation may instead summarise studies in terms of what the studies 
express (Dixon-Woods et al., 2006). Meta-ethnography adopts the former approach to reciprocal 
translation, as opposed to other forms of qualitative synthesis which are more descriptive in 
nature.  The second type of translation is refutational, where more elaborate translations are 
developed which uncover the relation between the main accounts of a study and competing 
explanations. Finally, line of argument synthesis involves uncovering the larger inference which 
is implicitly conveyed in the studies but is not explicitly stated i.e. identifying the full picture 
from the individual pieces.  
Conducting the meta-synthesis followed the seven-step process detailed by Noblit and 
Hare (1988). These are as follows: getting started, deciding what is relevant to the initial interest, 
reading the studies, determining how the studies are related, translating the studies into one 
another, synthesising translations and expressing the synthesis 
Identifying relevant papers 
The first stage of the meta-synthesis was ‘getting started’, which involved exploring the 
existing literature on individuals living with PD, to determine the suitability of an article focused 
on adjustment processes. This indicated the need for a review focused on adjustment specifically, 
which could bring together the existing literature on experiences of PD more generally. The next 
stage involved identifying the relevant focus of the review. This was determined following 
scoping searches of literature relating to PD and to adjustment in chronic illness more widely. 
Following this, relevant papers were identified by searching three databases: MEDLINE 
Complete, CINAHL and PsycINFO. Following guidance from an academic librarian, the search 
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involved three areas: (1) qualitative approaches, (2) adjustment and (3) Parkinson’s disease. 
Details of the free text terms and subject headings used in each database can be seen in Table 1. 
[Table 1 here] 
 
Inclusion/exclusion criteria 
Inclusion criteria for papers to be selected were: (1) used a qualitative approach to data 
collection (i.e. an approach which aimed to understand people's beliefs, experiences or attitudes 
and generated non-numerical data (Pathak et al., 2013)), (2) peer-reviewed, (3) focused on the 
experience of the individual with PD rather than a caregiver, and (4) at least one major theme (or 
concept) focused on the process of adjustment. Exclusion criteria were: (1) focused on 
adjustment after deep brain stimulation (DBS), (2) a comparative or dyadic study where the 
experiences of the individual with PD could not be clearly extracted, (3) focused on adjustment 
of aspects not specific to the condition e.g. coping with menstruation in individuals with PD 
(Tolson et al., 2002) and (4) the focus was predominantly on barriers to optimal adjustment. 
Search results 
During the search 1761 articles were identified, of which 904 were duplicates. The remaining 
papers were appraised for relevance based on the title and abstract. 807 were excluded because 
they were unrelated to the research question or not meeting eligibility criteria. 51 papers were 
accessed in full, either because the abstract suggested potential relevance to the research question 
or because there was insufficient information to exclude them based on eligibility criteria. From 
these 51 papers, 31 were excluded; 17 did not meet the inclusion criteria and 14 met exclusion 
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criteria. This resulted in 20 articles identified as being of relevance for inclusion in the review. 
See Figure 1 for details of this process. 
[Figure 1 here] 
Study Characteristics 
 Studies were conducted between 2002 and 2019. 14 studies were conducted in Europe, 
(including the UK, Nethelands, Spain, Sweden and Estonia) and six in the USA. Participants 
were all people with PD or people with PD; in total the review collates data from 458 
individuals, with individual study sample sizes ranging from 6 to 85. PD disease severity as 
categories by Hoehn & Yahr disease stages ranged from 1-5, with the majority of participants 
falling within 1-3 on the disease stage spectrum. ll studies used semi-structured interviews to 
collect the data and analysis included thematic analysis, grounded theory, interpretative 
phenomenological analysis and content analysis.  
Quality of the selected studies 
The quality of a meta-synthesis is somewhat dependent upon the quality of the selected 
studies, thus assessing the quality of the studies is important.  Furthermore, evaluating the 
methodological quality of a study is essential to determine the relevance of the findings for 
clinical practice (Harrison et al., 2017). However, rather than being constrained by the quality of 
the data in the studies, a meta-ethnography seeks to generate understanding which is not 
preconditioned by the nature of quality judgments of a single study (Booth et al., 2016). As such, 
the Critical Appraisal Skills Programme (CASP) checklist was used to support critical 
engagement with the studies but not used to exclude any individual studies.  The CASP checklist 
enables researchers to assess the trustworthiness, relevance and results of published papers and is 
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widely used in clinical research (CASP, 2019). Assessing the quality of the papers using this 
checklist involved identifying the standard of methodological reporting and study robustness and 
focused on three key areas; validity of the research, rigour of the findings, and utility of the 
results. Studies were assessed based on eight appraisal questions and each question was given a 
score of 1-3 according to the amount of evidence provided, with a total possible score of 24. 
CASP scores ranged from 14-22, with the majority of papers scoring between 17-22. Higher 
quality articles typically gave a more thorough description of the data collection and analysis 
process and produced a more detailed account of their consideration of the ethical issues. 
Considering the final themes, each sub-theme was present in at least two of the three strongest 
papers and thus no subtheme depended solely on the weaker papers. How the papers were 
evaluated with respect to the CASP tool and the eight appraisal questions used are detailed in 
Table 2.  
[Table 2 here] 
Analysis 
In a meta-ethnography, different levels of interpretation provide weight to the eventual 
findings, based on Schütz’ concept of first and second order constructs (Schütz’, 1962). First 
order constructs reflect the participants’ interpretations to the original questions asked within a 
single study. Second order constructs reflect the authors’ interpretations of the participants’ 
responses. Finally, third order constructs reflect the researcher’s interpretations of the original 
authors’ interpretations. A meta-ethnographic approach rests upon these third order constructs, 
which allows for an interpretative account of the shared concepts in adjustment rather than 
merely combining themes together. Each paper was read and annotated in detail, with key 
concepts drawn out for each paper, reflective of Schütz’ second order constructs. Key concepts 
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were translated into a table and the papers which contained each concept were noted; this is 
detailed in Table 4 of the Appendix. Consideration was also given to divergent concepts and how 
these might reflect either aspects of the concept which were difficult for some individuals to 
achieve e.g. acceptance, or how a broader definition of the concept might capture such 
refutations. The key concepts were then synthesised to generate three key themes, the third order 
constructs, which felt to capture the important aspects of individuals’ experience. How the 
concepts in each paper contribute to aspects of each theme is detailed in Table 3. Discussing 
these concepts with two supervisors helped to maintain the quality of the original findings and 
uphold methodological rigour (Thomas & Harden, 2008).    
[Table 3 here] 
Reflexivity 
A meta-ethnography extends beyond the original interpretations of the author, which 
gives rise to potential biases from the researcher’s own position. Nevertheless, despite its 
interpretative roots, a meta-ethnography must always be grounded in the data reported by the 
primary studies (Dixon-Woods et al., 2005). Since researcher preconceptions will always 
influence how data are gathered, interpreted, and presented (Tufford & Newman, 2012), the 
primary researcher regularly consulted with two supervisors. This enabled the researcher’s 
subjectivity to be explored for its meaning and relevance and helped to minimise the potential for 
bias (Elliott et al., 2012).  
 
Findings 
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In synthesising the 20 papers, three main themes relating to how individuals adjust to 
living with PD were constructed: (1) maintaining a coherent sense of self, (2) feeling in control 
and (3) holding a positive mindset. These three themes are described in detail below. 
Maintaining a coherent sense of self 
Maintaining a coherent sense of self felt to be important for individuals to adjust to the 
challenges of PD and to accommodate changes where necessary. There appeared a temporal 
dimension to this process. The early stages of the illness involved an individual’s initial 
recognition of the chronicity of their illness and what it meant for their identity. Individual 
responses were often aimed at preserving aspects of their pre-illness self, with the support of 
friends and family being crucial in this, in supporting them to do the activities they had always 
done and in encouraging them to retain valued roles. In later stages of the illness, given ongoing 
deterioration in physical and mental ability, it was often not possible to maintain many aspects of 
their pre-illness identity. Here, acceptance provided the context for reshaping one’s identity to 
incorporate the illness, in order to allow for positive self-evaluation and maintaining a coherent 
sense of self in the face of progressive deterioration. 
Support from friends and family. 
The support from friends and family was important in helping an individual to retain a valued 
social identity and maintain a coherent sense of self, finding the aspects of themselves which 
may initially have been lost following physical deterioration: “....with the help of caring and 
supportive family members, a few special friends, doctors and my husband I have been back to 
moving and finding my groove” (Gardenhire et al., 2019, p1786). 
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Despite some deterioration in their physical ability, family members enabled an 
individual to continue valued activity, reinforcing the coherence of their sense of self rather than 
someone whose identity had changed as a result of the diagnosis (Navarta-Sanchez et al., 2017; 
Kang & Ellis-Hill, 2015). Furthermore, by helping individuals with practical aspects of the 
condition such as daily planning or cooking, partners helped individuals with PD to maintain 
independence in the activities which mattered most (Gardenhire et al., 2019; Uebelacker et al., 
2014; Lutz et al., 2018). Individuals were determined to maintain their usual activities as far as 
possible even when this conflicted doctors’ advice about expected behaviours, only adjusting 
their behaviour when their habitual activities were no longer working for them (Lubi et al., 
2019). Although negotiating the role in the family was often necessary (Habermann, 1996), 
focusing on the continuity of these relationships allowed an individual to maintain who they 
wanted to be (Sperens et al., 2018; Williams & Keady, 2008; Habermann, 1996).  
Support groups were one forum where an individual gained friendship which encouraged 
a coherent sense of self. Coherence was provided by opportunities which allowed individuals to 
reinforce and confirm the experiences of themselves which mattered, such as through 
participation in enriching activity and offering reciprocal support (Sperens et al., 2018; Berard & 
Smith, 2019; Gardenhire et al., 2019):  
In helping others find theirs, I have created a purpose for myself and the amazing thing is 
I found that I began to enjoy life more! It was not just a service for others; it became a 
pathway to regain my lost dignity and optimism, and sense of value as a person 
(Gardenhire et al., 2019 p1788).  
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Despite disruption to their sense of self as a result of the illness, individuals were able to re-
establish coherence by providing support to others and maintaining purpose and valued social 
activity.  
Acceptance. 
Where an individual’s pre-illness self-image was no longer congruent with PD related changes, 
acceptance of the diagnosis and illness limitations was required to adjust to their condition. This 
allowed individuals to maintain a coherent sense of self despite alterations in their identity. The 
diagnosis for many was perceived as an emotional force which changed their identity and 
challenged fundamental aspects of themselves (Vann-Ward et al., 2017). Individuals faced a 
major challenge of moving from being overwhelmed to acknowledging the illness as their own 
(Habermann, 1996). In order to accept the disease, individuals described going through many 
different emotions from initial denial, through to sadness and anger, before eventually allowing 
themselves to be hopeful for their new future (Hellqvist et al., 2018; Nazzal & Khalil, 2017; 
Habermann, 1996). The process culminated in a shift in how they thought about their diagnosis, 
from having to adjust to living with a diagnosis they did not want, to a situation in which they 
were able hold an optimistic outlook and feel a sense of mastery in living with PD (Gardenhire et 
al., 2019; Lutz et al., 2018).  
For many individuals, acceptance involved modifying their expectations of what they were 
able to do, incorporating their disease related limitations into an identity which accommodated 
illness changes. The metaphor ‘like a bird with a broken wing’ highlights how participants 
accepted the things they were no longer able to do in order to adapt to the newfound 
circumstances (Smith & Shaw, 2017). There was an ongoing tension between preserving their 
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current sense of self and releasing aspects of the former self (Stanley-Hermanns & Engebretson, 
2010; Lutz et al., 2018) in order to adjust to a self which integrated ‘the broken wing’. Although 
aspects of their self might change, participants who had adjusted were able to build on past 
relationships and events to maintain coherence in their sense of self, integrating the PD into an 
altered understanding of the self (Williams & Keady; Vann-Ward, 2017). This acceptance 
facilitated proactive coping, such as through using mobility devices and making necessary 
adaptations to their activities, thus enabling continued social engagement alongside the ability to 
optimise care (Smith & Shaw, 2017; Lubi, 2019; Vann-Ward et al., 2017). By continuing to 
adapt their activities to allow for sustained wellbeing and activity participation, individuals were 
able to redefine themselves in relation to their impairments and activity limitations (Eriksson & 
Ahlgren, 2013; Vann-Ward et al., 2017; Lutz et al., 2018).  
Support groups for individuals with PD also helped individuals to accept a sense of self 
which incorporated the illness and offered a forum for individuals to normalise their situation 
and feel validated in their illness experiences (Charlton & Barrow, 2002; Smith & Shaw, 2017; 
Stanley-Hermanns & Engebretson, 2010; Lutz et al., 2018). Having the opportunity to talk to 
others in a similar situation helped individuals to reduce disease related distress and to value an 
identity which incorporated their PD diagnosis (Uebelacker et al., 2014; Charlton & Barrow, 
2002; Hellqvist et al., 2018).   
Feeling in control 
Feeling in control helped individuals to retain a sense of agency despite the illness 
limitations. Undertaking self-management of their condition was one way in which individuals 
gained back a sense of control while living with PD. In order to feel able to self-manage their 
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condition, information and resources were necessary to provide individuals with the required 
knowledge and expertise. 
Self-management. 
Feeling able to self-manage care was an important component of feeling in control.  Learning 
self-management techniques helped an individual to feel they had a greater understanding of 
their situation and thus strengthened feelings of being control: 
…and this education as a whole has helped me to take on my illness in a more powerful 
way. Maybe it’s because I’m relatively newly diagnosed…for me…this education gave 
me hands-on tangible things to do for myself. That felt good for me. (Hellqvist et al., 
2018, p3723). 
 
Feeling in control and of owning responsibility for management of symptoms were 
stressed as important across many of the studies (Soundy et al., 2019; Smith & Shaw, 2017; den 
Oudsten et al., 2011; Vann-Ward et al., 2017). When primary control of PD is not possible given 
the unknown and fluctuating course of the disease, feelings of secondary control (i.e. the ability 
to control the psychological impact of circumstances) were important to maintain some sense of 
self-efficacy. Even previously mundane tasks such as maintaining the physical environment were 
described as valued tasks in helping to occupy individuals in a way which contributed to their 
feelings of self-efficacy: “Taking care of the house keeps me busy, I enjoy doing woodwork and 
there is always something to attend to” (Sperens et al, 2018 p705). 
In many of the studies, individuals with PD actively monitored their health in order to 
tailor the management of their symptoms (Vann-Ward et al., 2017; Hellqvist et al., 2018).  
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Regarding medication, individuals made independent decisions about how and when to take 
prescribed and non-prescribed medications, often listening to their body in order to determine 
medication needs (Vann-Ward et al., 2017; Stanley-Hermanns & Engebretson, 2010; Williams & 
Keady, 2008; Habermann, 1996). Listening to the body often resulted in confrontation with the 
limits of formal knowledge and the acknowledgement that the person knew best in managing 
their condition. Medication helped individuals to stabilise their symptoms and maintain 
independence (Williams & Keady, 2008; Sperens et al., 2018), allowing individuals to feel 
‘master of [their] own fate’ (Plouvier et al., 2018 p141). Despite being an external way of 
managing physical symptoms, taking medication allowed individuals to feel they had control 
over their condition and gave them agency in practical aspects such as dosage, timing and the 
management of side effects (Habermann, 1996). 
It was often through physical activity where an individual first became motivated to be 
proactive at taking care of their own health (Soundy et al., 2019; Uebelacker et al., 2014; Sperens 
et al., 2018). Some individuals described how being motivated to exercise was something which 
came naturally, as physical activity was something they had always enjoyed (Soundy et al., 
2019; Hellqvist et al., 2018; Lutz et al., 2018). Others described dedicating time to exercise as 
more of a conscious effort, deliberately chosen because of its effects on their physical and mental 
wellbeing (Eriksson et al., 2013; Lubi, 2019; Kang & Ellis-Hill, 2015; Habermann, 1996). 
Engagement in physical activity and exercise classes was seen by these individuals as a way to 
challenge themselves and to be the active agent in maintaining their health (Kang & Hill, 2015; 
Williams & Keady, 2008; Nazzal & Khalil, 2017).  
Information and resources. 
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Information and resources were important for individuals to feel in control of their condition. 
Individuals reported how information about the medical aspects of PD were particularly useful in 
helping them to feel in control of their care (Sperens et al., 2018; Navarta-Sanchez et al., 2017; 
Soundy et al., 2019; Nazzal & Khalil, 2017).  Unfortunately, even in later studies, individuals 
still reported they often received little information from their healthcare professional or received 
information which was delivered without due regard for the impact which disclosure might have 
on the individual (Plouvier et al., 2018; Shaw & Schmidt, 2017; Habermann, 1996). 
Furthermore, lack of knowledge about the disease and its symptoms had forced some to conduct 
autonomous searches for information and try alternative solutions, to satisfy their “need to 
know” (Habermann, 1996 p. 404). Limitations of a service such as having insufficient resources 
and lack of professionals’ time were reported as making it difficult to ask the right questions, 
leading to concerns remaining unanswered and decreasing agency (Lubi, 2019; Nazzal & Khalil, 
2017). The progressive and fluctuating course of the disease, experienced differently in every 
individual, could create mystery and uncertainty which may be amplified by lack of knowledge 
(Smith & Shaw, 2017; Habermann, 1996).  
In contrast, participants who received regular contact from healthcare professionals really 
valued the support that was offered, describing it as sensitive to their needs and making them feel 
able to manage their condition (Hellqvist et al., 2018). Sufficient knowledge of- and education 
about- the disease could facilitate anticipation of change and could help individuals to feel more 
in control of their condition (Plouvier et al., 2018; Navarta-Sanchez et al., 2017; Lubi, 2019; 
Sperens et al., 2018). This sense of agency was important in helping individuals to feel better 
able to overcome the barriers of PD (Smith & Shaw, 2017). In empowering individuals to self-
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manage their condition, many individuals agreed that resources from healthcare professionals 
helped them to feel more capable of adjusting to PD (Navarta‐Sánchez et al., 2017).  
 
Theme 3: Holding a positive mindset 
Having a positive attitude enabled individuals to experience positive wellbeing despite 
the challenges raised by their condition. Social comparison-both upward (looking to others 
functioning better than oneself) and downward (reflecting on the worse situation of others) 
helped individuals to reflect on their ability to cope. A related concept, gratitude, helped 
individuals to value the things which they appreciated in their life.  
Social comparison. 
The ability to make both upward and downward positive social comparisons seemed to be 
important in helping individuals with PD to achieve a positive mindset. Self-help support groups 
were one environment whereby individuals had the opportunity to make social comparisons 
(Gardenhire et al., 2019; Charlton & Barrow, 2002; Sperens et al., 2018). Members of self-help 
groups were able to utilize the experience of peers to make a positive downward social 
comparison and reflect on their relatively good fortune (Charlton & Barrow, 2002; Hellqvist et 
al., 2018). Downward social comparisons were reflected in statements such as “There is always 
someone worse off than me” (Hellqvist et al., 2018, p3725). For many, reflecting on the worse 
situation of others could help to keep their own situation in perspective and facilitate emotional 
coping (Lutz et al., 2018). Strengthening self-image through downward social comparisons 
allowed individuals to adjust to their own situation and was experienced regardless of their own 
degree of impairment (Hellqvist et al., 2018; Eriksson & Ahlgren, 2013).  
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Participants were also able to make positive upward social comparisons to find 
inspiration and optimism from well adapted peers who had experienced PD for significantly 
longer duration (Charlton & Barrow, 2002; Soundy et al., 2019). By gaining inspiration from 
others who were coping well, broadening knowledge of PD management or 
heightening gratitude of their current functioning, social comparison helped individuals to 
maintain positivity (Soundy et al., 2019). This positivity translated into individuals perceiving 
their future as possible (Soundy et al., 2019; Gardenhire et al., 2019), with individuals realising 
that illness changes could be managed observing the positive and encouraging outcomes of peers 
(Soundy et al., 2019).  
 
Gratitude. 
In many of the studies, participants described how having gratitude helped them to maintain a 
positive mindset and facilitated their adjustment to the PD (den Oudsten et al., 2011; Lutz et al., 
2018). Having gratitude for present functioning facilitated the ability to place high value on the 
activities participants were still able to do, which translated into individuals feeling less burdened 
by their activity limitations (den Oudsten et al., 2011; Stanley-Hermanns & Engebretson, 2010). 
In the early stages of disease progression, individuals could be grateful that their body in some 
aspects functioned “normally”, and thus reflect upon how they were still themselves despite the 
PD (Eriksson et al., 2013; Kang & Ellis-Hill, 2015; Stanley-Hermanns & Engebretson, 2010). 
Even experiences of tiredness and sweating when exercising or being active were considered 
positive, and were longed for, since they meant expressions of a healthy body (Eriksson et al., 
2013). It also helped individuals to remain active in society, which they described as contributing 
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to feelings of being useful and maintaining high levels of self-worth (Kang & Ellis-Hill, 2015; 
Williams & Keady, 2008). 
Gratitude for friends and family was also described in many individuals’ accounts. For 
instance, kinship and sense of belonging were important sources of wellbeing and helped an 
individual with PD to reflect on the valued relationships they had despite the changes brought on 
by the diagnosis (Williams & Keady, 2008; Vann-Ward et al., 2017).  As one individual 
reflected on how their relationship with their partner had changed since diagnosis: “I mean we 
sort of found out that our feelings for each other had multiplied. We’ve got a lot more time for 
each other” (Smith & Shaw 2017, p18). 
 Gratitude for the present seemed to be a way in which individuals were able to live life to 
the full despite the challenges faced living with PD. Many of the individuals described the 
importance of acknowledging that their future was likely to be associated with symptom 
deterioration and reduced life expectancy, and the need therefore to live in the present with 
renewed energy and determination (Charlton & Barrow, 2002; Williams & Keady, 2008; Vann-
Ward et al., 2017). This renewed energy led participants to take up desired opportunities in the 
present and not the future, thereby leading to the sense that they were embracing the present 
(Smith & Shaw, 2017; Williams & Keady, 2008; Vann-Ward et al., 2017). By living for each 
day, their present became more manageable and they were able to be grateful for the things they 
could still achieve. For some individuals, gratitude and positive thinking felt to be part of their 
personality and a natural process, whereas for others it was more of a conscious strategy or 
through sense of obligation (Sperens et al., 2018). Many individuals experienced negative 
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reactions to the initial diagnosis of PD (Shaw & Schmidt, 2017), but gratitude helped an 
individual to navigate their path to finding an optimistic perspective (Gardenhire et al., 2019).  
 
Discussion 
The present review describes how, for many individuals, PD is experienced as a threat to 
their self-identity, thus maintaining a coherent sense of self was a key adaptive task in adjusting 
to their condition. This is in line with the Moss-Morris model of adjustment (2013) whereby 
critical events in an illness experience (such as the diagnosis or initial symptoms), alongside 
ongoing illness stressors, disrupt emotional equilibrium and quality of life. The goal of 
adjustment is to return to equilibrium, thereby reducing the impact of the illness on everyday life. 
However, the present review describes how maintaining a coherent sense of self did not just 
involve a restoration of an individual’s previous sense of self, as assumed in the aforementioned 
model, but also involved altering their sense of self to integrate the PD. This suggests that rather 
than restore equilibrium or return to previous assumptions, individuals living with a progressive 
condition need to alter their equilibrium to accommodate illness changes. As reflected upon by 
Frank (1995), the onset of illness disrupts our life narrative and the old maps which once guided 
us, and new maps need to be developed to navigate this new territory.  Williams’ (1984) 
describes how reconstructing an identity narrative helps an individual to understand the illness in 
terms of their past experiences and to reaffirm their sense of self as one of purpose and meaning. 
For individuals living with chronic fatigue syndrome, reconstructing an identity narrative has 
been shown to be a powerful way in which individuals make sense of their illness and in 
providing opportunities to connect with other individuals with similar illness narratives (Bulow, 
2004). In placing the experience of chronic illness within the framework of their life history, an 
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individual can find meaning to the events which have disrupted and changed their identity 
(Williams, 1984) and re-establish their relationship between their self, the world and their body 
(Bury, 1982). The ability of an individual to reconstruct a narrative which integrates their illness 
experience allows an individual to maintain a coherent sense of self, assumed to be key to 
psychological health (Reese et al., 2011).  In developing a sense of self which not only 
incorporates but is enriched by their illness experience, individuals may be better able to adjust 
to their condition. 
In order to alter their equilibrium to accommodate illness changes, individuals described 
the importance of gaining a sense of control over the management of their condition. Having a 
sense of control has consistently been linked to good psychological and physical adjustment to 
chronic illness (Taylor et al., 2000). Gaining control over symptoms through self-management 
(primary control) allowed individuals to feel more in control of their life and better able to adapt 
to disease related limitations (secondary control). This felt important given the uncontrollable 
nature of disease progression. Both increased perceptions of primary control (Pape & Kim, 2002; 
Krakow et al, 1999) and secondary control (McQuillen et al., 2003) have previously been 
associated with greater wellbeing and psychological adjustment in individuals with PD. Even if 
control of disease may not be possible, global life control and feelings of self-efficacy rather than 
control over the disease per se can also be important (Eccles & Simpson, 2011). Indeed, in one 
study investigating perceptions of cause and control in individuals with PD (Eccles et al., 2011), 
knowledge of aetiology and underlying physiological processes of PD did not contribute to a 
perception of control, although knowledge supporting management techniques was perceived as 
helpful. Whether knowledge of the disease contributes to a perception of control is likely to 
depend upon the individual and the meaning which potential knowledge has for them; including 
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whether it is congruent with their own understanding. Self-management processes can thus be 
understood as an ongoing negotiation between different perspectives, including own perspectives 
vs medical advice, present wellbeing vs future health and routines required in self-management 
vs being free (Audulv et al., 2009). Where individuals experience aspects of the negotiation 
process as complementary to one another, determining the course of self-management is 
unproblematic. In contrast, where individuals experience incompatibilities between advice given 
about self‐management behaviours and individual needs or preferences, individuals may 
experience a kind of inner conflict, reflecting a tension between what an individual wants to do 
and what they experience that they should do (Bazerman et al., 1998). This highlights the 
importance of ensuring that information and knowledge related to self-management is tailored to 
an individual’s understanding and experience of the disease.  
In line with the Moss-Morris model (2013), cognitive factors including gratitude and 
social comparison were important components for individuals living with PD to hold a positive 
mindset despite continuing deterioration. In comparing themselves with others and experiencing 
gratitude for the things one appreciated in life, individuals seemed able to come to terms with 
their condition. For many, reaching a place of optimism involved a series of emotional stages 
including shock, denial and anger (Gardenhire et al., 2019), situating it as a similar process to 
that of bereavement. This process of adaptation may be a healthy way in which an individual 
grieves for the person they once were (Reynolds & Prior, 2003). In making space for and 
allowing oneself to experience and share negative emotional experiences with others, individuals 
with chronic illness may be better able to self-regulate emotions (de Ridder et al., 2008). The 
ability to hold a positive mindset alongside co-existence of positive and negative emotions is 
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likely to facilitate an optimistic outlook in the face of adversity and adjustment to the challenges 
imposed by their condition (Tedeschi & Calhoun, 2004). 
Clinical implications   
In the present study, maintaining a coherent sense of self was described as an important 
factor in adjusting to living with PD. Where an individual is unable to find meaning, purpose or 
personal efficacy, psychological interventions which are biographically informed have been 
shown to help people with chronic illness to retain their pre-diagnosis identities where possible 
but also to develop new identities which accommodate illness changes (Hubbard et al., 2010). 
Biographically informed interventions involve identifying the roles which an individual valued 
prior to their illness and supporting them to develop ways in which they can adapt these activities 
to continue valued social activity (Bury, 2001). When individuals are given the appropriate level 
of support which allows them to maintain a coherent sense of self, they may experience an 
enhanced sense of responsibility over their illness (Pierce et al., 2003) requiring less input in the 
future from medical and psychological professionals. The implications of less professional input 
and increased empowerment are not only financially beneficial for health services but also helps 
enhance individual wellbeing and quality of life. It is essential that any intervention appropriately 
considers the point at which an individual is at in their adjustment journey, in order to offer 
support which helps them to adapt to a self which has changed. 
Feelings of being in control were important for individuals to adjust to living with PD, 
with information and resources being key to facilitating the participants’ perceptions of control. 
Consistency in the information provided by healthcare professionals is important to minimise 
distress related to confusion about their symptoms and to heighten individual’s self-efficacy in 
their ability to manage their condition. Several of the studies highlighted incidences where 
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individuals had felt information had been delivered insensitively or without due regard to an 
individual’s preference in the timing or setting for the delivery. Individuals described being 
informed of their diagnosis in non-private settings or in an abrupt and impersonal manner (Shaw 
& Schmidt, 2017). This may reflect the complexity of providing the right information at the right 
time (Eijk et al., 2015) or reflect clinician’s guilt about their inability to provide a medical 
treatment or cure, thus affecting their consideration of appropriate manner and timing of delivery 
(Schrag et al., 2018). Nonetheless it is concerning, given the importance of individuals feeling 
empowered through professional support to self-manage their care. Where professionals deliver 
recommendations without recourse to an individual’s practical understandings or idiosyncratic 
needs, individuals may feel forced into adopting habits they are not ready to adopt and available 
solutions can be unsettling (Lubi et al., 2019). Instead, an integrated approach including the 
individual with PD in any decision making is likely to help individuals to feel more like a partner 
and is considered the best way to manage PD (Post et al., 2011). This integrated approach would 
ensure that the provision of information is tailored to the needs of the individual so that they feel 
able to make good decisions about their current and future care (Shaw & Schmidt, 2017). Early 
intervention incorporating psychoeducation about the management of symptoms is key to 
heightening feelings of control and facilitating adjustment to PD. 
Participants across the studies spoke of the need to not dwell on their future deterioration 
but instead to embrace their present with renewed purpose, such that mindfulness-based 
cognitive therapy (MBCT) may be an effective intervention. MBCT typically takes places over 8 
weeks and teaches participants to become more aware of their present thoughts and feelings. It 
also encourages a more detached relationship with these thoughts and feelings, rather than 
viewing them as accurate representations of the self or reality (Batink et al., 2013). In developing 
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a detached perspective to difficult thoughts and feelings which may arise from living with PD, an 
individual may be less likely to experience the difficult thoughts as a reflection of their inability 
to cope and more able to fully engage with their present. Preliminary evidence suggests the 
experience of mindfulness can help individuals to access inner resources and reaffirm their 
existing coping ability, enabling them to confront previously avoided social situations and to 
have more confidence in their ability to self-manage situations which they may have previously 
avoided (Fitzpatrick et al., 2010). Facilitating this self-management and encouraging individuals 
to fully engage with their present experience may provide a protective mindset against PD 
related challenges and an acceptance of the feelings or emotions of having PD. In encouraging 
individuals to focus on their present and enhancing existing coping ability, MBCT may help 
individuals to adjust to their condition. 
An important theme across individual accounts was that optimal adjustment relates to 
embracing positive living despite a readjusted state of health, and healthcare professionals need 
to support an individual to accept this readjusted state wherever possible. Interventions based on 
acceptance and commitment therapy (ACT: Hayes & Storsahl, 2011) may help individuals to 
develop acceptance to the changes which PD brings. Acceptance is a stance an individual adopts 
rather than a process of coping and enables an individual to pursue a life in accordance with their 
values, despite the limitations imposed by their illness (Chan, 2013). ACT encourages this 
accepting stance through techniques such as cognitive defusion, which help an individual to 
detach from difficult thoughts and in doing so develop more flexible ways of responding to 
challenging situations (Hayes & Storsahl, 2011). In developing more flexible responses, 
individuals are supported to lead a meaningful life despite the continual challenges which PD 
presents. It is likely that any ACT protocol would need to accommodate the neuropsychological 
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profile of PD, where deficits in attention and executive control are common, and may lead to 
deficits in managing the demands of complex processing tasks (Foley et al., 2019), such as 
defusing from difficult thoughts. Although there is little evidence for the efficacy of ACT in PD 
populations, there is evidence that ACT may be effective in conditions such as MS, where 
greater acceptance of the condition (according to ACT principles) was found to relate to better 
adjustment (Pakenham & Fleming (2011). Furthermore, a recent intervention utilizing a trans-
diagnostic approach for individuals with chronic illness has highlighted the effectiveness of ACT 
principles in reducing psychological distress, reducing physical limitations, and increasing 
valued behaviour (Brassington et al., 2016). This effect was seen despite the individuals’ 
evaluation of their health changes remaining the same. It is important that the effectiveness of the 
intervention was independent of the evaluation of health status, given that the progressive nature 
of PD means that an individual’s health status is likely to continually deteriorate. The efficacy of 
ACT based interventions in other chronic illnesses highlights its potential efficacy in supporting 
individuals with PD to adjust to their condition.  
Limitations and future research 
Conducting a meta-ethnography largely ensures that the experiences of the participants’ 
in the individual studies are preserved (Britten et al., 2002). Nevertheless, the synthesizing of 
multiple studies meant that some of the individual experiences may have been lost. For instance, 
nuances in adjustment which may have reflected differences in disease duration, extent of 
symptoms and disease severity of individual participants were not considered in depth. 
Furthermore, the majority of the studies included individuals with PD of either low or medium 
severity. Although some studies included participants with PD of high severity, it is likely that 
these participants represent those individuals who are functioning relatively well despite the 
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severity of their condition. Although recruiting individuals with high severity PD is challenging, 
reflective of both the physical and cognitive aspects of severe PD which would make research 
contribution more difficult, future research should aim to explore how adjustment might differ in 
the more advanced stages of the disease. An additional avenue for future research would be to 
study the experience of individuals with PD who additionally experience cognitive impairment. 
Although not discussed in detail in the present synthesis it is nevertheless an important aspect to 
consider. It may be expected that cognitive changes would limit an individual’s ability to flexibly 
adapt their sense of self and to adopt self-management skills, with consequent implications on an 
individual’s ability to adjust to their condition. 
The characteristics of the included studies, in being all located in Western countries, 
means the findings are biased towards experiences of Western cultures and healthcare systems. 
Consequently, future research should explore the experiences of adjustment for individuals living 
with PD in non-Western countries. Furthermore, there is evidence to suggest that developing 
countries experience greater disease burden from chronic illness (Murray & Lopez, 2013), 
evidencing the need to understand and support individuals living with a chronic illness to adjust 
to and self-manage their illness.  
Conclusion 
Findings from this review indicate the need for individuals to maintain a stable sense of self and 
feel in control, in spite of illness related deterioration. Having a positive mindset was also 
important in helping individuals to experience positive wellbeing. Understanding how an 
individual adapts to living with a chronic illness is important not only to better understand the 
full implications of the condition but also so we are better able to offer early intervention for 
individuals who are finding adjustment difficult. Empowering individuals to self-manage their 
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Table 1: Table displaying the search strategy and the terms used for each database 



















(388 results)  
 “interview” OR “thematic 
analysis” OR “phenomenol*” 
OR “narrative” OR “focus 
group” OR “discourse 
analysis” OR “grounded 
theor*” OR “content analysis” 
OR “hermeneutic*” OR 
“heuristic*” OR “experience” 















“resilience”   
  
DE "Adjustment" 
OR  DE "Resilience 
(Psychological)" 
OR  DE "Adaptability 
(Personality)"  OR  DE 
"Self-Management"  




As above   MH "Qualitative 
Research"  
















As above  MH "Qualitative 
Studies"  
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High= 22-24)  
Soundy 2 3 3 3 3 3 3 2 High 
Uebelacker 1  2 2 2 2 1 2 2 Low 
Plouvier 3 2 3 3 2 3 3 2 High 
Shaw 2 2 2 1 1 2 2 2 Low 
Charlton 2 3 2 1 3 1 3 3 Medium 
Lutz 3 3 3 1 3 3 3 3 High 
Navarta-
Sanchez 
1 3 2 2 3 3 3 3 High 
Hellqvist 1 2 2 2 1 3 3 3 Medium 
Smith 2 1 2 1 1 3 3 2 Medium 
Gardenhire 3 3 2 3 3 2 3 3 High 
Sperens 3 2 3 1 2 3 3 2 High 
Den 
Oudsten 
1 2 2 3 3 1 2 2 Medium 
Eriksson 3 2 3 2 0 3 2 2 Medium 
Kang 2 1 3 3 2 3 3 2 High 
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Lubi 2 3 1 1 2 1 2 3 Medium 
Nazzal 3 1 2 1 2 3 2 3 Medium 
Vann-Ward 3 3 3 2 2 1 3 3 High 
Stanley-
Hermanns 
3 3 2 2 3 3 3 3 High 
Williams 3 2 2 1 2 1 3 3 Medium 
Habermann 3 2 2 2 2 2 3 2 Medium 
 
* CASP questions 
Research Design  Was the research design appropriate to address the aims of the research? 
Sampling  Was the recruitment strategy appropriate to the aims of the research? 
Data collection  Was the data collected in a way that addressed the research issue? 
Reflexivity  Has the relationship between researcher and participants been adequately considered? 
Ethical Issues  Have ethical issues been taken into consideration? 
Data analysis  Was the data analysis sufficiently rigorous? 
Findings  Is there a clear statement of findings? 
Value of research  How valuable is the research? 
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ble 3: Characteristics of the studies included for the synthesis 
First 
author 
Year Country Study Aim Participants Data 
collection 
Data analysis 
Soundy 2019 Oxford, UK To consider the impact 
of providing the First 
Steps program on the 
stories of people with 
Parkinson's Disease 
(PD) and to investigate 
the mechanisms which 
may explain this 
impact 
 
40 participants; 18 from 
the intervention group 
and 22 from the active 
control group 
16 female and 24 male. 
Mean age 66.7 years. 






Narrative analysis to 
consider the impact of 
the program. Thematic 
analysis to consider the 
established psychosocial 
mechanisms of impact  
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To identify and 
understand potential 
issues of importance to 
individuals with PDs 
when coping with 
Parkinson's Disease. 
75 individuals with PD 
who were participating 
in a Movement 
Disorders Program. 43 
male, 32 female. Aged 
47-88. Length of PD 0-
18 yrs.  Hoehn & Yahr 




Qualitative data analysis 
Plouvier 2018 Nijmegen, 
The 
Netherlands 
To explore PD 
individuals with PDs' 
coping with care 
changes 
16 people with PD (11 
male, 5 female). Aged 
58-79.  Hoehn & Yahr 






Inductive approach to 
comparative content 
analysis 
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Shaw 2017 North 
Yorkshire, 
UK 
To investigate the 
current ethical issues in 
relation to recognizing 
and managing 
Parkinson disease (PD) 
from the individuals 
with PD's perspective 
12 individuals with PDs 
living with PD who 
were from the medical 
school's Individuals with 
PDs as Educators 
program. 5 female, 7 
male. Aged 51-86. 
Length of PD 11mths-








Charlton 2002 Bolton, UK To investigate how 
Parkinson's disease had 
affected the lives of 
eight participants and 
explore coping 
methods they used 
8 participants; four of 
the participants were 
members of the 
Parkinson's Disease 
Society and four were 
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of PD 3-8 yrs. Disease 





To explore the 
meaning that coping 
with Parkinson's 
disease has for 
individuals with PDs 
and family carers and 
suggest the 
components of an 
intervention focused 
on enhancing their 
coping  
 
21 participants: 9 people 
with PD, 7 family carers 
and 5 healthcare 
professionals. Persons 
with PD: 6 male, 3 
female. Mean age 71 
yrs. Mean length of PD 
6.1yrs.  Hoehn & Yahr 
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Hellqvist 2018 Linkoping 
University, 
Sweden 
To identify and 
describe experiences 
valuable for managing 
daily life after 
participation in the 
NPS self‐management 
intervention 
25 persons with PD (14 
male, 11 female) and 17 
relatives. Length of PD 
<1yr-13yrs.  Hoehn & 
Yahr disease stages 






according to Braun and 
Clarke 
Smith 2017 Aston, 
Birmingham 
To investigate lived 
experience of 
Parkinson's disease 




Individuals with PDs 
and their partners (total 
9) recruited via a 
Parkinson’s UK support 
group. 4 PwD and 4 
partners, 1 widowed 
partner. Person with PD 
aged 67-85, length of 












ADJUSTING TO LIVING WITH PARKINSON’S DISEASE  1-52 
 
severity not described. 
Gardenhire 2019 Lubbock, 
USA 





85 first person accounts. 










To explore how people 
with Parkinson’s 
disease manage the 
effect of the disease on 
everyday life 
24 people with PD (12 
male, 12 female). Aged 
46-80. Length of PD 1-
19 yrs. Thirteen reported 












To identify factors that 
persons perceive as 
eminently important 
Participants included 
persons with PD, 












for QOL professionals. 38 people 
with PD (15 female, 23 
male). Aged 54-74. 






Eriksson 2013 Värmland, 
Sweden 
To explore and 
generate an 
understanding of the 
meaning of physical 
exercise in the lives of 
individuals with PD 
11 people with PD (6 
male, 5 female) 
participating in an 
exercise program. Aged 
61-81. Length of PD 2-
17 yrs.  Hoehn & Yahr 








Kang 2015 Durham, UK To explore how people 
with PD live life 
successfully and what 
8 people with PD (3 
male, 5 female). Aged 




Thematic analysis  
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contributes to this 
success  




Lubi 2019 University of 
Tartu, 
Estonia 
To examine the role of 
information seeking in 
the maintenance of 
existing lifestyle and 
illness related 
adjustments 
16 people with PD (9 
male and 7 
female).Aged 35-72 yrs. 







Thematic analysis using 
social practice theory 
Nazzal 2017 Irbid, Jordan To describe the daily 
living experiences and 
impact on lines of 
Jordanian individuals 
with PD 
8 people with PD (4 
male, 4 female). Aged 
32-76 yrs. Length of PD 
2-14 yrs. Hoehn & Yahr 







Thematic analysis  




2010 University of 
Texas, USA 
To provide a rich 
understanding of the 
illness experience of 
individuals living with 
PD 
14 people with PD (7 
male, 7 female). Aged 
38-82.  Hoehn & Yahr 



















day-to-day living with 
late-stage PD 
13 people (10 men and 3 
women) and their family 
carers. Aged 61-89. 
Length of PD 19-26 yrs. 







theory and centre-stage 
storyline generation 
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Vann-Ward 2017 USA To identify, explore, 
and theorize the social 
and psychological 
processes used by 
people with Parkinson 
disease 
15 men and 10 women 
with PD (ages 40–95). 
Length of PD 3mths to 
>30 yrs.  Hoehn & Yahr 














Habermann 1996 University of 
San 
Francisco 
To explore the 
experience of having 
Parkinson's disease in 
middle life 
16 people (9 men and 7 
women), aged 42-59. 
Length of PD 1-16 
years. Hoehn & Yahr 







framework of stress and 
coping guided the 
analysis 




Lutz 2017 University of 
Western 
Ontario 
To deepen the current 
understanding of the 
experience of living 
with Parkinson’s 
disease and its 
implications for 
occupation  
6 people with PD (4 
men and 2 women), 
aged 57-73. Length of 
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Appendix 1-B: Constructing the synthesis through the generation of initial concepts to develop the final themes. 
First author    Maintaining a coherent sense of 
self   
Sense of agency and independence  Staying positive in daily life   
Uebelacker 2014   • Medication as important to 
help diminish the tremor 
symptoms and to allow for 
continued activity   
• Support groups offer social 
interaction with similar 
others so one doesn’t feel so 
alone   
• Practical support allows an 
individual to maintain 
independence 
in others aspects of their life   
 
• Physical activity providing 
benefits on physical symptoms 
and in helping an individual feel 
in control over managing the PD   
 
• Emotional support helps 
with reducing anxiety for 
the future   
• Relaxation techniques, tai 
chi and massage create a 
less stressful environment 
and contribute to 
relaxation.   
Soundy 2019   • Acceptance of the PD and • Exercise/physical activity as a • The outcome of social 
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being willing to identify PD 
in social situations helping 
an individual to continue 
engaging in activities which 
mattered to them.   
way to look after yourself and 
manage your own wellbeing   
• Physical activity programs 
helping individuals to become 
more aware of their own 
limitations and better able to 
adapt accordingly   
• The effort of physical activity 
as contributing to the idea that 
action could be taken to promote 
mobility, balance and general 
health   
• An increase in self-
confidence and self-efficacy from 
the group leading to engaging in 
more activities 
comparisons and taking 
the messages of others on 
board in order to have a 
positive outlook on the 
future   
• Positive atmosphere of 
support groups providing 
a protective mindset 
against the experiences of 
PD symptoms   
• The ability to relate to 
other individuals and to 
compare coping strategies 
helping individuals to feel 
better about their own 
situation.   
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and social interaction.   
• The valuable role of information 
and advice in helping 
individuals to better understand 
how to manage their condition   
Smith 2017   • The difficulties in accepting 
the PD causing powerful 
ontological challenges for 
the individual   
• The feelings of being “taken 
over” by the illness leading 
to PD dictating what one 
could and couldn’t do.   
• Finding ways to maintain 
involvement in activities outside 
the home to retain a sense of 
vitality   
• The importance of agency and 
taking action to overcome 
barriers in helping one come to 
terms with PD    
• Holding onto optimism as 
a way to find new ways of 
supporting oneself and 
adapting to the 
newfound circumstances.   
• Focusing on the positive 
aspects of the diagnosis 
on relationships and 
experiencing gratitude 
from those connections.   
• Sense of urgency leading 
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to participants to take up 
desired opportunities in 
the present and not the 
future.   





disabilities and deficits.   
Navarta Sanchez 
2017   
• The importance of accepting 
and coming to terms with the 
PD in order to adapt and live 
with the disease   
• Carers supporting the 
individual to continue 
• Getting activity underway as a 
way to improve symptoms or 
overcome the difficulties in 
activities of daily living   
• The importance of information in 
order to manage the PD and 
• Focusing on the positive 
aspects of the condition 
and the way the PD had 
helped them find new 
balance in their lives.   
• Living in the present by 
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previously enjoyed activity.   reduce uncertainty   not thinking about the 
future; different to not 
ignoring the future, just 
not living in the future 
day to day.   
• Being positive because 
it’s the only thing one has 
to face the ups and 
downs.   
• Negativity as a cause of 
bitterness, both for 
themselves and all those 
around them.   
Sperens 2018   • The need to adapt 
occupational performance to 
accommodate obstacles   
• Efficacious medical treatment to 
manage the symptoms of 
PD helped individuals feel able to 
• Living with PD described 
as a conscious and 
demanding strive to 
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• Reducing expectations 
of performance-for some an 
unproblematic matter of fact, 
for others more troublesome 
and threatening their identity 
as a result   
• Maintaining connections 
with family and friends that 
were enriching was 
important to maintain 
who they wanted to be.   
cope  
• Managing time and energy so one 
could adapt according to daily 
functioning and activity-this 
helped to remain in charge of 
what they did each day   
• Physical exercise to keep up 
both mobility and wellbeing 
was an important way of 
challenging participants and 
helped them feel more in 
control.   
• Input from physiotherapists or 
attendance at a group were 
important aspects of social 
interaction and of motivation   
achieve satisfactory 
everyday life   
• Achieving a satisfactory 
life involved keeping up a 
good mood and having a 
good social life   
• Positive thinking for some 
as part of their 
personality and the way 
they had always acted, for 
others more of a 
conscious attitude or 
“act”.   
• The need to stay positive 
and keep spirits up due to 
their awareness of the 
ADJUSTING TO LIVING WITH PARKINSON’S DISEASE  1-72 
 
effect of PD on their 
loved ones.    
• The value of certain 
places and environments 
to provide 
peace, tranquility and 
comfort. Places just to 
enjoy being.   
Plouvier 2018   • The importance of accepting 
the inevitable disabilities and 
limitations in order to search 
for solutions 
that minimize the impact on 
their everyday life   
• Sufficient knowledge of the 
disease facilitating the ability to 
anticipate changes in care.   
• Not being able 
to anticipate changes in care 
leading to feelings of lack of 
control   
• Being able to make 
•   
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adjustments independently, 
helping individuals have realistic 
expectations of the post-change 
situation   
• Knowledge about medication 
leading to feelings that one can 
better manage the situation and be 
“master of your own fate”   
• When individuals were able to 
solve problems independently, 
this led to a sense of control over 
changes to care and the situation 
afterwards   
Gardenhire 2019   • The opportunity to listen and 
understand others’ stories 
and relate to their 
• The confidence to speak out that 
you have PD and to engage in 
more activities and social 
• The future as possible 
from listening to 
experiences of others and 
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experiences, providing an 
insight into how others cope. 
Equally, the opportunity to 
share their own experiences   
 
interaction, leading to feelings of 
self-efficacy and feeling 
confidence in living well with 
PD   
• The ability to embrace advice 
given and take it on board in 
order to adopt exercise and 
devote more time to it   
•  
taking on board positive 
messages in order 
to utilize it in their own 
life situation   
• The program as providing 
a protective mindset 
against the experiences of 
symptoms and acceptance 
of their emotions about 
having PD.   
•  
Charlton 2002   • The inability to accept 
physical deterioration 
leading to vivid fears for the 
future   
• Not wanting to accept the 
• The fear of increasing dependence 
and loss of mobility causing 
difficulties in everyday living   
• The importance of taking time out 
and switching activities where 
• Social comparison 
helping the individual 
to recognize their 
relatively good fortune   
• Living one day at a time 
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effects of the PD leading to 
feelings of loss of identity   
• Acceptance of the condition 
as crucial to manage the 
illness; for members of 
a self-help group, leading to 
adaptations to their life 
whereas for non-members, 
acceptance as something 
which you just had to do.   
necessary in order to deal with 
tremor and immobility   
and doing the things 
which mattered to them 
before it was too late   
• Maintaining a normal life 
as possible in spite of the 
illness   
• Maintaining a positive 
outlook either by positive 
thinking or by focusing on 
the positive aspects of the 
condition.   
• Dysfunctional cognitions 
and bias, such 
as catastrophizing, 
leading to low self-
esteem, low positive 
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affect and negative illness 
perceptions   
Hellqvist 2018   • Meeting others with PD 
helping individuals to find a 
sense of connection and to 
feel more comfortable in 
owning and sharing their 
experiences   
• Spending time with family as 
a way to forget about the 
disease and the symptoms for 
a while.   
• Accepting the disease as a 
way to acknowledge the 
present situation but to 
live life as well as possible 
• Long term relations and good 
access to healthcare staff helping 
individuals feel more confident in 
managing PD.   
• Taking ownership of the 
condition as important in adapting 
to it   
• Knowledge and advice about PD 
and medications helping to 
support decision making around 
finances and mobility aids   
• Having knowledge and seeking 
information as a way to 
understand and manage the 
• Support groups providing 
common ground and 
making participants feel 
less isolated   
• Support from others 
providing emotional 
support and promoting the 
feeling there was a 
hopeful and good future.   
• Thinking through 
situations which cause 
stress and anxiety and 
trying to make a plan to 
change negative thoughts   
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despite the PD.   changed conditions   
• Inner motivation and participating 
in a group helping individuals to 
initiate behaviour change with 
regard to physical activity and 
engaging more in self-
monitoring   
• Actively focused on the 
small things that 
generated happiness in 
daily life, such as 
acknowledging the good 
things in life and spending 
time with friends 
and family.   
Shaw 2017   • The importance of disclosure 
to help an individual to come 
to terms with the condition 
and reduce uncertainty 
related to unexplained 
symptoms   
• PD diagnoses being given in 
non-private settings leading 
• Loss of independence as a major 
challenge for participants, 
yet wanting to take charge of 
making decisions which impacted 
upon increasing dependence.   
• Lack of interdisciplinary 
cooperating amongst 
professionals causing individuals 
•  
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to perceptions of it being 
impersonal and undignified   
• Physical changes due to PD 
threatening their identity, 
leading to low self-esteem 
and worthlessness   
• Medication helping an 
individual to restore balance 
with their previous self   
to feel confused and not in control 
with their care.   
• The need to balance the provision 
of information according to an 
individual’s needs so as to equip 
individuals to make informed 
decisions but not overwhelm 
them in the early stages of the 
condition   
Den Oudsten 2011   • Taking leave 
of activities, they could not 
perform anymore in order 
to adapt to everyday life   
• The difficulties faced by 
individuals with PD in 
having to lose their job or 
• Individuals with PD stressed that 
it was very important for them to 
be able to take care of 
themselves, to be independent   
• The importance of 
thinking in positive ways, 
and putting high value on 
the activities one could 
still do   
• The challenges of 
maintaining their positive 
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knowing that they probably 
will lose it in the near future. 
Most of 
the participants stressed that 
they would like to be useful 
in some way in case they 
were not able to work 
anymore   
• Remaining active in society 
as way to maintain levels of 
self-esteem   
• The importance of support 
groups in offering a sense of 
belonging   
way of thinking, 
especially when the 
disease progresses   
Eriksson 2013   • Individuals aimed to 
continue to participate in 
• Being able to live independently, 
such managing daily activities 
• The rational decision to 
try to think positively to 
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valuable areas of life, even if 
support was needed for 
managing to do so. To retain 
their identity and to be 
needed by significant others 
was important to this   
• The importance of being part 
of a social context where the 
participants share 
mutual experiences was 
stressed by participants in 
order to generate feelings of 
coherence  
like grooming, dressing, moving 
around and managing house and 
garden were essential life goals   
• Confidence in own ability to 
attain goals and the determination 
to stay active, despite disease 
intrusion, were strongly 
connected with exercising   
• Acting in the best way according 
to their knowledge, beliefs and 
experiences enabled the 
individual to take as much 
responsibility and command of 
the body as possible   
• Exercising meant slowing or 
preventing progression of not 
try and make the best of 
the situation   
• Having gratitude that their 
body functioned in 
a “normal” way in order 
to maintain wellbeing.  
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only symptoms of the disease, but 
also the disease itself   
Kang, 2015   • Successful living as being 
able to live the usual life that 
they had before having PD. 
Participants rated their level 
of success by comparing 
between their pre-illness life 
and current life with PD   
• Pretending one had not been 
diagnosed with PD which 
seemed to be a positive 
psychological response at the 
earlier stage of illness   
• The importance of personal 
effort and the ability to 
• Participants felt success when 
their symptoms seemed not to be 
getting worse and when they 
became comfortable and 
competent with their new 
adjustment to illness   
• The importance of independence 
and contributing to others’ lives. 
This seemed to lead participants 
to believe in their self‐worth and 
the dignity of their lives   
• An important aspect linked to 
feeling successful was a sense of 
being in control   
• Having peace with oneself 
and with life was 
important in order to 
counteract social stigma 
and maintain a positive 
outlook on life   
• Participants tried to make 
most of life by being 
thankful to be alive and 
loving self and others   
• Social comparison and 
family support seemed to 
create positive feelings 
that they were not left 
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continue previous activities   
• Positive family support 
helped participants to 
manage their illness by being 
always beside them, being 
co‐operative, accepting their 
illness and treating them as 
normal rather than treat them 
differently   
• Engagement in physical activity 
and exercise classes as a way 
to challenge self and maintain 
health   
alone   
   
Nazzal, 2017   • Many participants had 
experienced shock, denial 
and grief. However, all 
participants stated that once 
they accepted the 
diagnosis they started to feel 
more in line.   
• Decreased independence and 
difficulty in performing a wide 
range of areas of occupation was 
the biggest challenge 
• Sense of helplessness lead to 
feelings of hopelessness and 
depression   
• Feelings of comfort from 
faith helping individuals 
to feel they could 
overcome the challenges   
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• Family support was reported 
by participants as an 
adaptation tool to overcome 
challenges of the disease 
and to accommodate the 
disease process into their 
lives   
• Information and advice helped 
individuals to take action to 
manage their condition   
• Participants reported that lack of 
communication with the 
physicians was a common 
practice. The delay in diagnosis at 
one hand, and lack of knowledge 
about the disease and its 
symptoms and treatment on the 
other hand, had forced some to try 
some natural alternative and folk 
remedies  
• Independence and taking charge 
of own activity was important.    
Lubi 2019  • The difficulty in accepting • Individual information-seeking   
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future deterioration making 
joining a individuals with PD 
society difficult  
• The need to hold onto 
previous lifestyle and 
activities related to it in order 
to feel better  
• The need in the early stages 
to continue existing practices 
to prove they are “normal”. 
In the later stages, hiding 
symptoms in every possible 
way.  
• Acceptance and knowing 
limits supporting individuals 
to tolerate reduced 
making it possible to maintain 
control over information and its 
inflow  
• Autonomous searches for other 
information and solutions were 
carried out despite 
acknowledgement of the rules of 
the medical system  
• Understanding of the benefits of 
exercise in promoting wellbeing 
and the need for individual 
responsibility  
• Lack of information can mean 
questions are unanswered leading 
to decreases or abandonment in 
agency  
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capabilities and continue in 
interrupted activities  
Stanley-Hermanns • Individuals had to accept the 
fact that PD will never go 
away in order to incorporate 
the PD into their perception 
of the self 
• There was an ongoing 
tension between preserving 
the self and releasing aspects 
of the former self in order to 
reconstruct a self which 
integrated PD  
• The need to continually assess 
wellbeing and determine daily 
activities accordingly, allowing 
individuals to continue doing 
things which mattered 
• Listening to their body helped to 
manage and negotiate daily living  
 
• Many individuals 
described gratitude for 
their current state 
• Reflecting on how they 
were still themselves 
despite the PD helped to 
maintain a sense of 
integrity 
• Support groups helped 
individuals to feel less 
alone 
 
Williams • In order to make sense of 
their present, individuals had 
to build on past relationships, 
• Individuals needed to feel a sense 
of control over late-stage PD by 
maintaining daily activities, 
• Finding meaninghelped 
individuals to focus on 
living in the present 
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identity and events in order 
to reconstruct the everyday 
in the light of PD 
• Focusing on past events 
helped individuals to provide 
continuity between previous 
relationships and a shared 
sense of identity with 
partners and professionals 
• Biography and previous life 
experiences helped 
individuals to shape their 
identity in the face of PD 
medication regimes and interests. 
• Taking control of routines was 
essential and involved 
participants developing expertise 
of their symptoms  
• Medication helped individuals to 
stabilise their symptoms and 
maintain independence 
• In order to maintain a perception 
of independence, individuals 
avoided seeing other PD 
individuals with PDs with more 
advanced symptoms, fearful of 
their own dependency 
whilst fighting the PD 
• Individuals were 
determined not to focus 
too much on their fears 
for the future 
 
Vann-Ward • Participants were determined 
and creative in efforts to 
• Individuals took responsibility for 
own care; they actively monitored 
• Relief and gratitude that 
their condition was not 
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maintain their identities and 
fulfill responsibilities 




Acknowledging losses of 
past identities was a means 
of coming to terms with their 
circumstances 
• Participants examined and 
adjusted former interests to 
accommodate what they 
were no longer able to do 
• Participants strove to be 
engaged in daily life. Most 
their health and showed 
proactivity regarding treatment 
due to beliefs that their efforts 
would maintain a sense of self-
responsibility, delay symptoms, 
and improve their condition 
• Individuals made independent 
decisions regarding how and 
when to take prescribed and non-
prescribed medications 
• Independence of activity was 
likewise important, such as 
planning how one would travel 
when driving was no longer 
possible 
more serious 
• Having the ability to 
relinquish negative 
relationships and nurture 
others.  New relationships 
providing companionship 
and feelings of closeness. 
• Renewed energy and 
motivation from 
Parkinson’s dance groups 
• Becoming more 
understanding of others 
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people became involved with 
volunteer activities; this 
helped them to maintain a 
sense of purpose and sense 
of self 
 
Habermann • The diagnosis necessitated 
acknowledgement and 
acceptance of the disease, 
but often this was 
experienced alongside 
feelings of anger and denial 
• Individuals faced a major 
demand of moving from 
being overwhelmed to 
acknowledging the illness as 
their own 
• Many began to view their body as 
uncooperative. The mind had to 
control the body, instruct it, and 
try to get it to cooperate 
• Participants identified a need to 
know about the disease.  
• After a few years of diagnosis, 
individuals confronted the limits 
of formal knowledge and began 
to acknowledge that they knew 
best re managing their condition 
• Being able to ask for 
support and receive 
support from others were 
key adaptive tasks in 
managing the demands of 
the illness 
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• Loss of identity as a working 
person was a major struggle 
for participants 
• Changes in role and 
reinterpreting responsibility 
was a necessary task within 
the family 
• Practical knowledge involving 
timing, dosage and side effects of 
medication was invaluable 
• Equally important was learning 
how diet and activity influenced 
functioning 
• Ongoing monitoring helped 
individuals deal with the 
unpredictability of the disease 
• Being unable to drive and giving 
up working were sources of 
feelings of dependence 
Lutz • Participants focused on the 
need to accept PD as part of 
their reality and how they 
saw themselves  
• participants developed ways to 
facilitate their engagement in self-
care tasks, connecting the 
importance of these tasks to 
• Social comparison with 
people of other diseases 
helped individuals feel 
lucky for having PD 
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• Some strove to maintain their 
sense of continuity with their 
pre-PD self and being a 
person with PD 
• New leisure engagements 
were important for 
reconstructing sense of self 
amidst life transition 
• For many, continuing 
engagement in occupations 
acted as a means to maintain 
the participants’ desired 
identities 
• Support from friends and 
family helped one maintain 
meaningful activity 
maintaining a sense of 
independence 
• Adaptations to physical activity 
helped individuals to maintain 
control over their identity 
• Photos often represented 
the positive memories and 
appreciation whilst living 
with PD 
• Participants were 
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Abstract  
This paper explored the experience of living in the pre-manifest stage of Huntington’s disease 
(HD)-a hereditary, neurodegenerative disorder. Pre-manifest refers to the stage between 
receiving a predictive genetic test confirming an individual has the HD gene expansion, and 
before the person reaches the threshold for receiving a formal diagnosis of clinical (or manifest) 
HD. Individuals thus know they will definitely develop the disease but live with the uncertainty 
of when this will be. Data was gathered from ten pre-manifest individuals at least one year after 
the genetic test using semi-structured interviews and analysed using interpretative 
phenomenological analysis. Three themes were developed from the data: ‘feeling limited by 
time’, ‘the perception of stalling time’ and ‘making the most of time’, all highlighting the way in 
which time holds significant meaning when living in the pre-manifest stage of HD. It is proposed 
that psychological support could be beneficial for individuals experiencing difficulties with 
living in the pre-manifest stage of the disease and suggestions for promising interventions are 
outlined.  
Keywords: Huntington’s disease; chronic illness; interpretative phenomenological 
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Introduction 
Huntington’s disease (HD) is a progressive neurodegenerative condition which is caused 
by an expanded CAG trinucleotide repeat in the gene encoding the huntingtin protein. HD is 
inherited in an autosomal dominant pattern, meaning a child of a parent with the HD gene has a 
50% chance of inheriting the disease. The age of onset differs across individuals, but signs of the 
condition and clinical diagnosis typically occur aged 30-50 (Carlozzi et al., 2016). The expansion 
number of the CAG repeat shows a very strong negative correlation with age at onset of motor 
signs, with a larger expansion number leading to earlier onset (Lee et al., 2012), but this is still 
hugely variable across individuals. A myriad of functional difficulties is experienced. These 
include problems with both voluntary and involuntary movements, such as difficulties with 
swallowing, balance and mobility as well as chorea and bradykinesia (Ho & Hocaoglu, 2011).  
Cognitive difficulties such as problems with concentration, memory and attention are often also 
experienced; communication ability is often impacted by motor speech disorders, linguistic 
difficulties and behavioural changes, leading to negative effects on social interaction and 
diminished quality of life (Nuzzi, 2018). Emotional difficulties are also common, including 
apathy, depression, irritability and anger, aggression, suicidal ideation, obsessional compulsive 
traits, anxiety and psychosis (Eddy et al., 2016; Wetzel et al., 2011; van Duijn et al., 2008). 
Motor and cognitive difficulties typically worsen with advancing disease progression, resulting 
in reduced health related quality of life (Carlozzi & Tulsky, 2013). In advanced stages, 
individuals are likely to require 24-hour care and become totally dependent on others for their 
most basic needs, a level of need which is very frequently not met by healthcare and social 
support services (van Walsem et al., 2015). 
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 In order to receive a diagnosis of HD, an individual must experience the onset of motor 
symptoms (Reilman et al., 2014).  However, difficulties across the motor, cognitive and 
psychiatric domains are likely to occur gradually and may be present more than a decade before 
the actual diagnosis (Paulsen, 2010). Furthermore, many individuals report anxiety related to 
potential symptom onset, often many years before showing motor difficulties (Konrad, 2003). 
There is no way of preventing the onset of the disease, currently no cure, and HD is generally 
fatal within 15-20 years of clinical diagnosis (Carlozzi et al., 2016).   Predictive testing has 
allowed individuals who are at risk of HD (because of their family history) to find out whether 
they will develop the disease, prior to showing motor symptoms. Although this has 
allowed researchers to study the natural course of the disease and provide opportunities for early 
intervention, the test raises significant ethical issues regarding the potentially devastating 
consequences which living with the test result entails (Lilani, 2005). Additionally, given the 
inherited nature of the disease, many individuals will have witnessed first-hand the impact of 
advancing deterioration. It is often the immediate family who take on responsibility of caring 
(Coulson et al., 2007); thus, many pre-manifest individuals may be caring or have cared for 
family members. By offering the predictive test, health services have an ethical and moral 
responsibility to understand the impact of genetic testing and to support individuals with the 
long-term consequences (Andersson et al., 2016).   
           Although much research has been done identifying psychological consequences of a 
positive test result, the focus is generally on clinical symptoms such as anxiety and depression or 
on adverse events such as family breakdown or suicide (Mccusker & Loy, 2017). Furthermore, 
the focus is generally on the short‐term (typically under one year since testing) psychological 
implications of predictive testing (Almqvist et al.,2003). These include symptoms of depression, 
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obsessive compulsiveness, anxiety, and psychoticism, as documented by large scale quantitative 
studies (Berrios et al., 2002; Duff et al., 2007; Crozier et al., 2014).  Yet there is little knowledge 
about the in-depth experiences of these individuals from a qualitative perspective, including the 
longer-term experience after having tested positive. For instance, there has been little research 
into how a person who has tested positive to the HD gene expansion but is not yet symptomatic 
perceives their status as ‘embodied risk’ (Kavanagh & Broom, 1997). The uncertainty about 
when individuals will develop the physical symptoms (and thus receive a diagnosis) is likely to 
compound any psychological difficulties not least because of the difficulties inherent in deciding 
whether symptoms in pre-manifest individuals constitute a clinical diagnosis (McCusker & Loy, 
2017).  
Whilst quantitative studies have highlighted the psychological and social difficulties 
experienced by those in the pre-manifest stage and sought to understand how they can affect 
quality of life, the research is limited in its ability to explore how an individual’s meaning of 
their experience affects them in everyday life. Furthermore, the implications of the research tend 
to be on the detection of subtle subclinical psychiatric symptoms which might indicate earlier 
markers for the disease, rather than on the implications for psychological support (Duff et al., 
2007; Berrios et al., 2002). Exploring the meaning of an individual’s experience is fundamental 
in order to better understand variations in psychological outcomes across individuals and how to 
provide effective psychological support to those experiencing difficulties. Few qualitative studies 
to date have focused on the lived experience of individuals in the pre-manifest stage of HD. In 
contrast to quantitative approaches, qualitative research is well suited to develop understanding 
of the everyday experience of pre-manifest individuals and substantiate the existing quantitative 
literature. Consequently, this study will take a qualitative approach and use interpretative 
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phenomenological analysis (IPA)  as the methodology because of its ability to explore in detail 
how individuals make sense of their experience (Smith et al., 2009). Thus, this study aimed to 
answer the question: ‘how do individuals experience the pre-manifest stage of HD’. 
Method 
Design 
The study design followed guidelines for IPA research (Smith et al., 2009). As a 
hermeneutic approach it gives precedence to the individual’s personal interpretation of and 
meaning given to their experience. As an idiographic approach, IPA provides a framework for 
thorough analysis of individual experiences (Smith et al., 2009), which felt important to capture 
the complexity of living with a chronic illness (Brocki & Wearden, 2006). Furthermore, IPA 
recognizes the important role of the researcher in making sense of an individual’s account of 
their experience (Smith & Osborn, 2003). This awareness felt important to the present study in 
order to continually reflect on the ways in which the researcher’s active involvement in the 
participant’s narrative might shape the research outcome (Pringle et al., 2011) and thus the 
importance of constructive self-reflection in the research process. IPA appreciates that it is 
through our experiencing that meaning is generated and enables the researcher to more fully 
explore the way the participant’s experience influences the meaning that they give to being 
human (Engward & Goldspink, 2020).  
Semi-structured interviews were used to ensure the focus was on the pre-manifest stage 
but were also guided by participants’ responses. Interviews were conducted via telephone due to 
differing geographical location of participants. Arguably, telephone interviews are an effective 
option for qualitative data collection due to it complementing the style of semi-structured 
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interview schedules (Cachia & Millward, 2011) and have been used previously in IPA research 
(Swift & Wilson, 2001).     
Expert by experience 
People with either pre-manifest or manifest HD were approached for their input into the 
design of the study via HD voice (a patient and public involvement group which sits within the 
UK Huntington’s Disease Association (HDA). They were asked their opinions on the participant 
information sheet and the invitation letter to ensure they were understandable and inviting. The 
flyer was simplified and made more professional following this discussion, and the questions in 
the interview schedule made more accessible.  
Participants 
To be included in the study, participants were required to be between 18 and 65 and to 
have tested positive for the HD gene expansion at least one year prior to the interview. It was felt 
that interviewing participants at least a year following the test would encourage participants to 
focus on their experiences of living with their genetic status rather than those of the testing 
period. Participants self-reported that they had the gene expansion for HD as confirmed through 
genetic testing. They also confirmed that they had not been diagnosed with the disease. 
Participants were excluded if they had a comorbid significant illness. In choosing the eligibility 
criteria, the researcher attempted to ensure homogeneity of sampling with regards to “obvious 
social factors or other theoretical factors relevant to the study” (Smith & Larkin, 2009 p. 50). 
Two participants were recruited through the HD clinic at an NHS Trust and 8 were recruited 
through a Facebook advertisement on the Huntington’s Disease Association’s webpage; all 
provided written informed consent prior to interview commencement. Pseudonyms were used in 
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all tables, transcripts and subsequent analyses and any other identifying information was 
changed. In brief, there were 3 male and 7 female participants, mean age was 38 years (range 25-
50) and mean time since their genetic test was 5 years (range 2-10). All were White British. 
There were 6 individuals who were married or in a relationship with one or more children, 2 
married with no children and 2 single with no children. Most (8) individuals were in paid 
employment. The demographics of participants is shown in Table 1. As can be ascertained from 
the aforementioned overview, there was some variance in their experience of the pre-manifest 
stage, which allowed the idiographic and divergent aspects of the experience to be explored.  
Recruitment and Data collection 
Participants were invited to take part through letters of invitation provided by research 
nurses at the host Trust, or by responding to the Facebook advertisement. The researcher’s 
contact details were included, and potential participants were asked to contact her if they were 
interested in participating. After answering any questions and confirming they were happy to go 
ahead, a mutually convenient time was arranged with each participant for the interview. Consent 
forms had to be completed in advance of the interview and emailed or posted back to the 
researcher; at the beginning of this meeting further questions were clarified and participants were 
asked to reaffirm consent. 
Data analysis 
Data analysis followed guidance from Smith et al. (2009). There were four stages to the 
analysis. The first stage involved multiple readings of an individual participant’s transcript with 
comments noted around points of interest (see Appendix A). These comments were closely 
grounded in the raw data. The second stage involved re-reading of the transcript, with emergent 
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themes noted in the right-hand column which attempted to describe the participant’s experiences 
(see Appendix A). In the third stage of the analysis, emergent themes were listed, and 
similar/connecting themes were grouped into superordinate themes (Appendix B). In the fourth 
stage, analysis was conducted across all the transcripts and superordinate themes for the entire 
data sample were generated by looking for concordance across participants (Appendix C). Bias 
was reflected upon and incorporated into the analysis using a reflective journal and regular 
supervision. Supervision was a space for analytic interaction, highlighting which interpretations 
belonged to the researcher and which belonged to the participants, strengthening the rigour and 
transparency of the interpretations (Engward & Goldspink, 2020). Sensitivity to context is 
equally important to high quality research (Yardley, 2008) and this was enhanced through 
regular discussion with one supervisor who works in a HD clinic. Furthermore, engaging with 
individuals with HD prior to data collection and once analysis was complete enhanced the 
commitment and rigour (Yardley, 2008). 
Reflexivity is a core component within IPA, given the need to continually reflect on the 
meaning which we generate from the data in the analysis process (Shaw, 2010). It was important 
to have space within supervision to reflect upon the researcher’s interpretations were filtered 
through the lens of the participant’s own sense making, in that access to the participant's 
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The study received ethical approvals from the UK Health Research Authority Tayside 
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The findings indicated that the way in which individuals adjust to living in the pre-
manifest stage of HD is underpinned through their representation of time. The results span past, 
present and future and are depicted by three main themes: ‘Feeling limited by time’, ‘The 
perception of stalling time’ and ‘Making the most of time’. Each of these themes and the sub-
themes are described in the following discussion.  
Theme 1: “It’s like a trigger for a countdown”-Feeling limited by time 
The theme feeling limited by time captures participants’ reflections of the way in which 
receiving their genetic test results felt to limit the time they had left. This theme incorporated two 
main sub-themes; the countdown to symptom onset and HD dictating the present.  
Countdown to symptom onset. 
One recurring theme across participants’ accounts was the way in which receiving their test 
results felt to initiate a process of counting down to symptom onset. The acuity of the countdown 
period was maintained by a hypervigilance towards any possible signs which might suggest 
symptom onset. The overwhelming fear of possible symptom onset was described by most 
participants and was alluded to by Daisy: 
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And if you do things like you forget things or names or you put your purse in the fridge 
or whatever, it only takes a couple of things to happen over a period of time for you to 
start panicking and think ‘oh my god, is this it, is it starting?’ 
Many individuals were able to question their fears and think through alternative 
explanations given the context of their experiences. As Sharon pointed out: “you know, it could 
well be it's a symptom, or it could just be that you're very, very stressed at that point and 
actually, the kinds of things that happened to the brain when it’s stress [ed] is very similar.” 
Despite this sense of rationality, symptom questioning was pervasive, resulting in the countdown 
to symptom onset being an ever-present feature in the background of the participants’ lives. Paul 
summed this up neatly: “is it Huntington’s starting? I’ll always have that” 
The idea of the HD status being an ever-present feature in an individual’s life was echoed 
by others, in which HD became part of “my forever radar rather than my temporary radar” 
(Daisy) and “an unresolved threat just lurking in the background” (Angie) . For Steve, there was 
a period at which “it settle(d) into the background noise and has kind of remained fairly constant 
ever since”. Alongside “threat”, “radar” and “noise”, the contextualized nature of “background” 
becomes apparent. It would seem as though the word ‘background’ reflects the underlying and 
insidious backdrop of HD in the participants’ lives, always reminding them of the countdown 
which commenced following the test result.  
The countdown to symptom onset was often made more pertinent by seeing the course of 
parental disease. As Catherine described, seeing the way her mum experiences symptoms: “can 
be upsetting sometimes because it is a window into your own future almost”. This window into 
the future is the lens through which many individuals described seeing their own onset. It is 
sobering that the phrase ‘window into the future’ often describes an opportunity which makes it 
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possible to see or understand something clearly, in order to affect the present in positive ways. 
Here though, this window only intensified the reality of their own symptom onset, in which the 
counting down was exacerbated by family experience of the disease. 
 Interestingly however, for some individuals, parental onset did not intensify their own 
fears for their future. Instead, many were too consumed by their caring role to give any space to 
their own fears. As Joanna explained of symptom onset: “Honestly at the moment it doesn't 
normally bother me I'm more focused on my mum.” 
Similarly, some were able to feel reassured by their knowledge of how disease 
progression is a very idiosyncratic experience and thus the way HD affected their parent could 
only give some indication of how it might affect them. Steve described how: “Even going to 
see mum it’s not, I’m not thinking that’s going to be me in a few years it’s just ‘oh it’s 
my mum’” 
HD dictating the present. 
The ways in which an individual’s HD status dominated their thought processes highlights how 
participants often felt HD was dictating their present. As Joanna explained with regards to her 
decision to change careers from events marketing to teaching following the test results: 
Honestly it was the Huntington's gene. Originally I trained in events, it's a very active job 
and you are up and down all the time running around different venues and it's not 
something I would be able to do long term. 
The personification of the Huntington’s gene depicts Joanna’s sense that the gene had control 
over her decision making, where she felt forced to re-train because she knew she may not be able 
to continue in her preferred career once motor difficulties started. The negotiations individuals 
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made with regard to their HD status is echoed in Angie’s account when speaking about 
navigating the dating world with HD, where she described that she had to “negotiate that with 
a ball and chain around your foot which is how I view Huntington's.” The ball and chain 
metaphor depicts an image of a criminal being physically restrained and held back; although 
participants were not to blame for having HD, perhaps this describes the regret Angie alludes to 
in taking the test, because before the test everything remained possible for her.  
It seemed the test results had prompted urgency about what one could realistically afford 
to do long term. A similar sense of urgency is reflected in Carol’s comments: “I've always been 
sort of a straightforward person, but it made me re-evaluate a lot of things. We moved house 
kind of because I knew that I needed to do certain things within a certain timeframe.” Here Carol 
described feeling “made” into re-evaluating things and making the house move due to the sense 
of urgency which came about from having the test. This sense of urgency is triggered by the 
knowledge that one has HD, such that one felt the result: “Is a trigger for a countdown if you 
like.” (Paul) 
Interestingly, the word “trigger” was used by several participants, highlighting the sense 
felt by participants of the results setting off something, whether that is forced decision making or 
emotional rollercoasters. It feels apt that the word trigger defines the mechanism by which one 
fires a gun; perhaps for some individuals the knowledge of the result creates a similar sort of 
finality to their life before the result. 
Theme 2: “I have no intention of becoming symptomatic”- The perception of stalling time 
The theme “perception of stalling time” encompasses the way in which individuals 
gained some sense of agency over the unpredictable and uncertain nature of living in the pre-
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manifest stage. Individuals were able to distance themselves from HD by viewing symptom 
onset as a future reality and by holding onto hope for future medical advances which might delay 
or eradicate symptom onset.  
 
Distancing self from HD. 
The perception of stalling time reflects participants’ perspectives that they were able to delay 
symptom onset by distancing themselves from the reality of their situation, or by situating it as 
very much a concern for the future. For some, distancing themselves was achieved by viewing 
their future as free of symptoms: 
So this time in 10 years I fully intend to be part of, if not a drug trials programmes, 
certainly using whatever it is that’s going to delay onset for as long it needs, so that’s 
where I’m coming from when I say I’ve no intention of becoming symptomatic. (Steve) 
Not only did Steve describe how he still expects to be asymptomatic in 10 years’ time, but also 
that he has no intention of becoming symptomatic. He distanced himself from present concerns 
about symptom onset by reinforcing his belief that it will not happen for at least another 10 
years.  
Most participants seemed to refer to family patterns of the disease in order to maintain 
the belief that symptom onset was very much for the future. Hannah explained how “nobody in 
the family [have shown any] symptoms til 60+ so I think I'm very lucky in that sense and I think 
I use that as sort of a crutch like ‘oh I won’t be sick until I’m 60’” 
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Similar certainty about onset was described by Daisy, who was working on an “18-year 
timeframe”, Catherine, who used her CAG count to "give (her) at least 20 healthy years” and 
Paul, who thought “there is a good chance that (he’s) got another 5 to 10 years”. For most 
participants, their own predictions of symptom onset seemed to be heavily influenced by parental 
experience of symptom onset, providing a sense of certainty that one had a defined period prior 
to showing symptoms. Thus, family experience of HD helped participants to create time between 
the present and their own symptom onset, thereby distancing themselves from HD.  
Holding onto hope. 
A closely related concept which links with an individual’s perception of stalling time was their 
ability to hold onto hope. As explained above by Steve, not intending to be symptomatic 
reflected his hope that drug trials and research programmes will eradicate or delay his symptoms. 
The hope that research progresses before symptom onset was also described by other 
participants. Carol described the hope she shared with her children when telling them that she 
had testing positive for HD: “’by the time mummy is 70 there will definitely be a medicine out 
there’.…so to look at it from that point of view, so the future isn’t all dark and bleak there is 
hope, there is hope there.” Here Carol described how she holds onto hope that future medical 
trials will alleviate or stop her symptom onset, much in the same way that Steve described his 
hope for future drugs progressing faster than his symptom onset. Carol’s use of the word 
“mummy” in the opening of this statement indicates the significance of hope for her; it is though 
she needs to remain hopeful as part of her responsibilities as a parent to her children.   
The idea that hope is almost necessary in order to manage life in the present is echoed by 
Catherine when responding to why hope was important: “because if you don't have hope then 
what do you have?” Hope was not around initially for Catherine. As she described: “there is a 
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massive adjustment that you go through when you are told you've got the gene and rather than 
think about hope and stuff you’re kind of adjusting to the news that you've got this defective 
gene”. This adjustment period is echoed by Steve, who describes that “once you find out it's 
quite an emotional roller coaster”, Jake, who thought: “it does take a period of adjustment”, 
Angie who had “a period of time where I was really anxious about them and upset by them” and 
Paul who mentioned that” initially I didn't see that there was a lot of hope and I guess I was 
approaching it from a terminal illness point of view.” It was almost against this backdrop 
however which hope emerged as even more significant in the participants’ lives. Paul summed 
up the importance echoed by many of having hope in their life: 
I guess it stood a chance of almost paralysing me knowing that it was happening or would 
happen …..But I kind of overcame that knowing that, well you could waste a lot of time 
which is bad for everyone around you…. I want to live my life with the view 
that I’m free of Huntington's. 
Thus, despite the very real difficulties which HD presents to individuals and their 
families, hope was a very tangible force for participants in preventing them from being paralysed 
by the fear of HD and allowing them to live their lives.  
Theme 3: “I could be hit by a bus tomorrow”-Making the most of time 
Making the most of time describes an individual’s acknowledgement that, despite 
symptom onset being a future reality, their time in the present was precious. This is reflected in 
the participants’ determination to stay positive, and in their determination to choose the people 
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For most participants, the need to stay positive was significant in helping them to make the most 
of their present. As Carol described: “I need to put all my time and energy into positive things 
and positive people and doing good things and making a positive impact.” The importance which 
Carol attached to remaining positive is reflected in its reiteration three times within this 
statement. It is by staying positive that she was able to maximize her time and energy and really 
make the most of the time she has, implicitly conveying her caution that she might not be able to 
make a positive impact for as long as she might like. Similar descriptions of the need to be 
positive were conveyed by Daisy, who talked about being positive about her future in order to 
embrace her present; Jake, who felt having a positive outlook prevented problems elsewhere in 
his life; Joanna, who expressed determination to keep positive until the symptoms started; and 
Steve, who talked about making a positive out of a negative situation. It is thus through positivity 
that individuals seemed able to make the most of the time they had symptom free and prevent 
themselves from dwelling on their potential future. 
 It is important to acknowledge that one participant found it more difficult to hold a 
positive outlook on her life. For Angie, the test result “changed things in terms of the way you 
view your future and your life” and  “is a thing that looks over your shoulder saying ‘oh no you 
can't do that now I'm going to close that door for you’”. Rather than having a positive outlook on 
her life and seeing possibilities, for Angie it felt as if all the doors were closing, limiting both her 
opportunities and her ability to be positive. Although she later reflected on ways she dealt with 
her fears for the future by finding ways to feel positive, her honesty about the realities of HD 
perhaps reflect the fears which others chose to avoid.  
Catherine for instance avoided dwelling on future fears by focusing on the things she 
wanted to do with her life and reflecting on the ways it might not be HD which limited her life. 
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As she explained: “I could dwell on it and worry myself sick about it and not do things that I 
want to do and then go out and get hit by a bus…” Interestingly, the phrase “I could get hit by a 
bus” is echoed in several participants’ accounts. It highlights that, for many of the participants, 
there was comfort to be gained from knowing that it is impossible to predict what can happen in 
the future, regardless of  having HD. An individual can either waste time worrying about 
something which may never transpire, or instead choose to live for today and be positive for 
what they currently have. In reflecting on the relative benefits of focusing on symptoms versus 
living their life with a positive mindset, many of the participants were able to “push it to the back 
of [their] mind and carry on living life” (Daisy). 
Choosing valued connections 
Making the most of time was also reflected in the way that individuals made conscious decisions 
about who to spend their time with. For many, spending time with family helped them to make 
the most of a symptom free present. As Sharon described: “The family is very supportive and it’s 
[HD] not something that’s not talked about”. For Sharon, it felt very important to talk about and 
share her concerns with family in order to move on from her worries and embrace her time in the 
present. This was echoed in others’ accounts: “But I guess I felt a lot better after I talked to Jane 
[partner] about my concerns in that my anxiety almost completely melted away” (Paul) 
In sharing concerns with family members, Sharon felt able to reduce the power of HD 
from being that which was hidden and stigmatized in the past to something which could be 
dropped into casual conversation, similar to Carol who valued talking with her family about her 
HD concerns even if it wasn’t “deep and meaningful”.  
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 Being selective with who one spent time with extended to being less tolerant of people 
who did not share their perspective about life. As Carol described when reflecting on some of the 
implications of the HD result: “And I think I've become less, not patient, I can't think of the word 
for it, less tolerant of idiots and people that are moaning about something completely ridiculous 
and shallow.” By discarding negative relationships, individuals were able to focus on the positive 
relations in their life, and even used their HD status as an impetus for coming together as a 
family. Joanna summed this up nicely when describing how HD had brought the family closer: 
“life cannot get in the way anymore. You can't be putting stuff off thinking I'll do it later I'm too 
busy because there might not be a later.” 
 
Discussion 
The results of this study describe the experience of living in the pre-manifest stage of 
HD. Embodied in participants’ accounts and reflected in each of the three themes is the salience 
of time; its ability to take on new meaning and value once an individual is aware of their test 
result. The participants’ experience of knowing they will develop a chronic illness induced 
different relationships to time than are experienced by an otherwise healthy person (Jowsey, 
2006), where expectations for the future changed, the meaning of their present altered and their 
past relationships to others also adjusted. For the present participants, this was reflected in their 
alterations of future plans, their discarding of negative past relationships and their determination 
to see gratitude in their present. The salience of time for individuals with chronic illness is not 
new and its origins can be found in the work of Bury (1982), who suggested that a chronic illness 
can disrupt a person’s previously accustomed experience of time and their expectations of living 
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within established time-frames of childhood through to old age. His work has since been applied 
to many chronic illnesses (e.g. Faircloth et al., 2004; Harris, 2009; Carricaburu & Pierret, 1995). 
Although this research differs from the experience of individuals in the present study who are not 
yet experiencing symptoms, Bury’s account of “biographical disruption” appears to mirror the 
participants’ accounts, in which their understanding of time and their life within it felt to be 
disrupted upon receiving the genetic test results. Similarly, Charmaz, in her longitudinal work on 
chronic illness describes how an individual’s struggle to control their illness is really an effort to 
control time and to preserve the defining image of the self (Charmaz, 1993). The experience of 
chronic illness presents ambiguity for an individual over whom they are in the world, which is 
translated by the individual and understood through their relation to time (Ellingsen et al., 2014). 
Such ambiguity and unpredictability are reflected in the participants’ accounts as they described 
their initial struggle when finding out they had tested positive. The uniquely certain entity in our 
lifeworld, which is time, becomes unpredictable and uncertain when knowing you will 
experience chronic illness in future. Thus, the participants’ way of adjusting to the results was to 
gain back some control over their present and to exercise some agency in decision making for an 
uncertain future.  
As illustrated in the first theme, many of the participants in the present study expressed 
hypervigilance towards potential signs of the disease and were constantly ‘symptom watching’. 
They began to interpret insignificant events through a lens of knowing they had the HD gene, 
generating meaning about an experience they were unsure of and believing it to be a sign of 
disease. Interestingly, this has also been demonstrated to occur in individuals who are aware they 
are at risk, but later go on to test negative for the gene (Hagen, 2018). Being unable to determine 
the meaning of illness-related events presents a life-long challenge for individuals with a chronic 
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illness (Mishel) and therefore interpreting events through a framework of HD may be a strategy 
to manage uncertainty and to create meaning (Hagen, 2018). When individuals experience high 
uncertainty, they are less able to process new information, predict outcomes and adapt to their 
illness situation (Mishel, 1990) and consequently may experience increased burden of managing 
chronic illness (Johnson et al., 2006). Mishel highlighted the importance of four factors in 
evaluating the perception of uncertainty; ambiguity, complexity, unpredictability and 
inconsistency (Mishel, 1990). For individuals in the pre-manifest stage of HD, indistinct and 
vague signs of possible symptoms contribute to ambiguity, the lack of contingency between 
these signs and the illness outcome (i.e. actual onset) contributes to unpredictability and the 
different messages individuals received about the significance of these signs from healthcare 
professionals versus their own perception contribute to inconsistency, indicating a high level of 
illness uncertainty (Giammanco et al., 2015). Reconfiguring this uncertainty into a tangible 
experience such as symptom onset-from which participants could generate meaning - was a 
complex undertaking which at times felt to dictate the participants’ lives.  
As indicated in theme 2, another way that participants managed the unpredictability was 
to distance themselves from the reality of HD. For many individuals, denial of the situation or of 
approaching symptom onset appeared to be part of a process which enabled them to gain control 
over an uncertain future. Within Mishel’s (1990) theory, denial might remove the 
unpredictability of the period between a positive test result and symptom onset. Interestingly, 
theories of coping typically propose a passive coping style of responding to a chronic condition 
(such as avoidance or denial of one’s future) to be associated with poorer adjustment to the 
condition (Hesselink et al., 2004; Klein et al., 2007; Park et al., 2008). In contrast, more active 
coping styles (such as using positivity to manage difficult thoughts or problem-solving activities) 
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are believed to be adaptive and lead to better adjustment (Pucheu et al., 2004). However, such 
broad coping styles neglect consideration of the ways in which the effectiveness of a distinct 
strategy is likely to be context specific (Smith et al., 1997). Denial, for instance, can be adaptive 
in helping the mind defend itself from threatening information which an individual can do little 
about, thus allowing them to accept and cope with the life-threatening effects of their condition 
(Siemerink et al., 2011). By denying knowledge of future deterioration, participants in the 
present study were able to focus on a present which was free of symptoms rather than a future 
plagued by uncertainty. 
An alternative way in which individuals managed the uncertainty was by holding onto 
hope. By holding onto hope for future medical advances which might prolong or even eliminate 
symptom onset, participants described how hope allowed them to live each day as if they didn’t 
have HD. Hope is an internal response which develops over time and helps individuals to deal 
with difficult and unexpected circumstances (Rustøen & Moum, 1997). In holding onto hope, an 
individual can visualise a positive outcome to their situation and believes in their ability to 
overcome the challenges presented to them (Acquaye et al., 2016). For individuals diagnosed 
with a life-threatening illness, with limited opportunities to improve the expected outcome of 
their predicament, hope offers a means to gain some agency over the situation and results in 
meaningful outcomes for the individual (Acquave et al., 2016). As a means of maintaining a 
healthy coping response despite the adversity they faced and helping them to feel able to cope 
with uncertainty, hope was an important factor in the participants’ wellbeing.   
Closely related to hope and the management of uncertainty was the ability to maintain a 
positive outlook, discussed in theme 3, which allowed individuals to embrace their present and 
lead a meaningful life. Embracing the present is reflected in another study of pre-manifest 
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individuals who saw their quality of life as being intertwined with their present attitude and 
behaviour, and thus were determined to live every day to the fullest (Ready et al., 2011). In the 
present study, participants also expressed gratitude for the ways in which they were still able to 
live life to the fullest, in the absence of HD symptoms. Gratitude is typically considered to be an 
important factor in an individual’s ability to find benefit after a traumatic experience (Peterson & 
Seligman, 2003) and may act as a protective factor in buffering the effects of adversity on a 
person’s wellbeing (Tugade & Fredrickson, 2007). Gratitude has been shown to be positively 
related to resilience and growth and negatively related to depressive symptoms in survivors of 
traumatic experiences (Fredrickson et al., 2003) and, as a dispositional trait, may represent the 
common factor underlying resilience and post-traumatic growth (Kashdan et al., 2006). Higher 
levels of gratitude may enable individuals to find possible benefits from their illness experience 
and develop personal qualities such as individual spirituality and appreciation of life; this in turn 
is likely to lead to a greater acceptance of adversity and improved coping to negative events 
(Cordova et al., 2001). This sense of gratitude and renewed energy is replicated in other genetic 
illness, in which individuals experienced new levels of strength and increased fulfilment, 
described as “redemptive adjustment” (McAllister et al., 2007, p2656). In that study, the 
experience of knowing they would develop a progressive condition, although traumatic, enabled 
individuals to find their positive characteristics they were not aware they had, such as their 
strength and ability to fight the negativity (McAllister et al., 2007). For participants in the present 
study, this strength and energy could be focused in new directions such as contributing to the 
research or the work of support groups, resulting in unexpected fulfilment. Embracing the 
present and finding meaning is one way to find hope for the future and holding a positive outlook 
in life worked well for many of the participants in this regard.  
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Clinical implications 
The participants in the study described the importance of a positive mindset and an 
optimistic outlook in order to accept and come to terms with an uncontrollable future. For those 
who find it hard to adjust to a positive genetic test result, psychological support may be 
beneficial in helping individuals to maintain control where possible and to support healthy 
cognitive appraisals towards the uncontrollable aspects of living in the pre-manifest stage. 
Preliminary evidence suggests that some individuals who are pre-symptomatic or in the early 
stages of HD value the opportunity to engage with psychological therapy in order to manage the 
psychological difficulties they experience (Theed et al., 2018). Techniques derived from 
acceptance and commitment therapy (ACT) such as cognitive defusion (seeing thoughts for what 
they are-just thoughts) can help individuals to manage difficult thoughts and anxiety, without 
such thoughts dominating their overt or covert behaviour in problematic ways (Harris, 2009). 
Supporting individuals to cognitively defuse may help enable the thoughts about loss of control 
and feelings of helplessness to recede into the background of their life, which many participants 
in the present study had found beneficial.  
For participants in the present study, being able to embrace their present was an 
important part of their wellbeing. An important component within ACT is encouraging 
individuals to fully engage with their present experiences and clarify their values, which enabled 
the participants to lead a meaningful life despite the limitations of their illness (Vowles et al., 
2007). ACT not only encourages individuals to step back from their thoughts but also encourages 
value congruent activity (Hayes et al., 2006). By fully embracing the present and committing to 
valued activity, individuals may be better able to embrace their pre-manifest status. 
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An alternative approach to supporting individuals to manage their anxieties related to 
symptom onset and minimise hypervigilance towards possible signs of the disease is mindfulness 
based cognitive therapy (MBCT). MBCT teaches individuals to detach from negative thinking 
habits and repetitive thought patterns by encouraging people to turn their perspective to more 
engaged, meaningful processing of their experience (Segal et al., 2002) and has been shown to be 
a promising approach for  pre-manifest individuals in helping them to adopt a non-judgmental 
and less reactive approach (Eccles et al., 2020). Indeed, MBCT encourages individuals to allow 
thoughts and feelings to occur even when they generate anxiety, placing greater emphasis on 
trying to understand the cognitive and psychological aspects of their experience rather than being 
overwhelmed by it (McCay et al., 2016).MBCT can thus help individuals to manage the 
overwhelm of facing an uncertain and uncontrollable future, instead encouraging them to accept 
and create meaning from their present experience. 
More generally, offering group based psychological interventions may be an important 
means of providing a space where individuals can experience commonality and validation in 
their experiences. The benefits of a group-based intervention were articulated by individuals in 
an MBCT feasibility study, where participants described how it was helpful to meet others in a 
similar situation and that just working together in a group was itself therapeutic (Eccles et al., 
2020). Furthermore, there is evidence to suggest that group sessions can help individuals in the 
pre-manifest stage of the disease to share personal stories and discuss sensitive areas of HD, 
which can sometimes be difficult outside of an established setting (Stopford et al., 2019). Many 
of the participants in the present study valued the forum of the HDA to gain validation and 
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Several limitations of the study should be acknowledged. Participants were largely 
recruited from a flyer advertised on the HDA website, which may have biased the sample to 
individuals who were already engaged with the HD community and thus more motivated to 
increasing awareness and understanding of HD. As a result, their attitude toward living in the 
pre-manifest stage may not generalise to others in the pre-manifest stage of HD. Secondly, as 
participants were required to proactively express their interest to participate, it is likely that the 
participants felt able to talk about their experiences and thus may have been coping better 
mentally and physically than the general population of HD gene expansion carriers.  
It was notable that the majority of the individuals in the present study were coping 
remarkably well in the pre-manifest stage of HD It may be anticipated that the eligibility criteria 
may have falsely limited the sample to those who were coping well; studies of the psychological 
impact of the test results highlight that the first year after testing may be especially difficult for 
individuals (Almqvist et al., 2003), possibly because of the difficult period of initial adjustment. 
Nevertheless, it is worth considering the participant’s level of insight of their situation, as lack of 
insight can be issue for individuals with manifest HD (Ho et al., 2006). It is possible that 
executive functioning deficits may have limited participants’ introspection; thus, relying solely 
on self-report is a limitation of the study. Future studies should therefore also obtain 
partner/family perspectives.  Nevertheless, for the participants in the present study, denying 
knowledge of future deterioration appeared to be a proactive coping mechanism, helping them to 
accept and cope with the threat of a future they could do little about (Siemerink et al., 2011). As 
evidenced too by Andrews et al. (2018), lack of insight seems to be more common in individuals 
diagnosed with manifest HD. 
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The participants’ experience of pre-manifest HD was varied regarding the length of their 
experience as pre-manifest, and their age both when receiving the test result and at interview. 
Considering IPA requires homogeneity regarding the research construct being explored, this 
divergence is a possible limitation. Future research should perhaps employ a more narrowly 
defined sample, where the timeframe since receiving the genetic test result is limited, say, to 2-5 
years. Nevertheless, Smith and Osborn (2003) suggest that how the specificity of a sample is 
defined depends upon the research construct; where the researched experience is rare (as is the 
case for individuals living in the pre-manifest stage of HD), the experience may itself define the 
boundaries of the relevant sample 
Future research  
Given the present sample may have represented a subset of individuals with relatively 
high levels of optimism than the typical pre-manifest population, future studies might explore 
levels of optimism in people with pre-manifest HD and the relationships between levels of 
optimism and other related factors such as locus of control, perceived stress and life events. A 
quantitative study would help to explore the relationships between these factors. Pre-manifest 
individuals could be divided into groups based on estimated proximity to HD diagnosis, using 
data obtained from their CAG repeat number and parental age of onset. Furthermore, a 
longitudinal study would be beneficial to consider how these variables change over the period of 
an individual’s pre-manifest journey. There is evidence to suggest that individuals less than 9 
years away from diagnosis may experience higher levels of wellbeing and lower perceived stress 
than other pre-manifest groups (Downing et al., 2012). There may be several reasons for this, 
such as that these individuals have had more time to adjust to the results (Downing et al., 2012) 
or have less insight into their difficulties (Duff et al., 2010). Alternatively, it may be that the 
 
 
THE EXPERIENCE OF LIVING IN THE PRE-MANIFEST STAGE OF HD  2-28 
longer period of time since diagnosis may have resulted in individual’s developing more 
adaptive views of their illness and experiencing meaning from their experience, both of which 
have been shown to lead to increased optimism in individuals with other chronic illness (Lee et 
al., 2006). Given little is known about the effects of optimism on perceived stress, mood and 
overall wellbeing, and the relationship between levels of optimism and HD disease trajectory, 
this exploration would offer an important avenue for future research.   
 
Conclusion  
This study has highlighted the difficulties experienced by individuals when adjusting to 
the pre-manifest stage of HD. The results found that the experience of living in the pre-manifest 
stage of HD involves navigating the difficulties of feeling limited by the time they have left 
symptom free by holding onto hope for future treatments and in making the most of their 
symptom free present. Indeed, positivity and hope were key factors in helping individuals to 
manage their anxieties and dealing with ongoing uncertainty related to future deterioration. In 
developing our understanding of how people in the pre-manifest stage maintain their wellbeing, 
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Table 1: Participants’ demographics 
 
Participant Gender Age Marital status Children Time since 
genetic test 
Paul Male 44 Married One 3 yrs 
Angie Female 36 Single None 4 yrs 
Daisy Female 31 Married Two 5 yrs 
Catherine Female 38 Single None 6 yrs 
Steve Male 50 Co-habiting One 3 yrs 
Joanna Female 29 Married Two 2 yrs 
Carol Female 50 Married Two 4 yrs 
Hannah Female 25 Cohabiting One 4 yrs 
Sharon Female 36 Married None 8 yrs 
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Appendix 2-C: From initial concepts to emerging themes (Steve) 
Initial concepts  Emerging themes  Supporting Quotes  
Having control over when one discloses the result  
Test taking as a way to find out the unknown  
The result enabling plans to be made  
Knowledge as something one can do something 
about  
The test result as providing power  It’s not so much keeping it a secret it’s just not letting information 
come out until it's ready to and in the right way  
It’s far better to know than not to know  
And again she tested positive before we told my mum. I told her 
and we sort of came up with the plan  
You can do something about it or not as the case may be. But can 
do something about it  
Reassurance provided by family history of the 
disease  
Reliance on the drug trials as a way to maintain 
belief in not getting symptoms  
Hope that one will never reach symptom onset  
Protecting himself from the emotional side of HD  
The ability to throw walls around in your mind  
  
No intention of becoming 
symptomatic  
  
So, it’s been up and down but obviously it’s mitigated by the fact 
it’s late onset  
I am relying on the fact that there are many drugs in the pipeline 
that will delay it  
I have no intention of becoming symptomatic  
So I could protect myself from the emotional side of things by 
thinking, you know, my mum’s gonna be really upset if she finds 
out  
It’s having an ability to throw, throw walls around in your mind 
throw walls around things you don’t want to think about  
The need to do things you’ve always wanted to do  
Living for the moment  
No stressing over the small stuff  
Think about the positive things  
Gratitude and feeling fortunate  
Re-evaluating what matters in life  
  
Yes, it does focus you, it means I do try to just do things I want to 
do   
…right you’ve got to go and do all your bucket list type things 
and do various things and live for the moment  
….try not to get too stressed about stuff  
It’s had a positive impact because it’s made me do things and 
appraise various aspects of my life  
I’m fortunate in that the work that I do is inside and outside so it’s 
quite a mixture  
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Participating in research as way to cope  
Research as a selfish act-a way to get the drugs 
first  
Research as a way to help others  
Making a positive out of a negative  
The need to contribute to the 
research  
  
It’s my own way of burying my head in the sand. Just ignoring it, 
and everyone that has got it, so I can take part in the research like 
I say in a slightly selfish version of if the drugs come out or if 
some form of delaying the onset comes about then I’m first in the 
queue to get it all  
Taking part in the research it makes you feel good because you 
are helping other people to find out thing  
trying to make a positive action now to something that is quite 
negative  
Constantly questioning  
HD as constant background noise  
Emotional rollercoaster as being a typical response   
Emotional rollercoaster of the 
result  
So that’s the biggest problem is just constantly going “yeah is that 
an early sign, or not?”   
It’s that sort of constant background noise in your life  
…this seems to be typical talking to people that have been 
through the testing process as well in that once you find out it's 
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Appendix 2-D: Theme identification across participant transcripts1 
 
1 All participants contributed to every theme 
Individual participant themes Refining Themes Superordinate 
theme (subordinate themes in 
brackets) 
Participants contributing 
to the theme 
Assuming the worst, feeling one knows the 
result, period of adjustment after the test, ups 
and downs, lack of control, test impacting 
future planning, test changing decision to 
have children, doors closing after the test 
The implications of test taking 
in limiting their life and the 
emotions which come with that  
Feeling limited by time 
(countdown to symptom onset, 
HD dictating the present) 
Paul, Angie, Daisy, 
Steve, Joanna, Catherine, 
Hannah, Sharon, Carol, 
Jake  
Activities aimed to prolong symptom onset, 
family experience of the disease, dark side of 
HD, knowing when one will get symptoms 
based on family pattern, hope for future cure, 
believing own symptom onset will be 
different, taking part in the research to 
contribute to the HD knowledge 
Using family experience of the 
disease to predict own onset 
whilst hoping for medical cures 
to alleviate symptoms 
The perception of            
stalling time (distancing self 
from HD, holding onto hope) 
Paul, Angie, Daisy, Steve,   
                   Joanna, 
Catherine, 
Hannah, Sharon, Carol, 
Jake  
Making the most out of life, holding onto the 
positives, being grateful for family and 
friends, feeling able to cope, refocusing 
attention, not worrying about the little things, 
avoiding thoughts of the future, reflecting on 
the worse situation of others, not putting up 
with negative environments 
Being positive in the present 
and making the most of the now 
and spending time with valued 
others  
The need to embrace time (the 
need to stay positive, choosing 
valued connections) 
Paul, Angie, Daisy,  Steve,  
Joanna, Catherine, 
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Overview 
This critical analysis will first consider how the findings from both the research paper 
and the literature review might relate to one another, and in doing so suggest themes which 
might be applicable to living with a chronic illness more widely. The analysis also reflects on 
the clinical implications of the two papers and the need for a more coherent definition of 
adjustment. The analysis which follows will then discuss personal reflections on conducting 
the research as well as considering the crucial role of reflexivity to this process. Finally, the 
paper will make suggestions for areas of future research.  
Research Findings 
Before drawing comparisons between the papers with the aim of discussing the 
implications for transdiagnostic themes for adjusting to living with a neurological condition, 
it is worth considering the validity of the findings of the individual papers. Regarding the 
meta-synthesis, the themes developed from the data were all present in several of the papers 
assessed as being of high quality on the Critical Appraisal Skills Programme (CASP) 
checklist, suggesting the validity of the findings of the review. Regarding the research paper, 
which sought to obtain the experiences of individuals in the pre-manifest HD, it is worth 
considering possible deficits in their levels of insight, as problems with executive function are 
observed in individuals with manifest HD (Ho et al., 2006). Regarding the research 
participants, whilst no objective determinant of their cognitive function was obtained, the 
participants seemed to demonstrate a high level of insight into the future challenges they 
faced, reflected in their planning for future deterioration. Whilst not expressing acute 
psychological distress, participants did reflect on the real psychological difficulties they had 
experienced at times; as such their avoidance of thinking about future deterioration did not 
reflect lack of awareness but served as a coping mechanism to help them cope with their 
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fears. As such, the research findings from both papers can be considered valid in considering 
the experiences of individuals of the phenomenology under question.  
 The research paper found three main themes that captured participants’ experiences 
of adjusting to living in the pre-manifest stage of Huntington’s disease (HD): (1) Feeling 
limited by time-“Trigger for a countdown”, (2) The perception of stalling time-“I have no 
intention of becoming symptomatic and (3) Making the most of time-“I could be hit by a bus 
tomorrow”. Such findings highlight how the nature of time takes on a new level of meaning 
for individuals when they become aware they will develop HD. Describing their experiences 
through the lens of time may be one way in which individuals make sense of their self as an 
individual with pre-manifest HD and create a coherent narrative of their illness experience 
(Ellingsen et al., 2014). Interestingly, the meta-synthesis-exploring how individuals adjust to 
living with Parkinson’s disease (PD)- proposed three main themes relating to the process of 
adjustment: ‘maintaining a coherent sense of self’, ‘feeling in control’ and ‘holding a positive 
mindset’. The theme ‘maintaining a coherent sense of self’ revealed a similar need for 
participants to create a narrative of their illness experience in order to maintain their sense of 
self. This narrative reflected how individuals with PD can integrate their illness identity into 
their previous sense of self through a process of accepting their limitations alongside the need 
to maintain past roles and responsibilities (Williams & Keardy, 2008). Although the research 
participants were not yet experiencing any symptoms of their condition, accounts from across 
the papers indicate that adjustment may be a process which begins at the point at which one 
experiences a threat to their sense of self.  
For individuals living in the pre-manifest stage of HD, regaining control over the 
uncontrollable helped them to manage its unpredictable nature, in which they described 
clinging onto hope for future medical treatments and contributing to the research as important 
ways of ‘stalling time’. This need to regain control over the illness trajectory was also 
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prevalent in the meta-synthesis, contributing to the theme ‘feeling in control’. For individuals 
living with PD, the physical and mental deterioration prompted many to start or re-engage 
with physical activities, in order to provide them with a sense that they were able to prolong 
illness deterioration. Similarly, medication management and control over their day to day 
routines helped individuals to feel better able to manage their symptoms. Consequently, both 
papers describe the connection between the uncontrollable nature of the illness and the 
personal efforts and motivation of participants to regain control. Interestingly, although some 
participants interviewed for the empirical paper described the importance of physical activity 
in order to prolong symptom onset, it did not emerge as a significant theme. Perhaps the very 
tangible nature of physical deterioration experienced by those with PD heightens the 
relevance of exercise in order to maintain one’s wellbeing. Gaining control over symptoms 
through self-management (primary control) allowed individuals to feel more in control of 
their life and better able to adapt to disease related limitations (secondary control). This felt 
important given the uncontrollable nature of disease progression. Even if control of disease 
may not be possible, global life control and feelings of self-efficacy rather than control over 
the disease per se can also be important for individuals experiencing PD symptoms (Eccles & 
Simpson, 2011). For individuals living in the pre-manifest stage of HD, primary control may 
be higher given their functioning remains intact and they are not yet experiencing symptoms, 
thus secondary control efforts (such as the belief that exercise can prolong symptom onset) 
may have less relevance. As long as an individual’s circumstances are able to promote 
personal control efforts, there is likely to be a fit between an individual’s perception of 
control and what they are actually able to influence, such that secondary control efforts are 
less important (Reich & Zautra, 1990).  
Despite the challenges imposed by a progressive, neurodegenerative condition, 
participants across both papers were able to reflect on the positive aspects of their 
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experiences. Indeed, such experiences were deemed integral to the adjustment process. It was 
this ability to focus on the positive aspects of the knowledge and embrace their present which 
helped the research participants to maintain a positive mindset and look optimistically 
towards one’s future. Many of the individuals living with PD also described how 
acknowledging their future deterioration allowed them to focus on their present with 
positivity and determination. By focusing on the small things which generated happiness in 
their daily lives and being grateful for one’s circumstances, individuals were able to reduce 
the burden of PD. A positive mindset and sense of gratitude were also reinforced in both 
papers through social comparison. It seems that irrespective of their own degree of 
impairment, an individual can strengthen their self-image by finding someone else to 
compare with who they perceive as worse off than themselves (Eriksson & Ahlgren, 2013). In 
a review outlining the process of adjustment to chronic illness, Sharpe and Curran (2006) 
highlight how benefit-finding in chronic illness is an adaptive strategy that decreases the 
incongruence between situational and global meaning. Congruence between an individual 
and their environment enables an individual to satisfy their needs and motivations and thus 
contributes to positive adjustment (Lawton, 1985).  
Of equal relevance is the way in which the papers provide novelty in describing 
condition-specific aspects of individuals’ experiences. Regarding the research paper, 
individuals described the emotional rollercoaster of the period after receiving the test results. 
Although the meta-synthesis described the emotional challenges of receiving a diagnosis, the 
complexity of this experience was not described in detail. In contrast, individuals living in the 
pre-manifest stage of HD described the seemingly precarious nature of the peaks and troughs, 
where fear and hope could be described as simultaneous experiences. It was this ability to 
hold onto hope despite the “constant background threat” of HD which allowed individuals to 
adjust to their situation. The meta-synthesis also described how some individuals perceived 
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PD as a threat to their identity, with physical and cognitive deterioration threatening 
fundamental aspects of who they wanted to be. However, in the research paper, this threat 
was transformed into something of an unrelenting nature; whilst most individuals with PD 
acknowledged the threat as a transitory concept, for individuals living in the pre-
manifest stage of HD this threat was always lurking in the background of their life. It was the 
fear of the unknown which seemed to heighten the intimidation of the threat; for individuals 
living with PD, diagnostic support and first-hand experience of symptoms allowed them to 
accommodate and manage how the threat operated within their lives.    
Clinical Implications 
Both papers indicate the psychological processes which seem to be beneficial to 
support someone either diagnosed with, or with the knowledge of, a progressive 
neurodegenerative illness. This is important considering that, in conditions such as PD, a 
greater understanding of the role of psychological difficulties in presenting distress has led to 
an increasing number of psychologically informed interventions for people with PD (Zarotti, 
Eccles et al., 2020). This has important relevance for the research paper, given the current 
research on psychological interventions is extremely limited in people affected by HD 
(Zarotti, Dale et al., 2020). The empirical research develops our understanding of the 
important factors which facilitate an individual’s adjustment to the condition, and in doing so 
provide a focus for the application of psychological approaches.  
The meta-synthesis identified the importance of peer support groups in offering a 
space for sharing and validating of one’s experiences, a concept echoed by individuals in the 
research paper in helping individuals to feel less alone. Providing a safe forum to share 
experiences and managing emotive group dynamics is an area of expertise which lends itself 
well to the role of clinical psychologist (Brown et al., 2002). The benefits of group-based 
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intervention was identified in the systematic review, and also in a study of individuals in the 
pre-manifest stage of HD, where participants described how it was helpful to meet others in a 
similar situation and that just working together in a group was itself therapeutic (Eccles et al., 
2020). Furthermore, there is evidence to suggest that group sessions can help to provide a 
safe space for self-expression (Stopford et al., 2020). Such group-based interventions may 
involve the principles of acceptance and commitment therapy (ACT), which encourages 
individuals to embrace valued living despite the challenges they face (Harris, 2009). ACT has 
shown promising evidence of its effectiveness for people with neurological conditions 
(Graham et al., 2014; McLeod, 2015; Whiting et al., 2019). Considering the literature on 
adjusting to PD highlighted the importance of social comparison in benefit finding and 
positive thinking, introducing ACT principles through a peer-support format appears fitting. 
Any group-based intervention needs to accommodate the neuropsychological profile of the 
individual group members, as an individual with cognitive difficulties may find abstract 
psychological concepts or ACT metaphors more challenging, or experience difficulties with 
inhibiting thoughts and thus struggle with cognitive defusion (Hill et al., 2017). Furthermore, 
difficulties in skills which underlie social cognition have been observed in conditions such as 
PD (Dodel et al., 2010), which could preclude therapeutic work which requires social 
interaction. Nevertheless, more recent studies have suggested that difficulties in social skills 
observed in some individuals may reflect deficits in executive function rather than social 
cognition per se, and impaired social cognitive performance can be eliminated by reducing 
the processing demands of the task (Foley et al., 2019).This highlights the need to adapt to 
tailor delivery of the approach to the person’s idiosyncratic neuropsychological context 
(Wilson et al., 2009). This might involve using more written handouts for complex concepts, 
using more visual aids, explaining metaphors using more concrete examples and repeating 
key messages (Hill et al., 2017).  
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Reflexivity 
An assumption of IPA is that researchers interpret data through the lens of their own 
psycho-social context and prior understandings (Shaw, 2004); IPA thus involves a dialogue 
between the participant’s understanding of their experience and the researcher’s interpretation 
of that understanding (Shaw et al., 2014). Reflexivity is thus a core component within IPA, 
given the need to continually reflect on the meaning which we generate from the data in the 
analysis process (Shaw, 2010). The active involvement of the researcher in the generation of 
the participant’s narrative has been criticised as potentially limited the validity of the research 
results (Pringle et al., 2011). Consequently, it was important to follow guidelines outlined by 
Yardley (2008) which help to improve the validity of qualitative research. I implemented a 
number of processes to improve the validity of this qualitative research. Of note, the 
supervisory process enabled me to explore the theme identification and content of the 
interviews to ensure credibility of the interpretation. Regular discussion with my field 
supervisor, who works in a HD clinic, also contributed to the sensitivity to context. With 
regards to the meta-synthesis, regular reflection using a reflective diary enabled me to 
appreciate my own preconceptions of what adjustment might mean when considering the 
relevance of papers and in the identification of papers. Consequently I was able to appreciate 
my own influence on both the way I which I collected data and the weight of interpretation 
given to participant accounts (Finlay, 2002).  
Personal reflections 
Recruitment of participants 
Recruiting participants was initially focused on inviting people through a clinical 
psychology service, as it was hoped this would provide accounts of individual’s who may 
provide insight into their experience of HD alongside an appreciation of what psychology can 
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offer to the adjustment process. It also meant that participants were already known to one of 
the supervisors, thus facilitating eligibility checks and enabling recruitment to be undertaken 
by research nurses who were already known to the individual. However, following initial 
difficulties with recruitment, and considering the additional burden it placed on the research 
nurses (who also maintained a clinical role), it felt appropriate to extend recruitment to the 
Huntington’s Disease Association (HDA), which was identified as the second recruitment 
route within the ethics application. In retrospect, it may have been helpful to recruit through 
one channel only, as a key aspect of IPA studies is the homogeneity of the sample (Smith et 
al., 2009), which produces an in depth analysis of participants’ accounts rather than a 
representative sample (Touroni and Coyle, 2002). I think recruiting through a community 
organisation rather than solely through NHS services ensured I also captured the experience 
of those not receiving the support required to adjust to their condition and this lack of 
healthcare support is something which many individuals with HD experience (Dawson et al., 
2004). 
 Eligibility criteria for participants were that they needed to have tested positive for the 
HD gene one year or more prior to interview and to have no significant comorbid physical 
condition.  This felt important because living with a comorbid physical health condition is 
likely to present significant additional challenges to living with HD pre-manifest and it would 
be difficult to separate out those experiences from the experiences which were related to 
having the HD gene. Nevertheless, future research should focus on the experience of those 
with pre-manifest HD and a comorbid physical health condition; given such a population are 
likely to be in even greater need of psychological support, a better understanding of their 
experiences is warranted. It was notable that the majority of the individuals in the present 
study were coping remarkably well in the pre-manifest stage of HD and themes of positive 
coping were predominantly not reflected in my field supervisor’s experience of those 
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accessing psychological input. It may be anticipated that the eligibility criteria may have 
falsely limited the sample to those who were coping well, given that studies of the 
psychological impact of the test results highlight that the first year after testing may be 
especially difficult for individuals (Almqvist et al., 2003). The experience of individuals in 
the pre-manifest stage of HD is unlikely to be one of linear adjustment and difficulties are to 
be anticipated when living with the knowledge of future deterioration. It has been suggested 
that individuals around 9-15 years away from HD diagnosis may experience increased stress 
due to possible signs of the disease becoming more evident (Downing, et al., 2012). Most of 
the participants in the present study were likely further away from diagnosis yet had 
experienced some time to adjust to the initial test results which in turn, may have contributed 
to them describing their adaptive experiences. 
Data analysis 
IPA was chosen as my method for data analysis given its ability to offer an 
idiographic lens on each of the participant’s experience. The way in which emphasis was 
placed on the uniqueness of each individual and the personal meaning ascribed to their 
experience (Smith et al., 2009) felt important to me in order to truly validate each person’s 
account. In contrast, an alternative approach such as grounded theory or thematic analysis 
focuses on the emerging patterns within the data or superordinate theories in its analysis, 
rather than the way in which an experience is embodied and given meaning by the 
individual’s relationship to their experience (Starks et al., 2016). IPA enables the patterns in 
the data to generate salience or meaning for the researcher, but crucially, an individual’s 
voice in those patterns are not lost.  
An alternative approach to hearing the voice of the participants is narrative analysis. 
Narrative analysis is an approach where the participants’ stories are the raw data (Bleakley, 
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2005) and focuses on the context of the narrator, including their culture, history, identity and 
lifestyle (Lieblich et al., 1998). An attempt is made to understand what participants do with 
narratives in the process of storytelling and how they position themselves in the storytelling 
process (De, Fina & Georgakopoulou, 2015). The narrative analyst also recognises that 
telling stories is fundamental to the process of identity construction and seeks to explore how 
this identity construction takes place in a situated social context.  It helps us to understand the 
different levels involved in stories and the way it functions as a means for the individual to 
share and disseminate knowledge. As an approach however, the focus is on studying a small 
number of individuals, collecting their stories and reporting their experiences and then 
chronologically ordering the meaning of those experiences (Creswell et al., 2007). The aim is 
to restory the participants’ narratives by collecting their story, analysing the key elements and 
then writing them within a chronological sequence (Ollerenshaw & Creswell, 2000). Whilst 
time did emerge through the process of data analysis, the meaning of time in relation to the 
individuals’ experiences did not account for a chronological order but reflected the 
participant’s concurrent differing understandings of time as situated in their present day 
experience. As an approach it does not typically deal with self-contained stories and does not 
treat an individual’s story as a holistic account, instead focusing on the meaning of an 
individual’s story as it unfolds in a societal context (Esin et al. 2014). As the aim of the 
present research was to gain a better understanding of the experience of the pre-manifest 
stage as obtained by individual accounts, rather than focusing on the context of an 
individual’s narrative and how it had shaped their experience, IPA was deemed more 
appropriate for the present research. 
 One criticism of the IPA approach, namely that it incorporates researcher bias (Kacen 
& Chaitin, 2006). Nevertheless, IPA openly acknowledges this criticism, being explicit about 
the assumptions of researcher involvement in interpretation of the data and highlighting the 
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importance of reflexivity as a means of quality control (Berger, 2013). Smith and Osborn 
(2003) acknowledge that the researcher often influences the direction of a participant’s 
account and must be mindful both of how much directing of the interview is acceptable but 
also that different directions often enlighten the exploration. An essential component within 
IPA research is the recognition that the researcher’s relationship to the participant’s account 
is dependent upon and shaped by their subjective perspective and that this subjective 
perspective also occurs within their specific context (Pietkiewicz & Smith, 2014). This 
researcher interpretation of the participant’s interpretation of their experience, a double 
hermeneutic, is made transparent within the research process. A fundamental part of the IPA 
process is continual reflexivity, ongoing engagement with personal context and immersivity 
with the data, which ensure the results are grounded in the data. IPA understands that the 
experience of an individual cannot be separated from the individual’s context and their 
relationships (Chapman & Smith, 2002); for the individuals in the present study, living with 
pre-manifest was a familial and social experience, thus IPA appeared to be the most 
appropriate approach. 
Future research 
The sample in the empirical paper were all White British, despite recruiting from an 
NHS Trust with a diverse ethnic population and a social media channel which was not limited 
to geographical location. Although this lent itself well to the requirements of homogeneity 
within IPA studies, it raises the questions as to whether services for individuals with HD/pre-
manifest HD are accessible to ethnic minority groups. Furthermore, the meta-synthesis 
included studies which were all conducted in European countries with western populations, 
suggesting research on adjustment processes more widely has been limited to Eurocentric 
populations. An inclusion criterion for the papers in the meta-synthesis was that the paper had 
to be written in English, further limiting the research to those conducted in Western countries. 
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This limits the generalisability of the study and means we have little understanding of 
adjustment processes to neurological disease within other cultures. It may be anticipated that 
adjustment is a culturally dependent construct, given many aspects of the adjustment process 
was intertwined with an individual’s social context and the meaning of illness within their 
society (Stanton et al., 2007). Future research should therefore seek to explore how 
individuals from other cultures adjust to the experience of a neurological disease.   
It is also noteworthy that the levels of optimism in the research participants’, whilst 
appearing to contribute to successful adjustment for the studied individuals, could be 
considered a form of denial. Their ambitious hopes for treatment which would prevent their 
own symptom onset was not matched by the reality of the medical advances; so too, their 
convictions that their own symptom onset was a distant reality because of their parent’s 
disease onset belied the reality that parental age of onset is only one predictor of the age of 
onset of the offspring. Both beliefs could be considered unrealistic levels of optimism which 
helped them to avoid or deny the reality of their likely future. Researching the longitudinal 
outcomes of unabated optimism to better understand whether there is an ‘optimal’ level of 
optimism is important in order to help psychological professionals to tailor their 
interventions. Regarding PD, there is evidence to suggest that the relationship between 
optimism and outcome may be non-linear (Hurt et al., 2014), where individuals with very 
high levels of optimism have been observed to use less adaptive coping strategies and do not 
experience higher levels of psychological wellbeing than those displaying medium levels of 
optimism (deRidder et al., 2000). It is suggested that high levels of optimism may prevent 
people from feeling the need to self-manage their condition or take action to minimise health 
related deterioration (deRidder et al., 2000), much in the same way the denial shown by 
participants in the present study may have prevented them from engaging in efforts to 
improve their wellbeing. Nevertheless, optimism has been shown to be beneficial for 
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individuals with PD in helping to protect against the effect of negative illness perceptions 
(Hurt et al., 2014), highlighting that some level of optimism is important. Future research 
needs to better understand the relationship between levels of optimism and clinical outcome 
for those experiencing other neurological conditions such as HD. Educating health 
professionals about how to empower individuals living with a progressive condition through 
realistic levels of hope, whilst broaching sensitive conversations about the very real 
prognosis, may better equip individuals with the tools needed to self-manage or indeed to 
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bodies reviewing your study. Please ensure you answer all the questions before proceeding with your applications. 
 
Please complete the questions in order. If you change the response to a question, please select ‘Save’ and review all the 
questions as your change may have affected subsequent questions.  
 
 
Please enter a short title for this project (maximum 70 characters)  
Living in the premanifest stage of Huntington’s disease. 
 
1. Is your project research? 
 
 Yes  No  
 
 
2. Select one category from the list below: 
 
Clinical trial of an investigational medicinal product 
 
Clinical investigation or other study of a medical device 
 
Combined trial of an investigational medicinal product and an investigational medical device 
 
Other clinical trial to study a novel intervention or randomised clinical trial to compare interventions in clinical practice 
 
Basic science study involving procedures with human participants 
 
Study administering questionnaires/interviews for quantitative analysis, or using mixed quantitative/qualitative 
methodology 
 
Study involving qualitative methods only 
 
Study limited to working with human tissue samples (or other human biological samples) and data (specific project 
only) 
 
Study limited to working with data (specific project only) 
 




If your work does not fit any of these categories, select the option below: 
 
 Other study  
 
 
2a. Please answer the following question(s):   
a) Does the study involve the use of any ionising radiation? Yes No 
b) Will you be taking new human tissue samples (or other human biological samples)? Yes No 
c) Will you be using existing human tissue samples (or other human biological samples)? Yes No 
   
   
3. In which countries of the UK will the research sites be located?(Tick all that apply)   
England   
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This study does not involve the NHS  
 
 
4. Which applications do you require? 
 
 IRAS Form 
 Confidentiality Advisory Group (CAG)  





Most research projects require review by a REC within the UK Health Departments' Research Ethics Service. 
Is your study exempt from REC review? 
 
 Yes       No  
 
 
5. Will any research sites in this study be NHS organisations? 
 
 Yes       No  
 
 
5a. Are all the research costs and infrastructure costs (funding for the support and facilities needed to carry out 
research e.g. NHS Support costs) for this study provided by a NIHR Biomedical Research Centre, NIHR Collaboration 
for Leadership in Health Research and Care (CLAH C), NIHR Patient Safety Translational Research Centre or Medtech 
and In Vitro Diagnostic Cooperative in all study sites? 
 
Please see information button for further details. 
 
 Yes       No 
 
Please see information button for further details.  
 
5b. Do you wish to make an application for the study to be considered for NIHR Clinical Research Network 
(CRN) Support and inclusion in the NIHR Clinical Research Network Portfolio? 
 
Please see information button for further details. 
 
 Yes       No 
 
The NIHR Clinical Research Network provides researchers with the practical support they need to make clinical studies 
happen in the NHS e.g. by providing access to the people and facilities needed to carry out research “on the ground". 
 
If you select yes to this question, you must complete a NIHR Clinical Research Network (CRN) Portfolio Application Form 
(PAF) immediately after completing this project filter question and before submitting other applications. Failing to complete the 
PAF ahead of other applications e.g. HRA Approval, may mean that you will be unable to access NIHR CRN Support for your 
study.  
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7. Do you plan at any stage of the project to undertake intrusive research involving adults lacking capacity to 
consent for themselves? 
 
 Yes       No 
 
Answer Yes if you plan to recruit living participants aged 16 or over who lack capacity, or to retain them in the study following 
loss of capacity. Intrusive research means any research with the living requiring consent in law. This includes use of 
identifiable tissue samples or personal information, except where application is being made to the Confidentiality Advisory 
Group to set aside the common law duty of confidentiality in England and Wales. Please consult the guidance notes for 
further information on the legal frameworks for research involving adults lacking capacity in the UK.  
 
8. Do you plan to include any participants who are prisoners or young offenders in the custody of HM Prison Service 
or who are offenders supervised by the probation service in England or Wales? 
 




9. Is the study or any part of it being undertaken as an educational project? 
 
 Yes       No 
 
Please describe briefly the involvement of the student(s):  
The student will be undertaking the research as part of a required piece of assessed work in order to obtain a 
doctorate in clinical psychology. The student will be the primary researcher supervised by a member of the university 
and an NHS psychologist.  
 
 
9a. Is the project being undertaken in part fulfilment of a PhD or other doctorate? 
 
 Yes       No  
 
 
10. Will this research be financially supported by the United States Department of Health and Human Services or any 
of its divisions, agencies or programs? 
 
 Yes       No  
 
 
11. Will identifiable patient data be accessed outside the care team without prior consent at any stage of the 
project (including identification of potential participants)? 
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Integrated Research Application System  
Application Form for Research involving qualitative methods only  
 
 
The Chief Investigator should complete this form. Guidance on the questions is available wherever you see this symbol 
displayed. We recommend reading the guidance first. The complete guidance and a glossary are available by selecting 
Help. 
 





Short title and version number: (maximum 70 characters - this will be inserted as header on all forms) 
Living in the premanifest stage of Huntington’s disease.  
 
 
PART A: Core study information  
 
1. ADMINISTRATIVE DETAILS  
 
A1. Full title of the research: 
 
Exploring individuals’ experiences of living in the premanifest stage of Huntington’s disease.  
 
 
A2-1. Educational projects 
 





 Title   Forename/Initials Surname 
 Miss  Gina Wieringa 
Address Lancaster University  
 Lancaster  
Post Code LA14YT  
E-mail g.wieringa@lancaster.ac.uk 
Telephone 07985185645  
Fax   
 
Give details of the educational course or degree for which this research is being undertaken: 
 
Name and level of course/ degree:  
Doctorate in clinical psychology 
 






Name and contact details of academic supervisor(s): 
 
Academic supervisor 1 
 
 
Title Forename/Initials Surname  
Dr Fiona Eccles 
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  Lancaster   
 Post Code LA14YT   
 E-mail f.eccles@lancaster.ac.uk   
 Telephone 44 (0)1524 592807   
 Fax    
      
 
Please state which academic supervisor(s) has responsibility for which student(s):  
Please click "Save now" before completing this table. This will ensure that all of the student and academic supervisor 
details are shown correctly. 
 
 Student(s) Academic supervisor(s)  
 
Student 1  Miss Gina Wieringa 
   
 
Dr Fiona Eccles 
 
   
     
     
     
 
A copy of a current CV for the student and the academic supervisor (maximum 2 pages of A4) must be submitted with the 
application.  
 






 Other  
 
 
A3-1. Chief Investigator:   
 Title   Forename/Initials Surname 
 Miss  Gina Wieringa 
Post Trainee Clinical Psychologist 
Qualifications BSc Psychology  
ORCID ID   
Employer Lancaster University  
Work Address Doctorate in Clinical Psychology 
 Lancaster University  
 Lancaster  
Post Code LA1 4YT  
Work E-mail g.wieringa@lancaster.ac.uk 
* Personal E-mail g.wieringa@lancaster.ac.uk 
Work Telephone   
 
* Personal Telephone/Mobile 07985185645 
Fax 
 
* This information is optional. It will not be placed in the public domain or disclosed to any other third party without prior 
consent.  
A copy of a current CV (maximum 2 pages of A4) for the Chief Investigator must be submitted with the application.  
 
A4. Who is the contact on behalf of the sponsor for all correspondence relating to applications for this project? This 
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 Title Forename/Initials Surname 
 Ms Becky Gordon 
Address Head of Research Quality and Policy 
 Research Services   
 Lancaster University   
Post Code LA1 4YT   
E-mail sponsorship@lancaster.ac.uk 
Telephone (0)1524 592981   
Fax     
     
       
A5-1. Research reference numbers. Please give any relevant references for your study: 
 
Applicant's/organisation's own reference number, e.g. R & D (if 
N/A 
available):  
Sponsor's/protocol number: N/A 
Protocol Version: 0.1 
Protocol Date: 25/03/2019 








Additional reference number(s): 
 
Ref.Number Description Reference Number 
 
 
Registration of research studies is encouraged wherever possible. You may be able to register your study through 
your NHS organisation or a register run by a medical research charity, or publish your protocol through an open 




A5-2. Is this application linked to a previous study or another current application? 
 
 Yes       No 
 
Please give brief details and reference numbers.  
 
 
2. OVERVIEW OF THE RESEARCH  
 
To provide all the information required by review bodies and research information systems, we ask a number of 
specific questions. This section invites you to give an overview using language comprehensible to lay reviewers 
and members of the public. Please read the guidance notes for advice on this section.  
 
A6-1. Summary of the study. Please provide a brief summary of the research (maximum 300 words) using language 
easily understood by lay reviewers and members of the public. Where the research is reviewed by a REC within the UK 
Health Departments’ Research Ethics Service, this summary will be published on the Health Research Authority (HRA) 
website following the ethical review. Please refer to the question specific guidance for this question. 
 
Huntington's Disease (HD) is an inherited neurodegenerative disorder which causes significant impairment in movement 
and thinking. Depression and other mood changes have been reported in individuals who have tested positive to the 
genetic test for HD but prior to showing motor symptoms (Martinez-Horta et al., 2014), which are necessary to receive a 
formal diagnosis. This suggests that living at risk of HD is itself very challenging emotionally and this study aims to 
explore the experience of these individuals. Interviews will be used to explore the process by which individuals adjust to 
the positive test result and how the individual’s identity changes to include being a gene-positive carrier. The study will 
explore both positive and negative coping mechanisms which individuals describe in order to get a better understanding 
of how they come to terms with finding out they will develop HD. The study will also 
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discuss the important clinical implications which arise from getting a better understanding of the process of 
adjustment; this includes a) long-term support for individuals who test positive to carrying the HD gene mutation but 
have not yet received a diagnosis and b) sharing important findings about coping strategies which may help 
individuals to show more positive adjustment responses.  
 
 
A6-2. Summary of main issues. Please summarise the main ethical, legal, or management issues arising from your study 
and say how you have addressed them. 
 
Not all studies raise significant issues. Some studies may have straightforward ethical or other issues that can be identified 
and managed routinely. Others may present significant issues requiring further consideration by a REC, R&D office or other 
review body (as appropriate to the issue). Studies that present a minimal risk to participants may raise complex organisational 





1. Confidentiality. The research team will not have access to participants' personal details without their consent. The 
nature of how we obtain personal details of the participant will depend upon the recruitment method: 
 
If recruitment is via one of the NHS Trusts, participants will be initially approached by a member of the clinical team 
involved in their care and will have to explicitly provide their details to members of the research team, or give their 
verbal consent to the clinical team for their details to be passed to myself (Gina). 
 
If enough participants cannot be recruited via the NHS Trusts, then participants will be recruited via the HDA website. 
Participants will have to approach myself in order to provide their details and give their verbal consent for their details 
to be used by the research team 
 
2. Risk of harm to participants. The interview is not expected to cause participants significant distress. However, 
participants who participate will be fully briefed beforehand about any possible adverse effects of the interview. Should 
any of the participants disclose they are at risk of harming themselves or others then a member of the participant's 
clinical team will be informed. For participants recruited via the HD , the appropriate authority will be informed. Where 
possible the participant will be informed if this is necessary. 
 
3. Risk of harm to researchers. In the event that researchers become distressed by the emotive subject of the 
research, there are support networks surrounding the research team which can be utilised for confidential emotional 
support. The students will be able to receive support from their supervisors. If conducting any home visits to conduct 
the interview, the researchers will follow Lancaster University's guidance regarding lone working. 
 
4. Data storage. All electronic data will be encrypted and stored on the secure University Network for the duration of the 
project. Such storage location may include secure cloud storage (e.g. Box) which is accessible via the university and is 
deemed to meet the university's requirements for secure storage. Again, this data will be encrypted via password 
protection. Paper data (e.g. consent forms) will be scanned in and destroyed.  
 
 
3. PURPOSE AND ESIGN OF THE RESEARCH  
 
A7. Select the appropriate methodology description for this research. Please tick all that apply: 
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Questionnaire, interview or observation study 
 
Randomised controlled trial 
 
Other (please specify)  
 
 
A10. What is the principal research question/objective? Please put this in language comprehensible to a lay person. 
 
How do individuals with pre-manifest Huntington's disease adjust to living with knowing they will develop the disease?  
 
 
A11. What are the secondary research questions/objectives if applicable? Please put this in language comprehensible to 
a lay person. 
 






A12. What is the scientific justification for the research? Please put this in language comprehensible to a lay person. 
 
Huntington’s disease (HD) is an inherited disorder which often starts with affective disturbances such as depression and 
culminates in significant cognitive deficits and motor abnormalities (Du, Pang, yc & Hannan, 2013). Predictive testing has 
allowed individuals who are at risk of HD to find out whether they will develop the disease, prior to showing any motor 
symptoms. Although this has allowed researchers to study the natural course of the disease and provide opportunities for 
early intervention, the test raises significant ethical issues regarding the potentially devastating consequences which 
living with the knowledge of the test result entails (Lilani, 2005). By offering the predictive test, the NHS has an ethical 
and moral responsibility to understand the impact of genetic testing and to support individuals with the long-term 
consequences (Andersson, Petersén, Graff & Edberg, 2016).  
 
Although much research has been done identifying psychological consequences of a positive test result, the focus is 
generally on clinical symptoms such as anxiety and depression, the implications for a person’s quality of life or on 
adverse events such as family breakdown or suicide (Codori & Brandt, 1994). There has been little research into how an 
individual who has tested positive to the HD gene but is not yet symptomatic adjusts to living in the knowledge they will 
develop HD. 
 
Additionally, the nature of adjustment to living in the pre-manifest stage of HD needs clarification because this process is 
likely to be idiosyncratic, depending on a multitude of different factors. The perceived prognosis of the condition (likely 
shaped by an individual’s experiences), the rapidity of any health decline and the duration of the asymptomatic period will 
all likely influence the adaptive nature of one’s adjustment to the illness (Stanton, Revenson & Tennen, 2007). Within the 
literature on chronic illness, there is a lack of consistency as to how adjustment is defined and no definitive way of 
measuring it as a construct (Moss-Morris, 2013). Yet the diagnosis of a chronic condition presents an individual with a 
significant challenge to their usual ways of coping (Dekker & deGroot, 2018) and thus psychosocial adjustment is key in 
order to maintain their quality of life. Although not clinically diagnosed until the individual shows unequivocal signs of 
involuntary movement (Sturrock & Leavitt, 2010), living in the pre-manifest stage of HD is likely to raise similar 
challenges to that presented by diagnosis of a chronic condition, especially given that many non-motor symptoms 
develop years before the onset of motor symptoms. Understanding the nature of this adjustment is key to supporting 
individuals to maintain a good quality of life (Hammond & Winthrope, 2018). 
 
Furthermore, there has been little research to how adjustment processes change according to unknown and 
unpredictable elements of chronic conditions, such as when symptom onset is uncertain, as is the case for individuals 
living with pre manifest HD. Yet this uncertainty is likely to be important to consider in understanding adjustment, given 
that uncertainty in illness has been associated with increased psychological distress, decreased quality of life, and 
difficulty coping (Johnson Wright, Afari, & Zautra, 2009). It is thus important to explore how these feelings of 
uncertainty fluctuate over the time since receiving the genetic screening results, in order to better understand the 
relationship between adjustment and uncertainty in chronic conditions where disease progression may not be known 
or already determined. 
 
Regarding HD, research has already indicated that individuals who have tested positive for the HD gene expansion are 
significantly more likely to experience depression and irritability than those without the gene expansion, even prior to 
experiencing disease related symptoms (Julien et al., 2007). Given that the period of adjusting to living with the gene-
expansion is likely to raise significant challenges for individuals in coming to terms with their gene-positive status, a 
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understanding will contribute to knowledge of the needs of this group and could help inform the types of support that 
are needed.  
 
 
A13. Please summarise your design and methodology. It should be clear exactly what will happen to the research 
participant, how many times and in what order. Please complete this section in language comprehensible to the lay person. 
Do not simply reproduce or refer to the protocol. Further guidance is available in the guidance notes. 
 
Design  
This study will collect qualitative data using Interpretative phenomenological analysis (IPA) 
 
Data collection  
The primary aim of the study is to collect data on the experiences of individuals living in the pre-mainfest stage of 
Huntington's disease. Semi-structured interviews will therefore be conducted to gain participants' experiences and 
their thoughts and opinions on these experiences. This data will be analysed using IPA which has its focus on how 
individuals make sense of their experiences and thus appears best suited to this line of research. 
 
Recruitment  
Participants will be recruited via three routes: 
 
In the first instance, participants will be recruited through a multidisciplinary team at Leicestershire Partnership NHS 
Trust which works with families affected by HD and includes a clinical psychologist (the field supervisor). Participants 
will be identified via research nurses working at the Leicestershire Trust who will identify people who meet the inclusion 
criteria and will invite them to participate (either in person or via post). 
 
In the second instance, participants will be recruited from Northamptonshire (an area which receives consultancy from 
the Leicestershire Service but where patients don’t receive ongoing HD psychological support via the same method). 
Participants will be identified via the advisory service for Northamptonshire which is commissioned by Leicestershire 
Trust 
 
If enough participants cannot be recruited via the first two methods, participants will also be recruited via the HDA 
website. In this instance, participants will be identified responding directly to myself (Gina) via an advert published on 
the HDA website. 
 
Once I have a potential participant’s contact details via one of the methods outlined above, I will then contact the 
potential participant to explain more about the study and to answer any questions. If the participant wishes to proceed 
with study participation, then a convenient time will be arranged to conduct the interview. This will be via phone or Skype 
(or another similar system) unless there are extenuating circumstances making this difficult, in which case I will arrange 
to conduct the interview in person. 
 
Participants  
All participants will be between 18 and 65 and will have to have tested positive for the HD gene expansion at least one 
year prior to the interview. This decision was taken because it was hoped that they will have had some time to live with 
the sure knowledge of their genetic status. Participants will have to be well enough to tolerate a one hour interview which 
may cause some distress. 
 
Participants will be asked to talk about their experiences of adjusting to living in the pre-mainfest stage of Huntington's 
Disease. Questions will be asked based on their responses. Participants will not be required to talk about anything they 
don't wish. An individual can choose to stop the interview at any time or move on from a question at any point. 
 
Service user involvement  
Experts by experience have been involved in the study design; members of HD voice (a patient and public involvement 
group which sits within the Huntington’s Disease Association (HDA)) were asked to comment on the proposed interview 
schedule with the aim that the experiences of people living in the pre-manifest stage will be accurately captured from the 
interview. The letter of invitation, the consent form, the flyer for the HDA and the information sheet were also reviewed to 
ensure it was understandable and inviting. On the back of this feedback, I simplified the questions in the interview 
schedule as feedback indicated this might be too complex for some participants, given that very early symptoms of HD 
can make cognitive processing more difficult. I also made the documents a lot more personal, as I felt it was important to 
acknowledge how much I appreciated participants' input. Furthermore, I clarified the support available for anyone who 





A14-1. In which aspects of the research process have you actively involved, or will you involve, patients, service 
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Design of the research 
 
Management of the research 
 
Undertaking the research 
 
Analysis of results 
 
Dissemination of findings 
 
None of the above 
 
 
Give details of involvement, or if none please justify the absence of involvement.  
People with the HD gene expansion were approached for their input in the study conduct through HD voice (a patient 
and public involvement group which sits within the HDA). 
 
The research findings will be disseminated to participants directly and published on the HDA website with 
permission. It will be presented at suitable conferences (e.g. European Huntington’s Disease Network Plenary 
Meeting) and Special Interest Groups. The research will also be published in peer-reviewed academic journals.  
 
 
4. RISKS AND ETHICAL ISSUES  
 
RESEARCH PARTICIPANTS  
 
A15. What is the sample group or cohort to be studied in this research? 
 






















Inflammatory and Immune System 
 














Renal and Urogenital 
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Gender:  Male and female participants 
Lower age limit: 18 Years 
Upper age limit: 65 Years 
   
     
A17-1. Please list the principal inclusion criteria (list the most important, max 5000 characters). 
 
Participants will need to be between 18 and 65. They will need to have tested positive for the HD gene expansion at 
least one year prior to the interview. Participants will have to be well enough to tolerate a one hour interview which may 
cause some distress. 
 
Participants will be taken on a first come first served basis. Participants will be recruited primarily through 
Leicestershire Partnership NHS Trust, and opened out to the HDA if we do not have enough participants recruited.  
 
 
A17-2. Please list the principal exclusion criteria (list the most important, max 5000 characters). 
 
Participants will be excluded if they have any significant physical illness and if they have already received a formal 
diagnosis of HD. Participants may also be excluded if sufficient responses have already been gathered but this will be 
made clear when the participant initially expresses an interest to participate.  
 
 
RESEARCH PROCEDURES, RISKS AND BENEFITS  
 
A18. Give details of all non-clinical intervention(s) or procedure(s) that will be received by participants as part of 
the research protocol. These include seeking consent, interviews, non-clinical observations and use of questionnaires. 
 
Please complete the columns for each intervention/procedure as follows: 
 
1. Total number of interventions/procedures to be received by each participant as part of the research protocol. 
 
2. If this intervention/procedure would be routinely given to participants as part of their care outside the research, 
how many of the total would be routine? 
 
3. Average time taken per intervention/procedure (minutes, hours or days) 
 
4. Details of who will conduct the intervention/procedure, and where it will take place. 
 
 Intervention or procedure 1 2 3 4  
 Conversation with research nurse or 1 0 10 esearch nurse or myself (Gina) 
 responding to H   A advert      
 Initial conversation with potential 1 0 20 Gina 
 participant      
 Consent forms completed (remotely) 1 0 15 Participant 
 Consent forms completed (in person) 1 0 15 Gina 
 Interview participant 1 0 45- Gina via skype or phone (or at a venue convenient to the 
    60 participant if Skype/phone is not possible) 
       
       
         
A21. How long do you expect each participant to be in the study in total? 
 
Participants will be involved in the study for approximately 3-4 months (though the actual interview lasts around one 
hour) 
 




A22. What are the potential risks and burdens for research participants and how will you minimise them? 
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to lifestyle. Only describe risks or burdens that could occur as a result of participation in the research. Say what steps 
would be taken to minimise risks and burdens as far as possible. 
 
The interview is not anticipated to cause any significant distress. However, some of the experiences of the individual 
may evoke some distressing reactions and/or discuss difficult content. 
 
If the interview is being conducted in person, the interview will be stopped as soon as any distress is identified by 
myself (Gina). The participant will be offered a break and, if a family member has attended the interview with them, 
whether they wish to request their support (presuming the family member is not already in the interview room). After 
any required break, they will be asked if they wish to stop the interview, or to continue the questions but move on from 
the distressing topic. Participants will also be made aware that they can rearrange the interview for another date if they 
wish to do so. 
 
If the interview is being conducted by phone or by Skype, distress may be more difficult to become immediately aware 
of, as subtle changes in body language are not always clear. However, the same principles will apply to interviews 
conducted via Skype and to those in person. However, there will need to be more confidence from myself that any 
distress that has been identified has been minimised appropriately as there will be no opportunity for face-to-face 
debriefing after the interview has ended. I will ensure before finishing the interview that I check on the wellbeing of the 
participant at the end. 
 
For both in person and Skype interviews, if any of the research team becomes concerned that a participant poses a 
risk of serious harm (to themselves or others) they will inform a member of the a member of the person's clinical team 
or their GP/A&E if deemed appropriate. 
 
Where an individual has been recruited via the HDA, any risk identified will be passed onto my supervisor and the 
rest of the research team who will decide if any intervention is necessary 
 
Participants can withdraw from the study at any time without giving a reason. They can choose to stop the interviews 
at any time. They can choose to withdraw their data that they have already given at any time up to the point at which it 
has been analysed. We will make every effort to withdraw data if a participant requests this, but will let them know if 
this is not possible (due to the data already having been analysed)  
 
 
A23. Will interviews/ questionnaires or group discussions include topics that might be sensitive, embarrassing 
or upsetting, or is it possible that criminal or other disclosures requiring action could occur during the study? 
 
 Yes       No 
 
If Yes, please give details of procedures in place to deal with these issues: 
 
I (Gina) will be conducting the study (ie performing the interviews) and am a trainee clinical psychologists who is able 
to assess for signs of distress and act accordingly. If an individual appears distressed at any point in the interview,I will 
stop the interview, check on the wellbeing of the participant and offer a break. The interview will only be resumed if the 
participant is willing and feels able to do so.  
 
 





A26. What are the potential risks for the researchers themselves? (if any) 
 
When conducting interviews and particularly when lone working the researchers will adhere to Lancaster University’s 
guidance on fieldwork. I (Gina) will leave the details of the interview (e.g., participant, date, time, location)in a sealed 
envelope/password protected document to a peer, which they could open if they couldn’t reach me. I will telephone or 
text this trainee when the interview is concluded. If this telephone call/text does not take place, attempts will be made to 
contact myself. If contact cannot be made, the appropriate authorities will be informed. It is also possible that I will use 
an electronic lone working system connected to an electronic database.  
If the student experience distress during the study they will be able to speak to their supervisors and they will receive 
regular supervision throughout the study.  
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In this section we ask you to describe the recruitment procedures for the study. Please give separate details 
for different study groups where appropriate.  
 
A27-1. How will potential participants, records or samples be identified? Who will carry this out and what resources 
will be used?For example, identification may involve a disease register, computerised search of social care or GP records, 
or review of medical records. Indicate whether this will be done by the direct care team or by researchers acting under 
arrangements with the responsible care organisation(s). 
 
Participants will be recruited via three routes: 
 
In the first instance, participants will be recruited through a multidisciplinary team at Leicestershire Partnership NHS 
Trust which works with families affected by HD and includes a clinical psychologist (the field supervisor). Participants 
will be identified via research nurses working at the Leicestershire Trust who will identify people who meet the inclusion 
criteria and will provide them with a participant information sheet for them to gain further information about the study 
(either provided in person or via post). If they are interested, the research nurses will invite them to participate. 
 
 
In the second instance, participants will be recruited from Northamptonshire (an area which receives consultancy from 
the Leicestershire Service but where patients don’t receive ongoing HD psychological support via the same method. 
Participants will be identified via the advisory service for Northamptonshire which is commissioned by Leicestershire 
Trust. 
 
If enough participants cannot be recruited via the first two methods, participants will also be recruited via the HDA 
website. In this instance, participants will be identified responding directly to myself (Gina) via an advert published on 
the HDA website.  
 
 
A27-2. Will the identification of potential participants involve reviewing or screening the identifiable 
personal information of patients, service users or any other person? 
 
 Yes       No 
 
Please give details below:  
Where recruitment is via research nurses working for the NHS, the clinical care team will use patients' clinical data to 
decide if they meet the inclusion criteria for the research. The research team will not have access to identifiable 
information without the permission of the potential participant themselves 
 
Where recruitment is via the HDA, no screening of identifiable patient information will be used.  
 
 
A27-3. Describe what measures will be taken to ensure there is no breach of any duty of confidentiality owed to 
patients, service users or any other person in the process of identifying potential participants.Indicate what steps 
have been or will be taken to inform patients and service users of the potential use of their records for this purpose. Describe 
the arrangements to ensure that the wishes of patients and service users regarding access to their records are respected. 
Please consult the guidance notes on this topic. 
 
None anticipated (as only the clinical team has access to patient's record)  
 
 
A27-4. Will researchers or individuals other than the direct care team have access to identifiable personal 
information of any potential participants? 
 




A27-5. Has prior consent been obtained or will it be obtained for access to identifiable personal information? 
 
 Yes       No 
 
If Yes, please give details below. 
 
Consent will be sought by the clinical care team where recruitment is via Leicestershire NHS Trust in order to for me to 
identify potential participants (only basic contact information such as their name and telephone number/email address 
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Where recruitment is via the HDA, potential participants will make contact with myself first, and provide their contact 
details to myself first.  
 
 
A28. Will any participants be recruited by publicity through posters, leaflets, adverts or websites? 
 
 Yes       No 
 
If Yes, please give details of how and where publicity will be conducted, and enclose copy of all advertising material 
(with version numbers and dates). 
 
If enough participants cannot be recruited via NHS trusts, participants will be recruited via an advert posted on the 
HDA website.  
 
 
A29. How and by whom will potential participants first be approached? 
 
Participants recruited through both Leicestershire and Northamptonshire NHS Trusts will first be approached by 
research nurses working for the Leicestershire Trust or via an invitation letter sent in the post. 
 
Participants recruited through the HDA will first be approached by advertising the study on the HDA website. 
 
If participants at the NHS trust meet inclusion criteria they will be given a pack of information or letter of invitation and 
asked to contact Gina directly. They can also indicate to their clinical that they wish for further details. 
 
For participants responding to the HDA advert, they will be able to contact Gina directly.  
 
 
A30-1. Will you obtain informed consent from or on behalf of research participants? 
 
 Yes       No 
 
If you will be obtaining consent from adult participants, please give details of who will take consent and how it will be 
done, with details of any steps to provide information (a written information sheet, videos, or interactive material). 
Arrangements for adults unable to consent for themselves should be described separately in Part B Section 6, and for 
children in Part B Section 7. 
 
If you plan to seek informed consent from vulnerable groups, say how you will ensure that consent is voluntary and 
fully informed. 
 
Participants will have had access to a written information sheet before deciding to opt in. 
 
Where consent is taken in person e.g. with the NHS recruitment route Gina will meet with the participant to take 
informed written consent (on a pre-prepared consent form) or the consent form will be sent in advance and posted 
back to me (Gina). 
 
Where participants are recruited via the H A (i.e. remote consent), consent forms will be sent to the person's 
address to be returned to myself. 
 
If you are not obtaining consent, please explain why not. 
 
Please enclose a copy of the information sheet(s) and consent form(s).  
 
A30-2. Will you record informed consent (or advice from consultees) in writing? 
 
 Yes       No  
 
 
A31. How long will you allow potential participants to decide whether or not to take part? 
 
Participants will have several days from receiving the information sheet to decide whether to take part in the interview.  
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A33-1. What arrangements have been made for persons who might not adequately understand verbal explanations or 
written information given in English, or who have special communication needs?(e.g. translation, use of interpreters) 
 
Participants will need to understand verbal explanations in English in order to participate in the intervention so they will 
be excluded if this is not possible. If someone was not able to understand written information (or not able, for instance, to 
see written information) then the participant information sheet would be read to them (or provided in large font, if this was 
helpful). Consent would be taken verbally and this would be audio recorded.  
 
 
A35. What steps would you take if a participant, who has given informed consent, loses capacity to consent during 
the study? Tick one option only. 
 
 The participant and all identifiable data or tissue collected would be withdrawn from the study. Data or tissue which is 
not identifiable to the research team may be retained. 
 
The participant would be withdrawn from the study. Identifiable data or tissue already collected with consent would 
 
be retained and used in the study. No further data or tissue would be collected or any other research procedures carried 
out on or in relation to the participant. 
 
The participant would continue to be included in the study. 
 
Not applicable – informed consent will not be sought from any participants in this research. 
 






If you plan to retain and make further use of identifiable data/tissue following loss of capacity, you should inform 





In this section, personal data means any data relating to a participant who could potentially be identified. It 
includes pseudonymised data capable of being linked to a participant through a unique code number.  
 
Storage and use of personal data during the study 
 
A36. Will you be undertaking any of the following activities at any stage (including in the identification of 
potential participants)?(Tick as appropriate) 
 
Access to medical records by those outside the direct healthcare team 
 
Access to social care records by those outside the direct social care team 
 
Electronic transfer by magnetic or optical media, email or computer networks 
 
Sharing of personal data with other organisations 
 
Export of personal data outside the EEA 
 
Use of personal addresses, postcodes, faxes, emails or telephone numbers 
 
Publication of direct quotations from respondents 
 
Publication of data that might allow identification of individuals 
 
Use of audio/visual recording devices 
 
Storage of personal data on any of the following: 
 




Social Care Service computers 
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Further details:  
 
 
A37. Please describe the physical security arrangements for storage of personal data during the study? 
 
Personal data on paper will be made electronic and destroyed immediately afterwards.  
Electronic personal data will be kept securely on the university secure network or on a secure cloud (e.g. Box) 
accessible through the university and which has similar security credentials to the university network 
 
The data recorders that the university uses do not encrypt so all data will be kept securely until it is uploaded onto the 
university system  
 
 
A38. How will you ensure the confidentiality of personal data?Please provide a general statement of the policy 
and procedures for ensuring confidentiality, e.g. anonymisation or pseudonymisation of data. 
 
All personal data will be kept confidential. Qualitative data will be anonymised as far as possible for publication. Names 
and identifiable information will not be used in any published quotes. Basic demographic information may be included 
alongside their quote but every effort will be made to anonymise participant identifiable data.  
 
 
A40. Who will have access to participants' personal data during the study? Where access is by individuals outside 
the direct care team, please justify and say whether consent will be sought. 
 
All members of the research team will have access to participants' contact details in order to communicate with them 
during the study. This will only take place when a participant has consented to be part of the study.  
 
 
Storage and use of data after the end of the study  
 
A41. Where will the data generated by the study be analysed and by whom? 
 
Data will be analysed by myself (Gina)at Lancaster University under supervision from Fiona Eccles and Maria Dale 
and will be shared with the research team members who work at Leicestershire Partnership NHS Foundation Trust  
 
 





 Title Forename/Initials Surname 
 Dr Fiona Eccles 
Post Lecturer  
Qualifications MPhys, DPhil, Grad Dip Psych, DClinPsy, Certificate in Academic Practice 
Work Address Doctorate in Clinical Psychology 
 Lancaster University  
 Lancaster  
Post Code LA1 4YT  
Work Email f.eccles@lancaster.ac.uk 
Work Telephone 01524592807  
Fax    
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Less than 3 months 
 
3 – 6 months 
 
6 – 12 months 
 
12 months – 3 years 
 
 Over 3 years 
 
 
If longer than 12 months, please justify:  
Consent forms and transcripts will be stored for 10 years or 10 years from publication, whichever is longer. These will 
be anonymised and kept separately. Audio recordings will be kept until thesis examination at the viva and then 
destroyed.  
All other personal data (e.g. to send participants a consent form/copy of the results) will be destroyed within 6 months of 
the study completion.  
 
 




Months: 0  
 
 
A45. Please give details of the long term arrangements for storage of research data after the study has 
ended.Say where data will be stored, who will have access and the arrangements to ensure security. 
 
Paper data (e.g. consent forms) will be scanned in electronically and deleted immediately after doing so.  
The electronic consent forms and transcripts will be stored securely on the Lancaster University network (or Box) by 
the research coordiantor of the doctorate in clinical psychology programme under the direction of the academic 
supervisor (Fiona Eccles) for 10 years and then deleted.  
 
 
INCENTIVES AND PAYMENTS  
 
A46. Will research participants receive any payments, reimbursement of expenses or any other benefits or 
incentives for taking part in this research? 
 




A47. Will individual researchers receive any personal payment over and above normal salary, or any other benefits 
or incentives, for taking part in this research? 
 




A48. Does the Chief Investigator or any other investigator/collaborator have any direct personal involvement (e.g. 
financial, share holding, personal relationship etc.) in the organisations sponsoring or funding the research that 
may give rise to a possible conflict of interest? 
 




NOTIFICATION OF OTHER PROFESSIONALS  
 
A49-1. Will you inform the participants’ General Practitioners (and/or any other health or care professional 
responsible for their care) that they are taking part in the study? 
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 If Yes, please enclose a copy of the information sheet/letter for the GP/health professional with a version number and date.  
 
PUBLICATION AND DISSEMINATION  
 
A50-1. Will the research be registered on a public database? 
 
 Yes       No 
 
Please give details, or justify if not registering the research.  
I am not aware a suitable database exists. 
 
Registration of research studies is encouraged wherever possible.  
You may be able to register your study through your NHS organisation or a register run by a medical research charity, 
or publish your protocol through an open access publisher. If you are aware of a suitable register or other method of 
publication, please give details. If not, you may indicate that no suitable register exists. Please ensure that you have 
entered registry reference number(s) in question A5-1.  
 
 
A51. How do you intend to report and disseminate the results of the study? ick as appropriate: 
 










Submission to regulatory authorities 
 
Access to raw data and right to publish freely by all investigators in study or by Independent Steering Committee 
 
on behalf of all investigators 
 
No plans to report or disseminate the results 
 
Other (please specify)  
 
 
A52. If you will be using identifiable personal data, how will you ensure that anonymity will be maintained 
when publishing the results? 
 
Care will be taken when publishing any demographic data to try to ensure anonymity is maintained  
 
 
A53. Will you inform participants of the results? 
 
 Yes       No 
 
Please give details of how you will inform participants or justify if not doing so.  
The research findings will be disseminated to participants directly should they express an interest in being contacted 
after the study with the results. The research findings will also be published on the HDA website with permission of the 
HDA administrators.  
 
 
5. Scientific and Statistical Review  
 
A54-1. How has the scientific quality of the research been assessed?Tick as appropriate: 
 
Independent external review 
 
Review within a company 
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Review within the Chief Investigator's institution or host organisation 
 
Review within the research team 
 




Justify and describe the review process and outcome. If the review has been undertaken but not seen by the 
researcher, give details of the body which has undertaken the review: 
 
For all studies except non-doctoral student research, please enclose a copy of any available scientific critique reports, 
together with any related correspondence. 
 
For non-doctoral student research, please enclose a copy of the assessment from your educational supervisor/ institution.  
 
A59. What is the sample size for the research? How many participants/samples/data records do you plan to study in 
total? If there is more than one group, please give further details below. 
 
Total UK sample size: 12 
 
Total international sample size (including UK): 12 
 
Total in European Economic Area: 12 
 
Further details:  
We aim to recruit between 8-12 participants  
 
 
A60. How was the sample size decided upon? If a formal sample size calculation was used, indicate how this was done, 
giving sufficient information to justify and reproduce the calculation. 
 
The study will aim to have around eight to twelve participants, in keeping with Smith et al. (2009), who suggest four to 
ten participants for professional doctorates using IPA. This number permits an in depth focus of each person’s 
experience (in line with IPA’s idiographic nature)  
 
 
A62. Please describe the methods of analysis (statistical or other appropriate methods, e.g. for qualitative research) 
by which the data will be evaluated to meet the study objectives. 
 
 
Analysis will be conducted using guidelines from IPA theory (Smith et al., 2009). Interviews will be transcribed and then 
analysed line by line, making note of all emerging themes and any apparent contradictions. Emergent themes will be 
collated and put into overarching categories. Continual re-reading will be used to ensure individual accounts are reflected 
in the themes and that the main themes are consistent with most of the data. Bias will be reflected upon and incorporated 
into the study through the use of a reflective journal and discussed during supervision.  
 
 
6. MANAGEMENT OF THE RESEARCH  
 
A63. Other key investigators/collaborators. Please include all grant co−applicants, protocol co−authors and other key 





 Title Forename/Initials Surname 
 Dr Maria Dale 
Post    
Qualifications DClinPsy  
Employer Leicestershire Partnership NHS Trust 
Work Address Mill Lodge Narborough Leicestershire 
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 Telephone  (0) 116 295 3649     
 Fax       
 Mobile  (0) 116 295 3649     
 Work Email  Maria.Dale@leicspart.nhs.uk     
      
        
      
 A64. Details of research sponsor(s)     
      
      
A64-1. Sponsor      
       
 Lead Sponsor      
 Status: NHS or HSC care organisation Commercial status: 
  Academic     
  Pharmaceutical industry     
  Medical device industry     
  Local Authority     
  Other social care provider (including voluntary sector or private     
 organisation)     
  Other      
 If Other, please specify:     
 Contact person      
 Name of organisation Lancaster University     
 Given name Becky     
 Family name Gordon     
 Address  Research Services     
 Town/city  Lancaster University     
 Post code  LA1 4YT     
 Country  UNITED KING   OM     
 Telephone  01524 592981     
 Fax       





A65. Has external funding for the research been secured? 
 
Please tick at least one check box. 
 
Funding secured from one or more funders 
 
External funding application to one or more funders in progress 
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Project that is part of a programme grant 
 
Project that is part of a Centre grant 
 




Other – please state:  
 
 
A66. Has responsibility for any specific research activities or procedures been delegated to a subcontractor 
(other than a co-sponsor listed in A64-1) ? Please give details of subcontractors if applicable. 
 
 Yes       No  
 
 
A67. Has this or a similar application been previously rejected by a Research Ethics Committee in the UK or 
another country? 
 




Please provide a copy of the unfavourable opinion letter(s). You should explain in your answer to question A6-2 how the 
reasons for the unfavourable opinion have been addressed in this application.  
 




 Title Forename/Initials Surname 
 Dr David Clarke 
Organisation    
Address Leicestershire Partnership NHS Trust 
 Research & Development Unit Swithland House 
 352 Londonoad Leicester 
Post Code LE2 2PL  
Work Email david.clarke@leicspart.nhs.uk 
Telephone 0116 295 7641  
Fax    
Mobile 0116 295 7641  
 
Details can be obtained from the NHS R&D Forum website: http://www.rdforum.nhs.uk  
 
 
A69-1. How long do you expect the study to last in the UK? 
 
Planned start date: 01/09/2019 
 




Years: 1 Months: 3 Days: 1  
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Other countries in European Economic Area 
 
Total UK sites in study 2 
 
Does this trial involve countries outside the EU?  
 Yes       No  
 
 
A72. Which organisations in the UK will host the research?Please indicate the type of organisation by ticking the box and 
give approximate numbers if known: 
 
NHS organisations in England 
 
NHS organisations in Wales 
 
NHS organisations in Scotland 
 
HSC organisations in Northern Ireland 
 
GP practices in England 
 
GP practices in Wales 
 
GP practices in Scotland 
 
GP practices in Northern Ireland 
 
 Joint health and social care agencies (eg 















Independent research units 
 































Total UK sites in study: 2 
  
    
A73-1. Will potential participants be identified through any organisations other than the research sites listed above? 
 




A73-2. If yes, will any of these organisations be NHS organisations? 
 
 Yes       No 
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A74. What arrangements are in place for monitoring and auditing the conduct of the research? 
 
The research team will be in regular contact during the study to ensure it is progressing as planned. The trainee 
clinical psychologist (Gina) involved in the study will receive regular supervision from her supervisors.  
 
 
A76. Insurance/ indemnity to meet potential legal liabilities  
 
Note: in this question to NHS indemnity schemes include equivalent schemes provided by Health and Social 
Care (HSC) in Northern Ireland  
 
A76-1. What arrangements will be made for insurance and/or indemnity to meet the potential legal liability of the 
sponsor(s) for harm to participants arising from the management of the research? Please tick box(es) as applicable. 
 
Note: Where a NHS organisation has agreed to act as sponsor or co-sponsor, indemnity is provided through NHS schemes. 
Indicate if this applies (there is no need to provide documentary evidence). For all other sponsors, please describe the 
arrangements and provide evidence. 
 
NHS indemnity scheme will apply (NHS sponsors only) 
 
Other insurance or indemnity arrangements will apply (give details below) 
 
Lancaster University legal liability cover will apply 
 
Please enclose a copy of relevant documents.  
 
A76-2. What arrangements will be made for insurance and/ or indemnity to meet the potential legal liability of the 
sponsor(s) or employer(s) for harm to participants arising from the design of the research? Please tick box(es) as 
applicable. 
 
Note: Where researchers with substantive NHS employment contracts have designed the research, indemnity is provided 
through NHS schemes. Indicate if this applies (there is no need to provide documentary evidence). For other protocol 
authors (e.g. company employees, university members), please describe the arrangements and provide evidence. 
 
NHS indemnity scheme will apply (protocol authors with NHS contracts only) 
 
Other insurance or indemnity arrangements will apply (give details below) 
 
Lancaster University legal liability cover will apply 
 
Please enclose a copy of relevant documents.  
 
A76-3. What arrangements will be made for insurance and/ or indemnity to meet the potential legal liability 
of investigators/collaborators arising from harm to participants in the conduct of the research? 
 
Note: Where the participants are NHS patients, indemnity is provided through the NHS schemes or through professional 
indemnity. Indicate if this applies to the whole study (there is no need to provide documentary evidence). Where non-NHS sites 
are to be included in the research, including private practices, please describe the arrangements which will be made at these 
sites and provide evidence. 
 
NHS indemnity scheme or professional indemnity will apply (participants recruited at NHS sites only) 
 
Research includes non-NHS sites (give details of insurance/ indemnity arrangements for these sites below) 
 
Lancaster University legal liability cover will apply 
 
 
Please enclose a copy of relevant documents.  
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PART C: Overview of research sites 
 
Please enter details of the host organisations (Local Authority, NHS or other) in the UK that will be responsible for 










   
      
 IN1 
NHS/HSC Site 
    







      
    Family name Dale 
    Email Maria.Dale@leicspart.nhs.uk 
  Organisation Leicestershire Partnership NHS Qualification 
DClinPsy   
name Trust (MD...)     
  Address Mill Lodge Country UNI  ED KINGDOM 
    
   Narborough    
   Leicestershire    
  Post Code LE19 4SL    
  Country GB    
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Introduction 
Huntington’s disease (HD) is an inherited disorder which often starts with 
affective disturbances such as depression and culminates in significant cognitive 
deficits and motor abnormalities (Du, Pang, Tyc & Hannan, 2013). Predictive 
testing has allowed individuals who are at risk of HD to find out whether they will 
develop the disease, prior to showing any motor symptoms. Although this has 
allowed researchers to study the natural course of the disease and provide 
opportunities for early intervention, the test raises significant ethical issues 
regarding the potentially devastating consequences which living with the 
knowledge of the test result entails (Lilani, 2005). By offering the predictive test, 
the NHS has an ethical and moral responsibility to understand the impact of 
genetic testing and to support individuals with the long-term consequences 
(Andersson, Petersén, Graff & Edberg, 2016).  
 
Although much research has been done identifying psychological 
consequences of a positive test result, the focus is generally on clinical symptoms 
such as anxiety and depression, the implications for a person’s quality of life or on 
adverse events such as family breakdown or suicide (Codori & Brandt, 1994). There 
has been little research into how a person who has tested positive to the HD gene 
but is not yet symptomatic perceives their status as ‘embodied risk’ (Kavanagh & 
Broom, 1997). This precarious status-known as “premanifest HD” is a prominent 
part of an individual’s experience with HD and of the way in which they adjust to 
this new identity, yet attention has not been given to this important time period in 
the lives of those affected. It is clear that more research is needed.  
 
Additionally, the nature of adaptive adjustment to living in the pre-manifest 
stage of HD needs clarification because this process is likely to be idiosyncratic, 
depending on a multitude of different factors. Within the literature on chronic 
illness, there is a lack of consistency as to how adjustment is defined and no 
definitive way of measuring it as a construct (Moss-Morris, 2013). Yet the diagnosis 
of a chronic condition presents an individual with a significant challenge to their 
usual ways of coping (Dekker & deGroot, 2018) and thus psychosocial adjustment is 
key in order to maintain their quality of life. Although not clinically diagnosed until 
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the individual shows unequivocal signs of involuntary movement (Sturrock & 
Leavitt, 2010), living in the pre-manifest stage of HD is likely to raise similar 
challenges to that presented by diagnosis of a chronic condition, especially given 
that many non-motor symptoms develop years before the onset of motor 
symptoms. Understanding the nature of this adjustment is key to supporting 
individuals to maintain a good quality of life (Hammond & Winthrope, 2018). 
 
Furthermore, there has been little research into how adjustment processes 
change according to unknown and unpredictable elements of chronic conditions, 
such as when symptom onset is uncertain, as is the case for individuals living with 
pre manifest HD.  Yet this uncertainty is likely to be important to consider in 
understanding adjustment, given that uncertainty in illness has been associated 
with increased psychological distress, decreased quality of life, and difficulty 
coping (Johnson Wright, Afari, & Zautra, 2009). It is thus important to explore how 
these feelings of uncertainty fluctuate over the time since receiving the genetic 
screening results, in order to better understand the relationship between 
adjustment and uncertainty in chronic conditions where disease progression may 
not be known or already determined.  
 
Regarding HD, research has already indicated that individuals who have 
tested positive for the HD gene expansion are significantly more likely to 
experience depression and irritability than those without the gene expansion, even 
prior to experiencing disease related symptoms (Julien et al., 2007). Given that 
the period of adjusting to living with the gene-expansion is likely to raise 
significant challenges for individuals in coming to terms with their gene-positive 
status, a better understanding of the psychological difficulties they face is 
necessitated. It is hoped that this understanding will contribute to knowledge of 
the needs of this group and could help inform the types of support that are 
needed.   
 
Interpretative phenomenological analysis (IPA), with its focus on how 
individuals make sense of their experiences, appears best suited to this line of 
research (Smith, Flowers & Larkin, 2009). IPA also lends itself well to the multiple 
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perspectives which give rise to shared experiences (Seamark, Blake, Seamark & 
Halpin, 2004).  The current study will utilise IPA in order to explore the 
adjustment experiences of individuals living with HD, an approach which has been 
shown to be useful in exploring adjustment to other neurodegenerative conditions 
(Ali & Bokharey, 2015) and￼ for individuals with long term health conditions (e.g. 





To be included in the study, participants will need to be aged between 18 
65 (i.e. be of typical working age in the UK). They will need to have tested positive 
for the HD gene expansion at least one year prior to the interview. This decision 
was taken because it was hoped that they will have had some time to live with the 
sure knowledge of their genetic status.  Additionally, previous research has 
suggested that symptoms of depression and anxiety are most common in carriers in 
the first two months post-test, but that levels of depression return to baseline 
level one year after the test (Huggins, Bloch & Wiggin, 1992). It was felt that 
interviewing participants at least a year following the test would encourage 
participants to focus on their experiences of living with their genetic status rather 
than those of the testing period. Participants will have to be well enough to 
tolerate a one hour interview. Participants with additional significant physical 
health conditions will be excluded from the study.   
 
The study will aim to have around 8-12 participants in keeping with Smith et 
al. (2009), who suggest four to ten participants for professional doctorates using 
IPA. This number permits an in depth focus of each person’s experience (in line 
with IPA’s idiographic nature) but also allows comparisons across participants’ 
narratives to highlight similarities and differences. 
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Participants will be made aware of the commitment involved in study 
participation, but as participation is entirely voluntary, a participant may choose 
to discontinue the study at any time without giving a reason, up until the point at 
which data analysis has commenced. The participant is not required to give a 
reason for discontinuing the study, any reason given will be documented.  Once 




The study will collect qualitative data consisting of participants’ responses. 
The primary aim of the study is to collect data on the experience of participants in 
adjusting to living with pre-manifest Huntington’s disease. Semi-structured 
interviews will therefore be conducted to explore their experiences.  
Experts by experience have been involved in the study design; members of 
HD voice (a patient and public involvement group which sits within the 
Huntington’s Disease Association (HDA)) were asked to comment on the proposed 
interview schedule with the aim that the experiences of people living in the pre-
manifest stage will be accurately captured from the interview. The letter of 
invitation, the consent form, the flyer for the HDA and the information sheet were 
also reviewed to ensure it was understandable and inviting. On the back of this 
feedback, I simplified the questions in the interview schedule as feedback 
indicated this might be too complex for some participants, given that very early 
symptoms of HD can make cognitive processing more difficult. I also made the 
documents a lot more personal, as I felt it was important to acknowledge how 
much I appreciated participants’ input. Furthermore, I clarified the support 
available for anyone who experiences distress. 
 
The methodology for the analysis will be interpretative phenomenological 
analysis (IPA), as this is in keeping with constructivist epistemology which is not 
guided by prior hypotheses. Choosing the constructivist epistemology of IPA serves 
two main aims: 
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1. Firstly, there is little previous research studying adjusting to the pre-
manifest stage of Huntington’s Disease and thus there is a paucity of prior 
hypotheses to guide the line of questioning from a theoretical perspective 
2. Secondly, adjustment to living with a chronic condition is likely to be a very 
idiosyncratic process, which cannot be indicated prior to in depth data 
collection and analysis. Hypothesising about adjustment processes within 
this participant group would likely misrepresent the convergence and 
divergence of participant experiences, key aspects which IPA focuses on. 
 
Furthermore, as phenomenology is a philosophical approach to the study of the 
experience of others (Boland, Levack, Hudson & Bell, 2012), IPA fits well with a 
study exploring how individuals make sense of their experience (Smith & Osborn, 
2003) and has a clear focus on psychological processes.  The flexible nature of the 
interview schedule in IPA and the broad, open ended questioning allows the 
participant to choose the aspects of their experience which feels most pertinent to 
them, and thus the participant’s narrative is what shapes the researcher’s 
understanding of the phenomenon (Smith et al., 2009).  
 
At the same time, the researcher is actively involved in the process, and my 
interpretations of what the participant discusses will be important part of trying to 
make sense of how the participant has come to understand their adjustment 
process. IPA can therefore be considered a double hermeneutic, as it involves two 
separate layers of interpretation (Smith & Osborn, 2007). 
 
Experts by experience were approached for their input in the study conduct; 
the principal investigator (myself) approached HD voice (a patient and public 
involvement group which sits within the HDA). They were invited to express their 
opinions on the suggested questions provided in the interview schedule as well as 
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Participants will be recruited via three routes:  
1. In the first instance, participants will be recruited through a 
multidisciplinary team at Leicestershire Partnership NHS Trust which works 
with families affected by HD and includes a clinical psychologist (the field 
supervisor). Participants will be identified via research nurses working at 
the Leicestershire Trust who will identify people who meet the inclusion 
criteria and will invite them to participate (either in person or via post). Any 
interested patients will be asked to contact me directly (using the contact 
details on the information sheet) or they can express interest to their 
clinician/nurse and then the nurse will pass on their details to myself. 
2. In the second instance, participants will be recruited from 
Northamptonshire (an area which receives consultancy from the 
Leicestershire Service but where patients don’t receive ongoing HD 
psychological support via the same method.) Participants will be identified 
via the advisory service for Northamptonshire which is commissioned by 
Leicestershire Trust. Interested participants will contact myself via the 
methods above. 
3. If enough participants cannot be recruited via the first two methods, 
participants will also be recruited via the Huntington’s Disease Association 
(HDA) website. In this instance, participants will be identified by responding 
directly to myself via an advert published on the HDA website.  
 
Consent 
The participant will provide consent prior to the interview.  
If the interview is being conducted in person, then written consent will be taken at 
the start of the interview. Interviews will only be conducted in person however if 
conducting it via Skype or phone is difficult for the participant. 
If the interview is conducted via telephone or skype (as it is anticipated will be the 
case with most or all participants) then the participant will complete a consent 
form in advance and return it to myself via email or post prior to the interview 
date. 
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Participants will have several days from receiving the information sheet to 
decide whether to take part in the interview. Participants can stop the study at 
any point (by just choosing not to take part in the interview). 
Data collection 
Semi-structured interviews will be used to ensure they are guided by 
participants’ responses, whilst also ensuring responses are framed around the 
process of adjustment. Semi-structured interviews are frequently used in IPA 
research (Smith et al., 2009). Interviews will be conducted either in person, by 
phone or via Skype dependent upon individual circumstances, but it is anticipated 
most will be via phone or Skype (or other similar online platforms).  
Interviews will be audio recorded.  
 
Analysis  
After each interview the data will be transcribed verbatim and made 
anonymous. Analysis will be conducted using guidelines from IPA theory (Smith et 
al., 2009). Interviews will be transcribed and then analysed line by line, making note 
of all emerging themes and any apparent contradictions. Emergent themes will be 
collated and put into overarching categories. Continual re-reading will be used to 
ensure individual accounts are reflected in the themes and that the main themes 
are consistent with most of the data. Bias will be reflected upon and incorporated 
into the study through the use of a reflective journal and supervision.  
Direct quotes will be used in the writing up of the findings but these will be 
anonymised.  Basic demographic information may be included alongside their 
quote but every effort will be made to anonymise participant identifiable data.  
 
Dissemination 
The research findings will be disseminated to participants directly and 
published on the HDA website with permission. It will be submitted as my thesis 
and presented at the thesis presentation day at Lancaster University. It will be 
presented at suitable conferences (e.g. European Huntington’s Disease Network 
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Plenary Meeting) and Special Interest Groups. It is also intended that the research 
will be published in peer-reviewed academic journals.  
  
Practical issues 
The recruitment of participants will be taking place in a location and Trust 
which is different from that of the person conducting the interviews. Where Skype 
(or another video calling facility) or phone is amenable to participants, this will be 
used to conduct the interviews to minimise research costs.  
Ethical concerns 
Risk to participants 
The interview is not anticipated to cause any significant distress. However, 
some of the experiences of the individual may evoke some distressing reactions 
and/or discuss difficult content. 
 
If the interview is being conducted in person, the interview will be stopped 
as soon as any distress is identified by the researcher. The participant will be 
offered a break and, if a family member has attended the interview with them, 
whether they wish to request their support (presuming the family member is not 
already in the interview room). After any required break, they will be asked if they 
wish to stop the interview, or to continue the questions but move on from the 
distressing topic. Participants will also be made aware that they can rearrange the 
interview for another date if they wish to do so.  
If the interview is being conducted by Skype, distress may be more difficult 
to become immediately aware of, as subtle changes in body language are not 
always clear. However, the same principles will apply to interviews conducted via 
Skype and to those in person. However, there will need to be more confidence 
from the researcher that any distress that has been identified has been minimised 
appropriately as there will be no opportunity for face-to-face debriefing after the 
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interview has ended. The researcher will therefore check on the wellbeing of the 
participant at the end of the interview. 
  
For both in person and Skype interviews, if any of the research team 
becomes concerned that a participant poses a risk of serious harm (to themselves 
or others) they will inform a member of the person's clinical team (if recruited 
from the NHS) who will assess if any intervention is required and seek guidance 
where necessary. If the person is recruited via the HDA website then I will ensure 
that appropriate action is taken (e.g. directing the person to their GP or to A&E as 
appropriate). 
 
Risk to researchers 
Where (if) interviews are conducted in person and particularly when lone 
working the researchers will adhere to Lancaster University’s guidance on 
fieldwork.  The interviewer will leave the details of the interview (e.g., 
participant, date, time, location) with another trainee clinical psychologist in a 
password protected document who will be able to access the details if they were 
not able to reach me. They will telephone another member of the team when the 
interview is concluded. If this telephone call does not take place, attempts will be 
made to contact the interviewer. If contact cannot be made, the appropriate 
authorities will be informed. The details of the interview will be destroyed as soon 
as the interview has taken place. It is also possible that the researcher will use a 
commercial electronic lone working system connected to a call centre, when 
details of the visit will be held briefly on the company database. 
Confidentiality and anonymity 
The personal information that participants provide will be kept confidential. 
The data collected for this study will be stored securely and only the researchers 
conducting this study will have access to the raw data. 
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• Audio recordings from the interviews will be kept until thesis 
examination and then securely destroyed  
• Lancaster University will keep copies of the interview transcriptions 
and the consent forms electronically for 10 years after the study has 
finished or 10 years from publication, whichever is longer. At the end 
of this time, they will be securely destroyed. Research supervisor 
Fiona Eccles will be responsible for overseeing the data during this 
time. 
• Files held on the computer will be encrypted (meaning no one other 
than the researchers can access them) and the computer itself will be 
password protected  
• The typed transcript interviews will be made anonymous by removing 
any identifying information. Anonymised direct quotations may be 
used in the report or in publications of the study.  
• Personal data collected by the researcher will be confidential and 
will be kept separately interview responses. 
 
Approximate Timetable for study completion 
July 2019: Ethics applications   
Sept-Dec 2019: Ethics approval  
Jan-Jun 2020: Recruitment and Data collection  
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Please note: This is the 
favourable opinion of the REC 
only and does not allow you to 
start your study at NHS site s 
in England until you receive H 
RA Approval 
 
Miss Gina Wieringa  
Trainee Clinical Psychologist 
Lancaster University 







Tayside medical Science Centre 
Residency Block Level 3  
George Pirie Way  
Ninewells Hospital and Medical School 




Date: 2 October 2019 
Your Ref:  
Our Ref: LR/AG19/E S/0105 
Enquiries to: Arlene Grub b 
Direct Line: 01382 383848 
Email: eosres.taysi de@nhs.net 
 
Dear Miss Wieringa 
 
Study title: Exploring individuals’ experiences of living in the  
premanifest stage of Huntington’s disease 
REC reference: 1 9/ES/0105 
Protocol number: N /A 
IRAS project ID: 2 64354 
 
Thank you for your letter of 30 September 2019, responding to the Committee’s request 
for further information on the above research and submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by the Chair. 
 
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I a m pleased to confirm a favourable ethical op inion for the 
above research on the basis describe d in the application form, protocol and supporting 
documentation as revised. 
 
Conditions of the favourable opinion 
 
The REC favourable opinion is subject to the following conditions being met prior to the start of 
the study. 
 
Confirmation of Capacity and Capability (in England, Northern Ireland and Wales) or NHS 
management permission (in Scotland) should be sought from all NHS organisations involved in the 
study in accordance with NHS research governance arrangements. Each NHS organisation must 
confirm through the signing of agreements and/or other documents that it has given permission for 
the research to proceed (except where explicitly specified otherwise). 
 
Guidance on applying for HRA and HCRW Approval (England and Wales)/ NHS 
permission for research is available in the Integrated Research Application System. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 









Sponsors are not required to notify the Committee of management permissions from 
host organisations 
 
Registration of Clinical Trials 
 
It is a condition of the REC favourable opinion that all clinical trials are registered on a 
publicly accessible database. F or this purpose, ‘clinical trials’ are defined as the first four 
project categories in IRAS project filter question 2. Registration is a legal requirement for 
clinical trials of investigational medicinal products (CTIMPs), except for phase I trials in 
healthy volunteers (these must still register as a condition of the REC favourable op inion). 
 
Registration should take place as early as possible and within six weeks of recruiting the first 
research participant at the latest. Failure to register is a breach of these approval conditions, 
unless a deferral has been agreed by or on behalf of the Research Ethics Committee (see here 
for more information on requesting a deferral: https://www.hra.nhs.uk/planning-and-improving-
research/research-planning/research-registration-research-project-identifiers/ 
 
As set out in the UK Policy Framework, research sponsors are responsible for making 
information about research publicly available before it starts e.g. by registering the research 




You should notify the REC of the registration details. We will audit these as part of the annual 
progress reporting process. 
 
It is the responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a site (as applicable). 
 
After ethical review: Reporting requirements 
 
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
• Notifying substantial amendments 
• Adding new sites and investigators 
• Notification of serious breaches of the protocol 
• Progress and safety reports 
• Notifying the end of the study, including early termination of the study 
• Final report 
 
The latest guidance on these to pics can be found at 
https://www.hra.nhs.uk/approvals-amendments/managing-your-a pproval/. 
 
Ethical review of research sites 
 
The favourable opinion applies to all NHS/HSC sites listed in the application subject to 
confirmation of Capacity and Capability (in England, Northern Ireland and W ales) or 
management permission (in Scotland) being obtained from the NHS/HSC R &D office prior 















Version D ate  
Confirmation of any other Regulatory Approvals (e.g. CAG)    
and all correspondence [REC response]    
Copies of advertisement materials for research participants 0.2 13 September 2019 
[Participant Flyer REC reviewed-highlighted]    
Copies of advertisement materials for research participants 0.2 13 September 2019 
[Participant Flyer REC reviewed-clean]    
Covering letter on headed paper [Study Approval]  17 July 2019 
    
Evidence of Sponsor insurance or indemnity (non-NHS  18 July 2019 
Sponsors only) [Sponsor Insurance]    
Interview schedules or topic guides for participants [Interview 0.1 25 March 2019 
Schedule]    
IRAS Application Form [IRAS_Form_30092019]  30 September 2019 
    
IRAS Checklist XML [Checklist_30092019]  30 September 2019 
    
Letter from sponsor [Sponsors hip letter]  08 August 2019 
    
Letters of invitation to participant [Letter of invitation] 0.1 25 March 2019 
    
Participant consent form [Participant Consent Form REC 0.2 13 September 2019 
reviewed-highlighted]    
Participant consent form [Participant Consent Form REC 0.2 13 September 2019 
reviewed-clean]    
Participant information sheet (PIS) [Participant Information 0.2 13 September 2019 
Sheet Highlighted]    
Participant information sheet (PIS) [Participant Information 0.2 13 September 2019 
Sheet Clean]    
Research protocol or project proposal [Research Protocol] 0.1 25 March 2019 
    
Response to Request for Further Information    
Summary CV for Chief Investigator (CI) [CV for Chief    
Investigator]    
Summary CV for student [CV for student]    
Summary CV for supervisor (student research) [Supervisor  14 June 2019 
CV]     
 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures for 




The Health Research Authority is continually striving to provide a high-quality service to all 
applicants and sponsors. You are invited to give your view of the service you have received 
and the application procedure. If you wish to make your views known pleas e use the 





We are pleased to welcome re searchers and research staff to our HRA Learning Events 










19/ES/0105 Please quote this number on all correspondence  
 
With the Committee’s best wish es for the success of this project. 
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IRAS ID: 264354 Version 0.1     Created: 25/03/19 
 
Semi-structured interview schedule  
 
This interview schedule indicates topic areas to be discussed during the interview with 
example questions. The exact questions will depend on participants’ responses and the focus 
of each interview will be partly guided by what the individual being interviewed deems to be 
important. It may be that several questions in each section are not covered, given that for 




Introduce myself. Revisit participant information sheet and purpose of interview (To explore 
the experience of individuals living with the Huntington’s disease (HD) gene expansion to 
gain a better understanding of their experiences) 
Remind them of information on consent form and limits of confidentiality (“All information 
you provide will be kept confidential unless you disclose information regarding risk to 
yourself or others. In such an event, you will be informed of the action that would be 
necessary in order to ensure your safety and that of others”). 
 
Collect basic info about age, gender, ethnic group, partnership status, living status (who they 
live with) and employment status 
 
Reflecting on initial genetic screening results  
 
In this section of the interview, I will get information about how long it has been since the 
genetic test and who else in the family knows they have the HD gene expansion. This section 
will also include their initial reactions and those of family members, and their expectations 
for the future. This will not be the focus of the interview but will provide context to their 
adjustment response. 
 
Example questions:  
1. How long ago did you initially receive your screening results?  
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2. Did you have difficulties in accepting the test results, if so for how long? 
 
Reflecting on experiences adjusting to living in the pre-manifest stage  
 
In this section I will ask about the participant’s experiences of having to adjust to living in the 
pre-manifest stage 
 
Example questions:  
1. How do you feel now knowing you will develop HD?  
2. How has living with the HD gene affected to your ability to achieve your life 
goals? 
3. How has living with the HD gene changed any future planning? 
4. Has there been any positive impact to living in the pre-manifest stage? 
5. How have you coped with the negative impacts of living in the pre-manifest 
stage?  
6. Have you shared knowledge that you will develop HD with others? 
7. Are you involved in the HD community? If so, what support have you had from 
them? 
8. If you could go back to finding out about your genetic results, is there anything 
that you think you would have done differently? 
9. Is there anything you find helpful in supporting your wellbeing? 
10. Tell me about others’ reactions to your positive test result? 
 
 
Reflecting on the situation now  
I will ask participants about the ongoing impact of the adjustment process 
Example questions:  
1. What are your thoughts about where you are at now in relation to and symptom onset? 
2. Has your relationship with HD changed since the initial test results? If so, what do 
you think has led to this change? 
3. What does living in the pre-manifest stage mean to you? 
4. Do you think things will change in future with how you view where you are at now in 
relation to HD?  
5. What kind of feelings and thoughts do you have for the future? 
6. Is there anything else you would like to share about your experiences which you think 
are relevant?  
 




In this part of the interview the participant will be thanked for taking part. I will ensure the 
participant has not been distressed by the interview and if necessary will direct the participant 
to sources of support on the participant information sheet.  
 




Living in the pre-manifest stage of Huntington’s disease 
 
IRAS ID: 264354 Version 0.1     Created: 25/03/19 
 
I am writing to you to see if you would be interested in taking part in the above study. The study 
is being conducted as part of my doctoral qualification in clinical psychology at Lancaster 
University. I am supervised by Dr Maria Dale, a clinical psychologist working at Leicestershire 
Partnership NHS Trust and Dr Fiona Eccles, a lecturer at Lancaster University. 
I am really keen to better understand the process an individual goes through in order to cope with 
living with the HD gene, in the period prior to receiving a diagnosis. I hope that this 
understanding will help others in a similar position to yourself to navigate what I imagine can be 
a difficult time period. There are no right or wrong answers to this and it is important to gain a 
variety of viewpoints because everyone will have different experiences.   
Before you decide whether or not you would like to participate in this study, it is important for 
me that you feel as though you understand what will be involved in this project should you 
decide to participate and have the opportunity to ask any further questions. I would appreciate if 
you could take time to read the enclosed information sheet carefully and think about whether or 
not you would like to take part.  
If you have any questions about the study then please do contact me. My email address is 
g.wieringa@lancaster.ac.uk or telephone 07852 516 566 and I will be happy to discuss with you 
any questions you may have. Alternatively, you can contact one of your clinical team at 
Leicestershire Partnership NHS Trust or Northamptonshire Healthcare NHS Foundation Trust, 
depending on where you receive your care.  
Thank you very much for reading this letter, 
Gina Wieringa (Lead investigator of the study) 
Dr Maria Dale (field supervisor)  
 
Dr Fiona Eccles (academic supervisor)  
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Participant Information Sheet 
 
Living in the pre-manifest stage of Huntington’s disease 
My name is Gina Wieringa and I am conducting this research as a student in the clinical 
psychology doctoral programme at Lancaster University, Lancaster. I really appreciate you 
taking the time to read this information sheet and your interest in my study. 
 
What is the purpose of this study? 
• To explore the experience of individuals living with the Huntington’s disease (HD) 
gene expansion to gain a better understanding of their experiences 
• To help inform long-term support for such individuals 
• To share important findings about coping strategies which may help others 
 
 
Why have I been approached? 
You have been approached because the study requires information from people who have 
received testing results which indicate they have the gene expansion for HD. Your contact 
details have been obtained via your clinical care team at Leicestershire Partnership NHS 
Trust who felt you may be interested in participated, or because you have responded to the 
flyer on the HDA website. 
 
Do I have to take part? 
No.  It’s completely up to you to decide whether or not you take part and any care you 
currently receive (in addition to any future care) will not be affected by your decision.  
Unfortunately you will not be eligible to participate if you are actively psychotic due to the 
difficulty in managing psychotic episodes within an interview situation 
 
 
What will I be asked to do if I take part? 
If you decide to participate, I will arrange with you a convenient time to conduct an 
interview, either by Skype or by telephone. If Skype/phone is not possible for you then I can 
arrange to meet you in person. This interview should last approximately one hour. During the 
interview I will ask you some questions about your experiences related to adjusting to living 
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1. How do you feel now knowing you will develop HD?  
2. Does it affect your life on a day to day basis?  
3. Has it had implications on planning for the years ahead (e.g. living arrangements, 
family support etc.)  
 
 
Will my data be identifiable? 
In order to enable the research to take place, I will need to audio record the interview. Only I 
will be involved in the audio transcription. All information you provide will be kept 
confidential unless you disclose information regarding risk to yourself or others. In such an 
event, you will be informed of the action that would be necessary in order to ensure your 
safety and that of others.  
o This research will be written up as part of my doctoral training and will also be 
submitted for publication in a journal article. This research may also be presented at 
conferences 
o Audio recordings and consent forms will be destroyed and/or deleted once the project 
thesis has been examined (December 2020) 
o Lancaster University will keep copies of the interview transcriptions and the consent 
forms electronically for 10 years after the study has finished or 10 years from 
publication, whichever is longer. At the end of this time, they will be securely 
destroyed. 
o The files on the computer will be encrypted (that is no-one other than the researchers 
will be able to access them) and the computer itself password protected. 
o The typed version of your interview will be made anonymous by removing any 
identifying information including your name. Anonymised direct quotations from 
your interview may be used in the reports or publications from the study, so your 
name will not be attached to them. 
o All your personal data will be confidential and will be kept separately from your 
interview responses. The exception to this is if it is thought that there is a risk of harm 
to yourself or others, in which case I will need to share this information with my 
research supervisor. 
o Research data will be discussed with my supervisor in order to ensure accuracy and 
reliability of any themes generated. 
o You can choose to withdraw your data that you have already given at any time, up to 







Lancaster University will be the data controller for any personal information collected as part 
of this study. Under the GDPR you have certain rights when personal data is collected about 
you: 
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• You have the right to access any personal data held about you, to object to the 
processing of your personal information, to rectify personal data if it is inaccurate, the 
right to have data about you erased and, depending on the circumstances, the right to 
data portability.  
• Please be aware that many of these rights are not absolute and only apply in certain 
circumstances.  
If you would like to know more about your rights in relation to your personal data, please 
speak to the researcher on your particular study. For further information about how Lancaster 
University processes personal data for research purposes and your data rights please visit our 
webpage: www.lancaster.ac.uk/research/data-protection 
 
What will happen to the results? 
The results will be summarised and reported and may be submitted for publication in an 
academic or professional journal and presented at conferences. I will also give you a copy of 
the results if you would like one. 
 
Are there any risks? 
There are no risks anticipated with participating in this study.  However, if you experience 
any distress following participation you are encouraged to inform me so that I can support 
you as best as possible. I will endeavour to minimise any distress you are experiencing and 
will stop the interview if necessary. It may be that I feel it is important to inform your HD 
care team (if you have one). Alternatively, you will be encouraged to see your GP if you feel 




Are there any benefits to taking part? 
Although you may find participating interesting, there are no direct benefits in taking part. It 
is hoped that gaining a better understanding of how individuals cope in this stage will help 
others in a similar situation to yourself. 
 
Who has reviewed the project? 
This study has been reviewed and approved by the Health Research Authority Research 
Ethics Committee and the Trust has also given approval for this study to be conducted. The 
East of Scotland Research Ethics Service REC 2, which has responsibility for scrutinising all 
proposals for medical research on humans, has examined the proposal and has raised no 
objections from the point of view of research ethics. It is a requirement that your records in 
this research, together with any relevant medical records, be made available for scrutiny by 
monitors from << name of sponsor company (if appropriate) >> and NHS <<insert name of 
Health Board/Trust>>, whose role is to check that research is properly conducted and the 
interests of those taking part are adequately protected 
 
Where can I obtain further information about the study if I need it? 
If you have any questions about the study or think you might like to take part, please feel free 
to contact me on 
g.wieringa@lancaster.ac.uk or telephone 07852 516 566. You can also post details to: 
Gina Wieringa, Doctorate in Clinical Psychology 
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Furness College,  
Lancaster University,  
Bailrigg, Lancaster,  
LA1 4YG 
 
You can also contact: 
Dr Maria Dale (field supervisor) on Maria.Dale@leicspart.nhs.uk or  




If you wish to make a complaint or raise concerns about any aspect of this study and do not 




Lancaster University,  
Tel: +44 (0)1524 592981 
Email: i.smith@lancaster.ac.uk 
 
If you wish to speak to someone outside of the Doctorate Programme, you may also contact:  
 
Professor Roger Pickup Tel: +44 (0)1524 593746  
Associate Dean for Research Email: r.pickup@lancaster.ac.uk  
Faculty of Health and Medicine  
(Division of Biomedical and Life Sciences)  





Thank you for taking the time to read this information sheet. 
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Living in the pre-manifest stage of Huntington’s disease 
• Are you willing to take part in an interview of ~1 hour to 
help with my doctoral thesis (due to be completed by 
December 2020), which aims to better understand how 
people comes to terms with HD? 
 
Participants (8 -12 required) 
• Need to have tested positive for the HD gene expansion at 
least one year ago, but not yet showing physical symptoms 
• Unfortunately, you will not be eligible to participate if have 
any other significant health difficulties as this may 
confound the results  
 
I would really value hearing about any experiences you would 
be willing to share. 
For further information (with no obligation to take part) please 
contact Gina Wieringa on g.wieringa@lancaster.ac.uk  
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Participant Consent Form 
IRAS ID: 264354 Version 0.2       
Project Title: Living in the pre-manifest stage of Huntington’s Disease (HD)  
Name of researcher: Gina Wieringa 
We are asking if you would like to take part in a research project exploring how individual’s 
experience the pre-manifest stage of Huntington’s Disease. 
Before you consent to participating in the study we ask that you read the participant information sheet 
and sign at the bottom if you agree with all the statements.  If you have any questions or queries before 
signing the consent form please speak to the principal investigator, Gina Wieringa  
 
 
1. I confirm that I have read the information sheet and fully understand what is expected of me 
within this study  
2. I confirm that I have had the opportunity to ask any questions and to have them answered.  
3. I understand that my interview will be audio recorded and then made into an anonymised 
written transcript. 
4. I understand that audio recordings will be kept until the research project has been examined. 
5. I understand that my participation is voluntary and that I am free to withdraw at any time 
without giving any reason, without my medical care or legal rights being affected.  
6. I understand that once my data have been anonymised and incorporated into themes it might 
not be possible for it to be withdrawn, though every attempt will be made to extract my data, up 
to the point of publication. 
7. I understand that the information from my interview will be pooled with other participants’ 
responses, anonymised and may be published. 
8. I consent to information and quotations from my interview being used in reports, conferences 
and training events. Any information and quotations used will be anonymised 
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10. I understand that any information I give will remain confidential and anonymous unless it is thought 
that there is a risk of harm to myself or others, in which case the principal investigator will need to 
share this information with their research supervisor. 
11. I consent to Lancaster University keeping written transcriptions of the interview for 10 years after 
the study has finished 




Name of Participant__________________ Signature____________________ Date ___________ 
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Miss Gina Wieringa 
Trainee Clinical Psychologist 
Lancaster University 






03 October 2019 
Dear Miss Wieringa 
Study title: Exploring individuals’ experiences of living in the 
premanifest stage of Huntington’s disease. 
IRAS project ID: 264354  
Protocol number: N/A 
REC reference: 19/ES/0105   
Sponsor Lancaster University 
I am pleased to confirm that HRA and Health and Care Research Wales (HCRW) Approval 
has been given for the above referenced study, on the basis described in the application form, 
protocol, supporting documentation and any clarifications received. You should not expect to 
receive anything further relating to this application. 
Please now work with participating NHS organisations to confirm capacity and capability, in 
line with the instructions provided in the “Information to support study set up” section towards 
the end of this letter. 
How should I work with participating NHS/HSC organisations in Northern Ireland and 
Scotland? 
HRA and HCRW Approval does not apply to NHS/HSC organisations within Northern Ireland 
and Scotland. 
If you indicated in your IRAS form that you do have participating organisations in either of 
these devolved administrations, the final document set and the study wide governance report 
(including this letter) have been sent to the coordinating centre of each participating nation. 
The relevant national coordinating function/s will contact you as appropriate. 
HRA and Health and Care 






Please see IRAS Help for information on working with NHS/HSC organisations in Northern 
Ireland and Scotland.  
 
How should I work with participating non-NHS organisations? 
HRA and HCRW Approval does not apply to non-NHS organisations. You should work with 
your non-NHS organisations to obtain local agreement in accordance with their procedures. 
 
What are my notification responsibilities during the study?  
  
The standard conditions document “After Ethical Review – guidance for sponsors and 
investigators”, issued with your REC favourable opinion, gives detailed guidance on reporting 
expectations for studies, including: 
• Registration of research 
• Notifying amendments 
• Notifying the end of the study 
The HRA website also provides guidance on these topics, and is updated in the light of 
changes in reporting expectations or procedures. 
 
 
Who should I contact for further information? 
Please do not hesitate to contact me for assistance with this application. My contact details 
are below. 
 







Email: hra.approval@nhs.net  
 
  
Copy to: Becky Gordon, Lancaster University, Sponsor contact 
 
 






List of Documents 
 
The final document set assessed and approved by HRA and HCRW Approval is listed below.   
 
 Document   Version   Date   
Confirmation of any other Regulatory Approvals (e.g. CAG) and all 
correspondence [REC response]  
    
Copies of advertisement materials for research participants 
[Participant Flyer REC reviewed-highlighted]  
0.2  13 September 2019  
Copies of advertisement materials for research participants 
[Participant Flyer REC reviewed-clean]  
0.2  13 September 2019  
Covering letter on headed paper [Study Approval]    17 July 2019  
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only) [Sponsor Insurance]  
  18 July 2019  
Interview schedules or topic guides for participants [Interview 
Schedule]  
0.1  25 March 2019  
IRAS Application Form [IRAS_Form_30092019]    30 September 2019  
IRAS Checklist XML [Checklist_30092019]    30 September 2019  
IRAS Checklist XML [Checklist_30092019]    30 September 2019  
Letter from sponsor [Sponsorship letter]    08 August 2019  
Letters of invitation to participant [Letter of invitation]  0.1  25 March 2019  
Organisation Information Document [Organisation Information 
Document]  
0.1  25 March 2019  
Participant consent form [Participant Consent Form REC reviewed-
highlighted]  
0.2  13 September 2019  
Participant consent form [Participant Consent Form REC reviewed-
clean]  
0.2  13 September 2019  
Participant information sheet (PIS) [Participant Information Sheet 
Highlighted]  
0.2  13 September 2019  
Participant information sheet (PIS) [Participant Information Sheet 
Clean]  
0.2  13 September 2019  
Research protocol or project proposal [Research Protocol]  0.1  25 March 2019  
Response to Request for Further Information      
Schedule of Events or SoECAT  1  05 September 2019  
Summary CV for Chief Investigator (CI) [CV for Chief Investigator]      
Summary CV for student [CV for student]      




IRAS project ID 264354 
 
Information to support study set up 
 
The below provides all parties with information to support the arranging and confirming of capacity and capability with participating NHS 






















per the protocol 
and other study 
documents will 









England or Wales 
prior to their formal 
confirmation of 
capacity and 
capability to deliver 
the study.  
An Organisation 
Information Document 
has been submitted 
and the sponsor is not 
requesting and does 
not expect any other 




















No Honorary Research Contracts, Letters 
of Access or pre-engagement checks are 
expected for local staff employed by the 
participating NHS organisations. Where 
arrangements are not already in place, 
research staff not employed by the NHS 
host organisation undertaking any of the 
research activities listed in the research 
application would be expected to obtain a 
Letter of Access based on standard DBS 
checks and occupational health 
clearance. 
 
Other information to aid study set-up and delivery 
This details any other information that may be helpful to sponsors and participating NHS organisations in England and Wales in study set-up. 
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